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AA amino acid
antibioticR resistant to the indicated antibiotics
AS acetosyringone (3’,5’-dimethoxy-4’-hydroxyacetophenone)
bla β-lactamase gene
bhr broad host range
bp base pairs
carb carbenicillin
CLB crosslink buffer
cm chloramphenicol
CTD C-terminal domain
CV column volume
DSS disuccinimidyl suberate
DTT dithiothreitol
(d)NTP (2’-deoxy)nucleoside-5’-triphosphate
ery erythromycin
GlcNAc N-acetylglucosamine
His6 hexa-histidine
IMAC immobilized metal affinity chromatography
kan kanamycin
kDa kilo dalton (1000 g/mol)
kb kilo basepairs
MTFPT 4-methyl-2-[4-(trifluoromethoxy)phenyl]-1,2,4-thiadiazolane-3,5-dione
MurNAc N-acetylmuramic acid
MW molecular weight
NTD N-terminal domain
PBS phosphate-buffered saline
PMSF phenylmethylsulfonylfluoride
PSB protein storage buffer
psi pounds per square inch
RT room temperature
SB sample buffer
SDS sodium dodecyl sulfate
SDS-PAGE SDS polyacrylamide gel electrophoresis
SLT soluble lytic transglycosylase
spc spectinomycin
str streptomycin
T4SS type IV secretion system
tm trimethoprim
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 Introduction
1. A successful mechanism used for diverse applications
When David Bruce was rewarded with a knighthood in 1908, this was not only for his
achievements in discovering the transmission mode of the sleeping sickness. Having started
his career in the English Army Medical Service twenty-five years earlier on the island of
Malta, the occurrence of “Malta fever” not only caught the attention but, fortunately, also
challenged the investigative talent of the young surgeon. While conducting examinations on
his Mediterranean post, he discovered that the cause for this disease, which sometimes
resembled typhoid fever and sometimes malaria, was an organism he called Micrococcus
melitensis. It became later known as Brucella melitensis. The reservoir of infection was
traced to the Maltese goat, and drinking milk from infected animals seemed to be the main
cause of infection. The genus Brucella is characterized by species like B. melitensis, B.
abortus and B. suis, which all reside within animal hosts. They are also pathogens of
humans, where they cause zoonotic infections. The symptoms of this long-lasting febrile
illness are severe, but brucellosis is rarely fatal for humans. Patients who have experienced
the disease, which requires antibiotic treatment for nine months or longer, describe it to be
like having “the flu times ten” (Winstead, 2004; LSHTM, 2004).
This debilitating nature of brucellosis encouraged the US-military’s interest in the
disease and more importantly in properties of its causative agent. In the 1950s the cold-war
superpowers attempted to weaponize a number of pathogenic bacteria and the US military,
among other projects, focused on creating bioweapons that would not kill but rather disable
attacking troops for a prolonged period. B. suis, typically isolated from pigs, was cultivated,
processed and filled into bomb shells, which were never used for other goals than
maintaining the balance of power. These bombs were destroyed in 1969 when the
bioweapon program was abandoned (Winstead, 2004). Aside from such questionable
applications, the military contributed to progress in the life sciences and medicine by being a
driving force in the development of antibiotics and vaccines. Nevertheless, the mechanisms
of bacterial virulence remained unknown until the late 20th century, when techniques of
biochemistry and molecular biology started to unravel the molecular basis of bacterial
pathogenicity.
In the last 30 years, research conducted with the plant pathogenic bacterium
Agrobacterium tumefaciens brought a number of fundamental insights for both the fields of
plant science and bacterial pathogenesis (reviewed by Zupan and Zambryski, 2000; Baron et
al., 2002; Binns, 2002). A. tumefaciens was shown to transfer single stranded DNA (T-DNA)
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to plant cells where it is stably integrated into the genome (Zambryski, 1992). Due to the
genes encoded in the T-DNA, the plant cell is forced to proliferate while producing certain
organic compounds called opines, which can be preferably utilized by the Agrobacteria (Petit
et al., 1970). This example of gene transfer into eukaryotic species by a bacterium is unique.
The virB operon was identified to be important for this process (Kuldau et al., 1990), and ten
of the eleven genes encoded in it are indispensable for virulence (Berger and Christie, 1994).
The operon-encoded proteins VirB1 to VirB11 build up the VirB-complex, a macromolecular
membrane-spanning apparatus responsible for secretion of the T-DNA into the plant cell.
With the onset of efficient DNA-sequencing techniques the growing amount of sequence data
led to the discovery that many proteobacteria possess orthologous genes coding for proteins
that constitute similar membrane-spanning machineries. The obvious similarities between the
A. tumefaciens virB operon, the tra operon of broad host range plasmid pKM101 and the ptl
operon from Bordetella pertussis were among the first findings in this area (Weiss et al.,
1993; Winans et al., 1996). In order to distinguish them from other common secretion
machineries in bacteria, the vir-encoded membrane-spanning translocation apparatus was
denominated type IV secretion system (T4SS). It is apparent that proteobacteria generally
take advantage of T4SS for three different purposes.
First, in A. tumefaciens and broad host range (bhr)-plasmid-carrying bacteria the
T4SS serves to transfer ssDNA together with associated proteins to recipient eukaryotic and
prokaryotic cells, respectively. Second, many bacterial pathogens utilize T4SS to deliver
effector molecules to the host, thus ensuring their survival and propagation inside the host
cell (e.g. Legionella pneumophila, Brucella spp. and Bartonella spp.) and outside of the host
cell (e.g. Bordetella pertussis and Helicobacter pylori). Third, it was observed that the
transfer of IncQ plasmids between A. tumefaciens cells is drastically improved when recipient
cells display the virB-encoded T4SS (Bohne et al., 1998) and H. pylori obtains natural
transformation competence by expression of an operon that encodes T4SS core components
VirB4, VirB8, VirB9 and VirB10 (Hofreuther et al., 2001). Together, these data show the
importance of T4SS not only for DNA delivery to other cells, but also for DNA uptake into
cells.
 An ecologically diverse group of proteobacteria utilizes T4SS for an equally diverse
set of applications (Table 1), and the different lifestyle of A. tumefaciens and B. suis is
obvious though there are many similarities between the two organisms. After completion of
the genomic sequence of the intracellular animal pathogen B. suis, it became apparent that
this organism is in fact a close relative of extracellular plant pathogen A. tumefaciens.
Despite their preference for hosts belonging to different kingdoms, these organisms share
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genes, have a similar genome structure and biological pathways, a fact that is also
exemplified by comparison of the T4SS of the two organisms (Paulsen et al., 2002; Tsolis,
2002).
Table 1. Diversity of T4SS utilization by different proteobacteria. (Nagai and Roy, 2003; Christie
and Vogel, 2000; Masui et al., 2000; Shamaei-Tousi et al., 2004, Baron et al., 2002; Brock et al., 1997;
Harb et al., 2000).
genus
proteobacteria
group
host
relation
habitat lifestyle
virB operon
localization
VirB
orthologs
substrate(s)
Agrobacterium α pp soil, plants ec
Ti plasmid,
cryptic plasmid
1-11
ssDNA-VirD2,
VirE2, VirF
Bartonella α p
mam. blood,
arthropods
ic genome 2-11 unknown
Bordetella β p
upper
respiratory
tract
ec genome 2-4,6-11
Pertussis
toxin
(Ptx)
Brucella α p
soil,
animals
ic genome 1-11 unknown
Escherichia γ s/c/p
gastrointestinal
tract
ec
broad-host-range
plasmids
1-11
ssDNA,
proteins
Helicobacter ε c/p
stomach,
duodenum
ec genome 1,4,9-11 CagA
Legionella γ c/p
protozoa,
animals
ic genome 10,11 RalF, DotA
Wolbachia α s/c/p
arthropods,
nematodes
ic genome 4+8-11 unknown
pp: plant pathogenic, p: human and animal pathogenic, s: symbiotic, c: commensal, ec: extracellular,
ic: intracellular, mam.: mammalian.
2. Similarity between the A. tumefaciens and B. suis T4SS
The 11.8 kb virB operon of B. suis was identified following the observation that
TnblaM insertion mutants in that region were unable to multiply in the intracellular
environment of macrophages. The DNA sequence flanking the transposon insertion showed
significant sequence similarities to genes encoding B. pertussis PtlG and A. tumefaciens
VirB9. Sequence determination of the surrounding region identified the virB operon and its 12
orfs, which was subsequently proven to be also present in B. abortus, B. canis, B. melitensis,
B. neotomae and B. ovis. Comparison of the virB region of A. tumefaciens and B. suis
showed that the newly discovered operon consists of genes encoding orthologs to all VirB
proteins of A. tumefaciens plus an additional gene for the putative lipoprotein VirB12
(O’Callaghan et al., 1999). The structures of the virB operons of B. suis and A. tumefaciens
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are almost identical (Fig. 1A). While many genes overlap the preceding one either with their
Shine-Dalgarno sequence or their start codon like in the A. tumefaciens virB operon, the
presence of intergenic regions between virB1 and virB2, virB5 and virB6, virB6 and virB7 is
special for B. suis. This raised the question whether the 12 genes constitute an operon.
Moreover, there are two degenerate Brucella-specific repeat regions denominated BruRS1
and BruRS2 (Halling and Bricker, 1994), which succeed virB1 and virB12. Finally, sequence
comparison of orthologous B. suis and A. tumefaciens VirB proteins showed good
conservation of their general predicted properties, such as export signals, lipoprotein
modification signals, membrane-spanning domains and membrane topology (Fig. 1B).
Due to the presence of a highly conserved sequence motif, VirB1 was identified as a
putative lytic transglycosylase. The orthologs from A. tumefaciens and B. suis both possess
a signal sequence and are therefore directed to the periplasmatic space by the general
secretion pathway (sec pathway) (O’Callaghan et al., 1999; Llosa et al., 2000), where their
enzymatic activity likely leads to localized cell wall lysis, creating space for accommodation
of the T4SS (Mushegian et al., 1996). The sequence identity between the two proteins as
determined by a ClustalW-alignment is 22%. In A. tumefaciens, VirB1 is the only protein that
is non-essential for action of the T4SS since its absence merely causes a 10- to 100-fold
attenuation of virulence (Berger and Christie, 1994). A similar observation was made for B.
abortus VirB1 (den Hartigh et al., 2004).
The identity values between the T4SS core components of A. tumefaciens and B.
suis are 21.5% for VirB3, 21% for VirB6, 27% for VirB7, 24.5% for VirB8, 26.5% for VirB9
and 32.5% for VirB10 (O’Callaghan et al., 1999). Genetic and biochemical experiments
suggest that these proteins constitute a membrane-spanning pore, which connects the outer
and the inner membrane through periplasmatic interactions and homo-oligomer formation
(Cascales and Christie, 2003). These proteins are indispensable both for virulence of A.
tumefaciens and for Brucella’s ability to reach the proper intracellular niche and to replicate
within HeLa cells or macrophages (Berger and Christie, 1994; O’Callaghan et al., 1999; Siera
et al., 2000; Comerci et al., 2001).
The proteins constituting the T-pilus in A. tumefaciens are required for all functions of
the T4SS. It is interesting to note that the lowest values of identity between the A .
tumefaciens and B.  suis VirB orthologs were found in case of VirB2 (18%) and VirB5 (19%)
(O’Callaghan et al., 1999). VirB2 is exported via the sec pathway, but may subsequently
remain associated with the inner membrane where it undergoes a number of post-
translational modifications in A. tumefaciens (Eisenbrandt et al., 1999), resulting in a cyclic
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peptide, which is the main constituent of the T-pilus and it is likely responsible for plant cell
contact (Hwang and Gelvin, 2004). VirB5, which is also directed to the periplasm by a
classical N-terminal apolar leader peptide, is an indispensable part and minor component of
the T-pilus. The protein, which is supposedly rich in α-helices, was proposed to be either
membrane-associated (Schmidt-Eisenlohr et al., 1999a), or to act as a chaperone for VirB2
(Sauer et al., 2000). Certain mutants of the VirB5 ortholog TraC from the tra region of the
IncN-plasmid pKM101 (29% identical to B. suis VirB5) were unable to promote DNA transfer
and to serve as receptor for the donor-specific bacteriophage IKe (Yeo et al., 2004).
Nevertheless, incorporation of the protein variants into the pilus occurred normally,
suggesting a role of VirB5 for pilus biogenesis and adhesion (Yeo and Waksman, 2004). The
outer membrane lipoprotein VirB7 was shown to interact with VirB9, and VirB6 participates in
formation of this complex while exerting a stabilizing effect on VirB2 (Jakubowski et al.,
2003). Moreover, VirB2, VirB5 and VirB7 were co-isolated from vir-induced A. tumefaciens
cells suggesting that VirB7 links the pilus structure to the membrane-spanning structure
constituted by the core components (Krall et al., 2002). It is unknown whether B. suis
produces a pilus under virulence-inducing conditions (Boschiroli et al., 2002). If this should
be the case, VirB2 and VirB5 may establish contact with the host. This would explain the
relatively low conservation of these proteins in the two species compared here, reflecting
suspected differences of receptor molecules on the plant cell surface and inside mammalian
cells.
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A)
B) Fig. 1. The virB regions from A .
tumefaciens and B. suis and the
hypothetical structure of the
membrane-spanning T4SS.
Comparison of the A. tumefaciens and
B. suis virB region (A). The functions of
the proteins are indicated. Orhologs are
in the same colour. Intergenic regions
are symbolized by a dash, Brucella-
specific regions are depicted as grey
boxes (O’Callaghan et al., 1999;
modified). (B) The localization of VirB
protein is suggested by different lines of
experimental evidence (Cascales and
Christie PJ, 2003). The color code for
the proteins is the same as in A.
The virB operons of A. tumefaciens and B. suis each encode two NTPases, VirB4
(30% identity) and VirB11 (29.5% identity). VirB4 forms dimers and homo-multimers
embedded in the inner membrane and A. tumefaciens requires an intact NTPase site of
VirB4 for substrate secretion. Enzyme activity could not be demonstrated in vitro, but there is
little doubt that the protein hydrolyzes NTPs in the context of the T4SS (Rabel et al., 2003).
Parts of VirB4 may traverse the inner membrane to contact periplasmatic VirB proteins
(Dang et al., 1999). In fact, interactions with VirB1, VirB8, VirB10 and VirB11 were suggested
based on the results of a dihybrid study (Ward et al., 2002). VirB11-like proteins seem to be
especially important, since orthologs of VirB11 are found not only in T4SS but also in a wide
range of gram-negative and gram-positive bacteria and even in Archaea (Planet et al., 2001).
The hexameric ATPase VirB11 is located in the inner membrane and is essential for A.
tumefaciens virulence. It was proposed that this protein either acts as an assembly factor for
the T4SS or that it is responsible for driving pilus subunits or substrate molecules across the
envelope. Like proteins VirB2-VirB10, VirB11 is required both for pilus biogenesis and
substrate secretion, but certain amino acid substitutions in VirB11 cause uncoupling of the
two features, enabling T-DNA transfer without pilus formation (Sagulenko et al., 2001). This
observation can be rationalized if VirB11 indeed carries out two tasks.
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3. A dual role of the soluble lytic transglycosylase VirB1
3.1. The catalytic mechanism of SLTs
Despite the well-known area of lysozyme biochemistry, proposals for the catalytic
mechanism of lytic transglycosylases were published only recently. While the well-known
lysozymes like hen egg white lysozyme (HEWL), goose egg white lysozyme (GEWL) or the
human lysozyme break up murein by hydrolysis of the β(1→4)-glycosidic bond between the
MurNAc C1 and the GlcNAc C4, the lytic transglycosylases lyse this substrate in a
transglycosylation reaction utilizing the C6-OH residue of the same MurNAc. Thus, no water
is required for the reaction that produces a 1,6-anhydromuramic acid terminal residue (Fig.
2). Special features of the active site that distinguish the lytic transglycosylases from
lysozymes must explain the mechanistic difference.
The classical mechanism of murein/chitin degradation by lysozyme was described as
follows: A hexa-glycosidic stretch of a murein fiber binds to lysozyme, each GlcNAc and
MurNAc residue is positioned to certain subsites in the active site cleft of the enzyme,
denominated A-F. MurNAc residues cannot bind to subsite C since their large lactyl side
chain will not fit into that position. This leaves only one possible arrangement of the
substrate, with MurNAc in subsites B, D, F and GlcNAc at A, C, E. Cleavage is catalysed by
an E (Glu) and a D (Asp) residue and occurs at the glycosidic bond connecting C1 of
MurNAc (subsite D) and C4 of GlcNAc (subsite E). The E (Glu) residue donates a proton and
thus cleaves the glycosidic bond under formation of a carbenium ion at C1 that is stabilized
by the deprotonated D (Asp) residue. The positively charged C1 subsequently attracts a
water molecule leading to completion of hydrolysis and re-protonation of E (Glu)
(Stryer, 1995).
There are three major differences that might explain
why the C1 carbenium ion is not attacked by water
but instead by the 6-OH group of the same molecule.
First, lytic transglycosylases do not possess a D
(Asp) residue in the right position to ensure
stabilization of the carbenium ion. Second, in contrast
to lysozyme, the GlcNAc residue at subsite E is
deeply buried inside the active site crevice and forms
numerous interactions with the enzyme. In lysozyme
the saccharides at sites E and F are able to quickly dissociate, allowing water to enter into
the active site, whereas no water is available during catalysis in the lytic transglycosylases.
Third, MurNAc needs to be heavily distorted into the half chair conformation to fit into subsite
D, bringing 6-OH into proximity of the carbenium-ion (Leung et al., 2001). Thus, by necessity,
Fig. 2. The 1,6-anhydromuropeptide.
GlcNAc: N-acetylglucosamine, R: lactyl-
peptidyl sidechain (Höltje, 1998;
modified)
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complete degradation of a murein strand by a lytic transglycosylase results in the formation
of 1,6-anhydromuropeptides (Fig. 2).
Since VirB1 orthologs present in the T4SS of many pathogenic bacterial species are
members of the lytic transglycosylase family, it is noteworthy that the 1,6-
anhydromuropeptide is known to cause a vast number of physiological responses. The 1,6-
anhydromuropeptide N-acetylglucosaminyl-1,6-anhydro-N-acetylmuramyl-L-alanyl-D-
glutamyl-meso-diaminopimelyl-D-alanine is released by B. pertussis and causes cell
damage. Somnogenic, arthriogenic and pyrogenic effects have been reported and moreover,
release of interleukin-1β, interleukin-6 and granulocyte colony-stimulating factor was induced
by 1,6-anhydromuropeptides (Leung et al., 2001).
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3.2. VirB1 interacts with T4SS components
When VirB1 was identified as a lytic
transglycosylase, its importance for the A .
tumefaciens  T4SS was largely attributed to its
proposed catalytic activity. This notion was
repeatedly confirmed by the observation that active
site mutants of the protein failed to complement virB1
deletion strains (Mushegian et al., 1996; Höppner et
al., 2004). VirB1 of A. tumefaciens is processed in
the periplasm, yielding a C-terminal processing
product denominated VirB1*. VirB1* and the N-
terminus representing the SLT domain independently
enhanced tumorigenicity, which implied an additional
function of VirB1 (Llosa et al., 2000). Further
evidence for this hypothesis was generated when it
was shown by co-immunoprecipitation, that VirB9
interacts with VirB1* in A. tumefaciens (Baron et al., 1997). A high-resolution dihybrid screen
with protein components of the A. tumefaciens T4SS suggested self-interaction and a
number of uni- and bi-directional interactions between VirB1 and VirB4, VirB8, VirB9, VirB10
and VirB11 (Fig. 3). Unfortunately, the study failed to further narrow down the interaction
domain within the VirB1 protein and biochemical evidence for the interactions was not
presented (Ward et al., 2002).
4. The VirB11-like hexameric (d)NTPase of T4SS
4.1. General characteristics and role in the system
Gram-negative bacteria utilize a number of macromolecular secretion machineries,
which contribute to their virulence and pathogenicity. Dependent on their general
characteristics (number of protein components, sequence similarities and membrane
localization), the secretion systems were classified as type I through type V, and their task is
to translocate proteins or nucleoprotein complexes across the two membranes and the
peptidoglycan layer of the bacterial cell (Thanassi and Hultgren, 2000). Whereas
fundamental differences exist between the systems, there are mechanistic similarities like the
utilization of (d)NTPases to energize assembly of the apparatus and substrate secretion
(Planet et al., 2001). The VirB11-PulE (d)NTPase-family comprises a vast number of
(d)NTPases. Many of the orthologs identified to date are not only essential components of
the sec-independent type IV secretion systems but also are constituents of the main terminal
Fig. 3. Interactions of A. tumefaciens
VirB1 as found by yeast dihybrid
analysis. Arrows indicate interactions
among VirB-proteins from bait to prey
(Ward et al., 2002)
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branch of the sec-dependent type II secretion systems. Other functions are the participation
in naturally competence-related DNA uptake systems and a role in twitching motility (Cao
and Saier, 2001).
Studies on the T4SS (d)NTPases HP0525 from H. pylori, TrwD from the R388 and
TrbB from the RP4 conjugative systems have yielded fundamental insight into general
properties of these enzymes. In addition, research conducted on (d)NTPases from type II
secretion systems, which are implicated in the formation of type IV pili, confirm common
features of a number of proteins that belong to this family (Krause et al., 2000a; Sakai et al.,
2001; Machón et al., 2002). The amino acid sequences of proteins belonging to the VirB11-
PulE family is characterized by four sequence motifs, namely the Walker A and Walker B
nucleotide binding site, a D box (Asp Box) and a H box (His Box). Functional studies
suggested multimer formation since dominant negative mutants could be created by site-
directed mutagenesis (Sagulenko et al., 2001), and native protein was purified in assemblies
of much larger molecular mass than the monomer. Characterization of the enzymology of
T4SS ATPases yielded a multitude of results concerning substrate specificity, optimal pH
and other factors that influence activity, like fatty acids and phospholipids (Machón,
unpublished; Krause et al., 2000a).
It was demonstrated that cardiolipin (CL) and phosphatidylglycerol (PG) stimulate the
enzymatic activity of the VirB11 orthologs HP0525 from H. pylori and TrbB from pRP4. TrwD
from pR388 was shown to promote the hemifusion of lipid vesicles consisting of CL and PG.
Hemifusion (also coined close apposition) of vesicles is a process in which the outer
monolayers of vesicles are mixed whereas the inner aqueous content is not. The membrane-
destabilizing action of TrwD is required during the process of T4SS assembly or DNA
transfer (Machón et al., 2002). Electron-micrographic images of the hexameric protein TrwD
were obtained and it was discovered that ATP binding effects large conformational changes
in the hexamer (Krause et al., 2000a; Krause et al., 2000b). This observation could be
explained after determination of the structure of the hexameric VirB11 ortholog from H. pylori
(Yeo et al., 2000). Analysis of the X-ray structure showed that an ATP binding and hydrolysis
cycle effects rigid body rotation of the N-terminal domain of some monomers around the
linker region, a flexible AA stretch around R133 that is interconnecting the two domains of
HP0525. Certain non-functional variants of HP0525 had enhanced ATPase activity and a
reduced ability to form the native hexameric shape. Together, these data led to the
postulation of a four-step mechanism of HP0525 dynamic action. The main characteristics of
this mechanism are:
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1) Occurrence of a nucleotide-free asymmetric form in which the C-terminal domain
(CTD) is responsible for maintaining the pseudohexameric scaffold while the N-
terminal domain (NTD) uses its general flexibility to contact potential target
molecules.
2) Upon binding of three molecules of ATP, an equal number of subunits are locked in a
rigid conformation.
3) Hydrolysis and binding of three additional ATP molecules to the remaining nucleotide-
free subunits creates a rigid symmetric hexamer.
4) After hydrolysis of all ATP molecules, the symmetric hexamer regains its flexibility
(Savvides et al., 2003).
Whereas VirB11-PulE orthologs were reported to reside in the inner membrane (Possot and
Pugsley, 1994), the outer membrane or the cytoplasm (Rivas et al., 1997), the NTD of inner
membrane protein HP0525 was proposed to contact the periplasmatic space where it might
be involved in interactions with proteins of the core complex, possibly acting as an assembly
factor (Ward et al., 2002; Cascales and Christie, 2003). Recent studies showed that VirB11
and VirB4, the two multimeric ATPases common to most T4SS, not only interact with each
other but also seem to coordinate their actions which are required for substrate secretion
(Ward et al., 2002; Cascales and Christie, 2004).
4.2.  Choice of VirB11 orthologs as drug targets
A growing concern of modern medicine is the massive spread of antibiotic resistance
that has occurred ever since the classical antibiotics were widely applied, not only for the
treatment of microbial infections, but also as growth promoters in animal breeding facilities.
The problem will become even bigger since a considerable innovation gap in antibiotic
development is obvious as indicated by a recent inspection of drug candidates that are being
advanced through clinical trials (Walsh, 2003). Targeting bacterial cell functions that are non-
essential for microbial growth could drastically reduce the velocity by which selection and
horizontal gene transfer cause resistance to spread. Classical antibiotics exert a broad-
spectrum effect by targeting processes essential for bacterial cell viability while anti-infective
drugs could specifically target pathogenic species possessing characteristic virulence
factors. If successfully applied, it can be anticipated that the favorable property of reduced
resistance development would be combined with reduced negative impact of antimicrobial
chemotherapy on the commensal and symbiontic microorganisms colonizing the human
body (Alksne and Projan, 2000).
VirB11-PulE orthologs from type IV and type II secretion machineries are found in a
number of pathogenic bacteria. Among them are enteropathogenic E. coli and Pseudomonas
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aeruginosa, which causes nosocomial infections in hospitalized patients. T4SS are the major
virulence factors in an impressive number of Gram-negative pathogenic bacteria, but also the
spread of antibiotic resistance genes can be attributed to this mechanism (Cascales and
Christie, 2003). While other components, like the ATPases VirB4 and VirD4, are often not
present in the virulence-related T4SS of pathogens, VirB11 is highly conserved. The
enzymatic activity was shown to be required for its role in the secretion system. Moreover,
the structure of a representative member of the family was solved and the 3-dimensional
shape of the active site was modeled. VirB11 orthologs were purified either by classical
purification methods or by affinity purification of N-terminally tagged fusion proteins, and
(d)NTPase properties were determined (Krause et al., 2000a; Sakai et al., 2001). Target
molecules from different T4SS are therefore available, which is an important prerequisite to
assay broad-spectrum effects in in vitro assays. Due to the essential function(s) of VirB11
orthologs and the large amount of available information, they constitute ideal targets for the
development of drugs, which will disarm but not kill many bacterial pathogens. The
knowledge gained concerning these (d)NTPases must be especially appreciated considering
the number of diseases that are caused by organisms utilizing T4SS as important virulence
factor.
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5. Social and economic impact of some T4SS-mediated diseases
Brucellosis,
also called undulant or Malta fever is a zoonotic disease mostly caused by one of the three
species B. melitensis, B. abortus or B. suis (Corbel, 1997) The disease is endemic (def.:
constantly present to a low degree) in countries of the Mediterranean basin, the Arab
peninsula, western Asia, the Indian subcontinent, parts of Africa and in Latin America. The
causative agent is spread by the common domestic animals in these countries.
This severe, and long-lasting but rarely fatal disease was almost eradicated in
countries possessing an effective and standardized public and domestic animal health
program. Tests for seropositivity in humans and the number of reported cases allow
estimates of the actual importance of Brucellosis in the human population. However, due to
inaccurate diagnosis, the disease might remain unrecognized in many cases, resulting in an
actual infection rate 10 to 25 times higher than suspected. Countries like the USA, which by
virtue of a rigorous eradication program managed to reduce the disease to very low levels,
now report less than 0.1 cases annually per 100,000 people (Ragan and Gilsdorf, 2001).
Estimates for disease prevalence in endemic areas are in the range of 1.2 to 70 annual
cases per 100,000 people and might go as high as the 540 annual cases per 100,000
reported for Kuwait. Nevertheless, serological evidence of exposure to Brucella can be found
in approximately 5% to 20% of the population in these areas, and in up to 55% of the
population reported for Nigeria (Rust and Worrell, 2004)
The World Health Organisation (WHO) recommends 45 days doxycycline/rifampine
therapy for treatment that costs $225.96 for a dosage sufficient to cure an adult (FAO, 1986).
Assuming that 2 billion people live in areas of endemic Brucellosis and a hypothetical low
prevalence of 10 annual cases per 100,000 would bring the cost to a sum of $45 million per
year, just to finance treatment. This does of course not take into account the cost of lost labor
power, which is undoubtedly much more severe when no treatment is pursued.
Although a number of formulations had been used for vaccination of humans with
limited efficacy (Corbel, 1997), the main effort to prevent infection is through controlling the
disease in the animal host. This strategy is useful since major savings can be achieved in the
livestock and dairy industry by successful eradication. In 1952, annual losses from lowered
milk production, aborted calves and pigs and reduced breeding efficiency in the USA
accounted for more than $400 million. In contrast, today, after more than fifty years of the
“Federal Brucellosis Eradication Program”, the annual loss is only $1 million (Ragan and
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Gilsdorf, 2001). Consistent with these data are estimates that B. abortus alone accounts
even nowadays for an annual veterinary toll of $700 million in South America (Rust et al.,
2004). Since data on human and veterinary cases of the disease are not available for all
countries with endemic Brucellosis, an estimation of the overall impact is difficult. A simple
approach to assess the overall veterinary cost is to compare the overall number of domestic
animals (buffalo, cattle, goat, pig and sheep) in Latin America with the total number of these
animals in other countries and regions with endemic Brucellosis (Africa, India, the Arab
peninsula, Eastern Europe, Iran, Greece, Spain, Portugal and Italy) and suppose the same
cost per animal of Brucellosis as in Latin America. Whereas 573 million of the mentioned
domestic animals live in Latin America, about 1.6 billion are estimated in the other countries
(FAO, 2004). This would imply a yearly loss of $1.95 billion for these countries, a total of
$2.65 billion globally. Though all statements are based on assumptions, it is clear that the
veterinary toll of Brucellosis by far outruns the cost of human treatment.
Crown gall or Hairy Root
is the plant disease named after the morphological manifestation of an Agrobacterium
infection. Although reviews sometimes underscore the economically significant crop loss that
Agrobacterium is responsible for, it is very hard to obtain data supporting this notion. The
genus is present in soil all over the planet but the only significant damage occurs in fruit and
nut orchards, vineyards, and nurseries situated in areas that experience drastic temperature
variations in winter and spring. The resulting frost damage together with the manipulative
techniques applied in cultivation creates lesions on the plants that enable Agrobacterium to
infect the stem and cause the formation of tumors, called crown galls. Relative to the large
impact of other plant pathogens like insects and fungi on agriculture, Agrobacterium plays no
major role. Data concerning agriculture in the state of Georgia/USA shows that formation of
crown galls plus costs of controlling of the disease account for 2.7% of the total financial loss
in the bunch grape harvest (Williams-Woodward, 2002). Interestingly, crown gall disease
caused by plant pathogenic A. tumefaciens can be controlled with agrocine producing
Agrobacterium radiobacter K84, the first reported example of successful biocontrol (Jones et
al., 1991). A. tumefaciens has no severe impact as compared to other pests and there are no
reports of other crops damaged.
In an economical sense, a different aspect of A. tumefaciens’ capability to transform
plants is much more important. Transformation of plants with Agrobacterium has evolved to
be one of the most important techniques that are used to create genetically modified crops
by inserting exogenous genes into the plant genome (Binns, 2002). The fate of transgenic
plants with advantageous properties is still an issue of discussion between authorities in the
USA and the EU. The debate is about labeling and traceability requirements for genetically
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manipulated foods (GM foods). Nevertheless, it is clear that Agrobacterium plays a mayor
role in the creation of crops that in the future might be of global importance in an effort to
solve urgent problems of food production (Evenson and Santaniello, 2004).
Bartonellosis
shares many characteristics with Brucellosis. The causative agents B. bacilliformis, B.
tribocorum, B. quintana, B. henselae and B. vinsonii are predominantly found in animal
hosts, typically feline, canine and rodent species. While direct transmission of Bartonella
from animal to human seems to be rather exceptional, insect vectors like the sand fly
(Lutzomyias sp.), the human body louse (Pedicular humanis), cat fleas (Ctenocephalides
felis) and ticks (Ixodes sp.) seem to play an important role for the spread of this intracellular
pathogen (Breitschwerdt and Kordick, 2000). Clinical manifestations are rather broad,
including Carrion’s disease (Verruga peruana), trench fever, cat scratch disease, bacillary
angiomatosis peliosis, bacteraemia and endocarditis. Especially immunocompromised
patients may suffer from the formation of vasoproliferative tumors due to the organism’s
proliferation in endothelial cells (Dehio, 2001), where it causes increased production of
vascular endothelial growth factor (VEGF) (Kempf et al., 2001).
There are no reliable data on the frequency of the disease in the human population
but seroprevalence as a measure for the risk of infection ranges between 2% and 6% in
healthy blood donors from the USA. However, seroprevalence of 30% in homeless patients
from Marseille and 51.1% in a group of European veterinarians were reported, which
demonstrates that risk groups with a very different socioeconomic background may be found
due to the transmission mode of Bartonellosis (Breitschwerdt and Kordick, 2000).
Gastric ulcer
can be caused by H. pylori , an organism which has infected approximately half of the world
population (Covacci et al., 1999). This ε-proteobacterium was identified to be a causative
agent of gastric adenocarcinoma and duodenal ulcer disease. Prevalence of infection is
linked to many factors such as socioeconomic status, sex and age and males over 40 years
of age that live in developing countries are the most likely infected by the organism. A
number of diseases have been ascribed to Helicobacter infection, best documented are
duodenal ulcer, gastric ulcer, gastric adenocarcinoma and gastric lymphoma (Pisani et al.,
1997). Though there are also other reasons, it was estimated that 5 million new cases of
these diseases occur due to Helicobacter infection worldwide per annum (Parsonnet, 1998).
A different study that tried to assess the economics of ulcer disease in the USA estimated
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annual health care costs of approximately $ 6 billion, consisting of physician office visits,
hospitalization and decreased productivity (Sonneberg and Everhart, 1997).
Whooping Cough
caused by Bordetella pertussis was largely controlled by global vaccination programs, but for
some years the number of infections has been on the rise again. Since an all time low in
1976, with only 1,000 reported cases in the USA, the number rose to more than 8,000 cases
in 2002 (CDC, 2004). About 20% of the infected patients require hospitalization, but the rate
is much higher in infants younger than 6 months (63%), which are especially prone to the
infection (CDC, 2003). The disease is fatal in 0.04% of the cases in developed countries and
in 3% of the cases in developing countries (Galazka, 1991), but the many complications that
the primary symptoms create drastically increase the impact. Apart from hemorrhages in the
eye, nosebleeds, hernias and physical damage to the lungs there is a considerable danger of
encephalopathy, seen in 0.7% of all cases and often leading to brain damage (Siber and
Samore, 1998).
Onchocerciasis and Wolbachia
Another important example for the impact of T4SS comes from the genus Wolbachia.
Wolbachia spp. are α-proteobacteria and have an extremely broad host range, which
enables them to reside within host-derived vacuoles in the cytoplasm of arthropods and
filarial nematodes (Taylor and Hoerauf, 1999). Whereas it is still discussed whether the
species is beneficial or detrimental to the arthropode host, Wolbachia spp. are essential
endosymbionts in filarial nematodes, where their abundant presence in tissues of all
developmental stages was shown to be essential for nematode embryogenesis (Hoerauf et
al., 2003). Wolbachia harbors a functional T4SS (Masui et al., 2000), and there are strong
indications that, like in other intracellular pathogens of the proteobacteria, the T4SS is
essential for establishment and maintenance of intracellular survival (McGraw and O’Neill,
2004).
About 200 million individuals worldwide suffer from filarial nematode parasites like
Brugia malayi, Wucheria bancrofti and Onchocerca volvulus, the causative agent of
onchocerciasis, due to its transmission by riverbank inhabiting mosquitoes also called “river
blindness”. This disease, which is endemic in 35 countries throughout Africa, the Americas
and the Arab peninsula, accounts for the debilitating infection of 18 million people annually,
which suffer from skin and ocular lesions caused by the high titer of filarial nematodes that
are released into the blood by an adult nematode residing under the skin (WHO/TDR, 2002).
450,000 people worldwide are suspected to have lost their vision due to the disease. The
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depopulation of fertile river valleys in the African savannah is a direct result of the disease,
and constitutes a major obstacle to socioeconomic development in that region (The Carter
Center, 2002-2003).
Eradication of Wolbachia from O. volvulus by doxycyclin treatment drastically
improved all disease symptoms, which is due the inhibition of filarial development. Even
more importantly, the treatment reduced the blindness-promoting inflammatory response in
the cornea, which seems to be caused by Wolbachia antigen alone (Saint André et al. ,
2002). The current control strategy of this disease is based on a single microfilaricidal drug
(Ivermectine), but treatment that negatively affects the endosymbiosis between O. volovulus
and Wolbachia spp. should be a viable alternative to fight onchocerciasis. This example
shows that by promotion of endosymbiosis, the Wolbachia T4SS might contribute to one of
the major global health problems.
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6. Aim of this work
Type IV secretion systems have an important role for the virulence of many obligate
and opportunistic pathogens. Studies in many laboratories have yielded fundamental insights
into the roles of the participating proteins (reviewed in: Baron et al., 2002; Cascales and
Christie, 2003, Zupan and Zambryski, 2000).
Lytic transglycosylases similar to A. tumefaciens VirB1 were of special interest in a
number of studies (Mushegian et al., 1996; Bayer et al., 2001), but their actual task in the
function of the T4SS was not elucidated in detail. Many of the T4SS known to date do not
possess VirB1-like proteins and even if they are present, they are most likely non-essential.
Dihybrid data indicated multifold interactions of VirB1, but biochemical data were not
provided (Ward et al., 2002). Experiments with purified recombinant B. suis proteins have the
potential to demonstrate VirB1 interactions, while functional studies conducted with the A.
tumefaciens model should permit insights into the importance of the active site requirements
and the processing site of the protein.
In contrast to VirB1, the traffic NTPase VirB11 has orthologs in all T4SS described so
far. Thus, the protein is an exellent target for anti-infective drugs, which could block either the
NTPase activity or the formation of homo-oligomers, both essential features of VirB11 action
(Savvides et al., 2003). A potential inhibitor of NTPase activity of VirB11 orthologs was
identified in a high throughput screen conducted at CHIRON (Emeryville, USA and Siena,
Italy). Different in vitro and in vivo analyses were conducted to clarify the effect of this
compound on VirB11 orthologs from different T4SS. In addition, the analysis of interactions
of VirB11 with other components of the secretion apparatus could further define its role as a
drug target, and its contribution to T4SS function. The development of an effective broad-
spectrum VirB11 inhibitor with good pharmaceutical properties would provide an alternative
drug for the treatment of a number of severe and long-lasting bacterial infections. The
presented work should lay the foundation for the development of such an inhibitor.
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 Materials and Methods
1. Bacterial strains, bacteriophages and plants
1.1. Bacterial strains
Table  2. Bacterial strains
strain genotype or description source or reference
Escherichia coli
DH5α
F’ Φ80dlacZΔM15 Δ(lacZYA-argF)U169 deoR recA1
endA1 hsdR17(rK
- mK
+) phoA supE44 λ- thi-1 gyrA96
relA1
Woodcock et al.,
1989
JM109
F’ (traD36 proAB+ lacIqZΔM15) recA1 endA1 gyrA96
thi-1 hsdR17 relA1 supE44 Δ(lac-proAB)
Yanisch-Perron et
al., 1985
WL400
cmR, strR araD139 Δ(araF-lac)U169 ptsF25 deoC1
relA1 flb5301 rpsL150 ΔselD204::cat
W. Leinfelder
FM433
spcR araD139 Δ(argF-lac)U169 ptsF25 deoC1 relA1
flbB5301 rpsE13 Δ(srl-recA)306::Tn10
Zinoni et al., 1990
GJ1158
ompT hsdS gal dcm ΔmalAp510 malP::(proUp-T7
RNAP) malQ::lacZhyb11 Δ(zhf-900::Tn10dTet)
Bhandari and
Gowrishankar, 1997
BMH71-18mutS
thi supE Δ(lac-proAB) [mutS::Tn10] [F’ proAB
lacIqZΔM15]
Wallace et al., 1981
TOP10
F- mcrA Δ(mrr-hsdRMS-mcrBC) Φ80lacZΔM15
ΔlacX74 recA1 deoR araD139 Δ(ara-leu)7697 galU
galK rpsL (strR) endA1 nupG
Invitrogen
Agrobacterium tumefaciens
A348 Wild type, pTiA6NC Garfinkel et al., 1981
UIA143 A348, eryR Bohne et al., 1998
UIA143pTiA6 UIA143, pTiA6NC Bohne et al., 1998
PC1001 pTiA6NC carrying an in frame deletion of virB1
Berger and Christie,
1994
PC1011 pTiA6NC carrying an in frame deletion of virB11
Berger and Christie,
1994
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1.2. Bacteriophages and plants
The donor-specific bacteriophage IKe (Kathoon et al., 1972) was used to assess the
functionality of IncN-determined conjugative pili. Four to six week old plants of Kalanchoë
diagremontiana were used to assay the virulence of A. tumefaciens strains.
2. Plasmids and genomic DNA
Table 3. Plasmids
plasmid genotype reference
pTrc200
strR, spcR, pVS1 origin, lacIq, trc promotor
expression vector
Schmidt-
Eisenlohr et
al., 1999b
pTrc300  pTrc200 with NcoI-site deleted
Schmidt-
Eisenlohr et
al., 2002
pTrc300-VirB3-B6
pTrc300 expressing virB3-B6 of the B. suis
virB operon (Fig. 14)
Q. Yuan
pTrc300-VirB7-B12
pTrc300 expressing virB7-B12 of the B. suis
virB operon (Fig. 14)
Q. Yuan
pTrc300-VirB3-B12
pTrc300 expressing virB3-B12 of the B. suis
virB operon (Fig. 14)
Q. Yuan
pTrc300-VirB2-B12
pTrc300 expressing virB2-B12 of the B. suis
virB operon (Fig. 14)
this work
pTrc300-VirB1-B12
pTrc300 expressing virB1-B12 of the B. suis
virB operon (Fig. 14)
this work
pTrc300-VirB1+B3-B12
pTrc300 expressing virB1 and virB3-B12 of
the B. suis virB operon, 56 bp insert after
virB1 (Fig. 14)
this work
pTrc300-VirB1+B2-B12
pTrc300 expressing virB1 and virB2-B12 of
the B. suis virB operon, 56 bp insert after
virB1 (Fig. 14)
this work
pTrc300-VirB1E27A-B12
like pTrc300-VirB1-B12, virB1 active site
variation (Fig. 14)
this work
pTrcB11
pTrc200, A. tumefaciens virB11 treated
BspHI/XbaI, for expression
this work
pTrcB11s
pTrc200, B. suis virB11 treated BspHI/XbaI,
for expression
this work
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pTrcB1
pTrc200 with 759 bp NcoI/BglII virB1 fragment
from A. tumefaciens
Schmidt-
Eisenlohr et
al., 1999a
pTrcB1s
pTrc200 with 717 bp NcoI/ScaI virB1 fragment
from B. suis
this work
pTrcTraL
pTrc200 with 735 bp NcoI/ScaI traL fragment
from pKM101
this work
pTrcF169
pTrc200 with 507 bp NcoI/ScaI orf169
fragment from the F plasmid
this work
pTrcHP0523
pTrc200 with 507 bp NcoI/ScaI hp0523
fragment from H.pylori chromosomal DNA
this work
pTrcB1E→A pTrcB1 active site variant E60A this work
pTrcB1sE→A pTrcB1s active site variant E27A this work
pTrcTraLE→A pTrcTraL active site variant E53A this work
pTrcB1*
pTrc200 with 222 bp NcoI/BglII virB1 fragment
from A. tumefaciens
this work
pTrcB1ΔAA
pTrcB1 cleavage site variant A172, A173
deleted
this work
pTrcB1A→D pTrcB1 cleavage site variant A172D this work
pTrcB1Q1→E pTrcB1 cleavage site variant Q174E this work
pTrcB1Q2→E pTrcB1 cleavage site variant Q175E this work
pTrcB1Q1→E/Q2→E pTrcB1 cleavage site variant Q174E, Q175E this work
pTrcB1A→P pTrcB1 cleavage site variant A173P this work
pTrcB1E→P/T→W
pTrcB1 cleavage site variant
E170P, T171W
this work
pTrcHP0523-B1*
pTrc300 with 507 bp EcoRI/NcoI fragment
from H.pylori chromosomal DNA and 225 bp
NcoI/Acc65I virB1*  fragment from
A. tumefaciens
this work
pTrcSP-HP0523-B1*
pTrcHP0523-B1* with 90 bp SP fragment of
A. tumefaciens virB1 inserted into EcoRI site
this work
pLS1
carbR, IncQ plasmid for VirB/D4-mediated
transfer experiments
Stahl et al.,
1998
pKM101 carbR, mucA, mucB IncN conjugative plasmid
Langer and
Walker, 1981
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pRP4 kanR, IncPα conjugative plasmid
Pansegrau et
al., 1994
pR388 tmR, IncPα conjugative plasmid
Datta and
Hedges, 1972
pT7-7
carbR, vector for T7-promotor controlled
expression
Tabor and
Richardson,
1985
pT7-7NcoI carbR, pT7-7, NdeI-site substituted with NcoI
Schmidt-
Eisenlohr et
al., 2001
pT7-StrepII
carbR, pT7-7NcoI with 50 bp NcoI fragment
coding for StrepII-Tag and factor Xα cleavage
site
Balsiger et al.,
2004
pT7-StrepII-VirB11 B. suis
pT7-StrepII with full-length Acc65I/ HindIII
fragment of virB11 from B. suis
this work
pT7-StrepII-VirB11 A.
tumefaciens
pT7-StrepII with full-length Bsp1407I/NcoI
fragment of virB11 from A. tumefaciens C58
this work
pT7-StrepII-TrwD
pT7-StrepII with full-length Acc65I/PstI
fragment of trwD from pR388
this work
pT7-StrepII-TraG
pT7-StrepII with full-length Acc65I/PstI
fragment of traG from pKM101
this work
pT7-StrepII-HP0525
pT7-StrepII with full-length Acc65I/PstI
fragment of hp0525 from H. pylori
this work
pT7-7-VirB4
pT7-7 with 2499 bp NcoI/EcoRI fragment of
virB4 from B. suis
this work
pT7-StrepII-VirB8
pT7-StrepII with 492 bp Acc65I/PstI fragment
of virB8 from B. suis
N. Domke
pT7-StrepII-VirB9
pT7-StrepII with 813 bp Acc65I/PstI fragment
of virB9 from B. suis
N. Domke
pT7-StrepII-VirB10
pT7-StrepII with full-length 1020 bp
Acc65I/PstI fragment of virB10 from B. suis
N. Domke
pT7-H6TrxFus
carbR, for T7-based expression of N-terminal
hexa-histidine and trxA (thioredoxin)-fusions
Kromayer et
al., 1996
pT7-H6Trx-VirB7
pT7-H6TrxFus with 126 bp PstI/XbaI fragment
of B. suis virB7
A. Carle
pT7-H6Trx-VirB8
pT7-H6TrxFus with 492 bp Acc65I/PstI
fragment of B. suis virB8
N. Domke
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pT7-H6Trx-VirB9
pT7-H6TrxFus with 813 bp Acc65I/PstI
fragment of B. suis virB9
N. Domke
pT7-H6Trx-VirB10
pT7-H6TrxFus with 1020 bp Acc65I/PstI
fragment of B. suis virB10
N. Domke
pT7-H6Trx-VirB11
pT7-H6TrxFus with full-length Acc65I/HindIII
fragment of VirB11 from B. suis
this work
pT7-StrepII-VirB1
pT7-StrepII with 654 bp Acc65I/PstI SP-less
fragment of virB1 from B. suis
this work
pT7-StrepII-VirB1/VirB4
pT7-StrepII-VirB1 with 2499 bp NotI/EcoRI
fragment of virB4 from B. suis
this work
pT7-StrepII-VirB1/VirB8
pT7-StrepII-VirB1 with 524 bp PstI/HindIII
fragment of virB8 from B. suis
this work
pT7-StrepII-VirB1/VirB9
pT7-StrepII-VirB1 with 776 bp NotI/EcoRI
fragment of virB9 from B. suis
this work
pT7-StrepII-VirB1/VirB10
pT7-StrepII-VirB1 with 1011 bp NotI/EcoRI
fragment of virB10 from B. suis
this work
pT7-StrepII-VirB1/VirB11
pT7-StrepII-VirB1 with 1194 bp NotI/EcoRI
fragment of virB11 from B. suis
this work
pET21b-BC
carbR, pET21b derivative with two RBS in the
polylinker for T7-driven bi-cistronic
expression, determines hexa-His tagged C-
terminus of second ORF
S. Höppner
pET24d-VirB1-His6
kanR, pET24d with 654 bp NdeI/EcoRI B. suis
virB1 fragment
this work
pET21b-VirB8/VirB1-His6
pET21b-BC with 524 bp  NcoI/NotI virB8 and
654 bp NheI/EcoRI B. suis virB1 fragment
downstream
this work
pET21b-VirB9/VirB1-His6
pET21b-BC with 776 bp virB9 and 654 bp B.
suis virB1 fragment downstream
this work
pET21b-VirB10/VirB1-His6
pET21b-BC with 1011 bp virB10 and 654 bp
B. suis virB1 fragment downstream
this work
pET21b-VirB8
pET21b-VirB8/VirB1-His6, virB1 gene
removed with SalI/XhoI and religated
this work
pET21b-VirB9
pET21b-VirB9/VirB1-His6, virB1 gene
removed with SalI/XhoI and religated
this work
pET21b-VirB10
pET21b-VirB10/VirB1-His6, virB1 gene
removed with SalI/XhoI and religated
this work
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pUC18VirB carbR, virB region from B. suis 1330
O’Callaghan et
al., 1999
pGK217 carbR, virB region from A. tumefaciens C58
Kuldau et al.,
1990
pCR®2.1-TOPO
carbR, kanR for direct cloning of PCR
fragments
Invitrogen
pCR®2.1-TOPO-VirB1
pCR®2.1-TOPO with 733 bp virB1 fragment
of B. suis
this work
pCR®2.1-TOPO-VirB1-II
pCR®2.1-TOPO with 733 bp virB1 fragment
of B. suis, SacI-site mutated to NheI (proximal
to the virB1 stop codon)
this work
pCR®2.1-TOPO-VirB1
E27A
pCR®2.1-TOPO with 733 bp virB1 fragment
of B. suis featuring active site mutation
this work
Genomic DNA from Helicobacter pylori 26695 (ATCC 700392) was used as template for
PCR (K.A. Eaton).
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3. Oligonucleotides
3.1. PCR primers
Table 4. PCR primers
primer name sequence
primers for construction of bi-cistronic vectors:
VirB1suisNcoIBC5': 5'-GCGCGCCCATGGCAGCAATCGTGCAGGTCGAGT-3’
VirB1suisBC3': 3'-GACTGCGGCCGCGAAAACAACTACGCCGTCCG-3’
B1suisExp-5': 5'-CGATGGTACCCGCAATCGTGCAGGTCGAGTCGG-3'
B1suisExp-3': 5'-CGATCTGCAGTTAGAAAACAACTACGCCGTCCG-3'
StrepBCVirB8- 5:
5'-GGGGGGCTGCAGTAATTAACTAGAAGGAGCGGCCGCA
TGCGCGTCAACGCACAGAC-3'
VirB8 3':
5'-GGGGGGAAGCTT/GAATTCTCATTGCACCACTCCCATT
TCTGG-3'
VirB8 suisBC5': 5'-GCGCGCTAGCCGCGTCAACGCACAGAC-3'
VirB8 suisBC3': 5’-GCGCGAATTCTCATTGCACCACTCCCATTTCTGG-3’
VirB9-5': 5'-GATCGAGTGCGGCCGCATGATTCAGTATGTCGATTAC-3'
VirB9suisBC5': 5'-GCGCGCTAGCATTCAGTATGTCGATTACAATTC-3'
VirB9suisBC3': 5'-GCGCGAATTCTCATTGCAGGTTCTCCCCGGGC-3'
VirB10-5': 5'-GCGCGCGCGCGGCCGCATGGGCAATGCAGAGAATAAt-3'
VirB10suisBC5': 5'-GCGCGCTAGCGGCAATGCAGAGAATAATCACC-3'
VirB10suisBC3': 5'-GCGCGAATTCTCATTGCAGGTTCTCCCCGGGC-3'
VirB11-5':
5'-GCGCGCCTGCAGTAATTAACTAGAAGGAGCGGCCGCA
TGATGTCCAACCGAAGT-3'
VirB11suisBC3': 5'-GCGCGAATTCTTATATGCGTGATATGCGGCTGCAC-3'
VirB4sNcoI 5’: 5’- GCGCGCCCATGGGCGCTCAATCCA-3’
VirB4-5': 5'-GCGCGCGCGCGGCCGCATGATGGGCGCTCAATCCA-3'
Strep VirB4-5': 5'-GCGCGCGGTACCCATGATGGGCGCTCAATC-3'
VirB4suisBC3': 5'-GCGCGAATTCTCATTGCAGGTTCTCCCCGGGC-3
primers for construction of the hp0523-virB1* -fusion:
523-5’ EcoRI: 5’-CGATGAATTCTTGTTCGAGAAATGGATTGGTC-3’
523-3’NcoI: 5’-GCTACCATGGCTCGTTATATCGCACTTGAGA-3’
B1*-5’ NcoI: 5’-CTAGCCATGGGCCGCTCAACAGCTCGTCCCC-3’
B1*-3’ Acc65I: 5’-GATCGGTACCTTATTGCGGACCTCCTTGATTTAA-3’
SPVirB1-5’:
P-5’-AATTCATGAGCTTGGGGAGATGGGGAATGTTGAAGG
CAACAGGGCCGCTGTCGATTATCTTACTGGCCTCCACGT
GCCCGTCGAGTGGTGCTGCCG-3’
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SPVirB1-3’:
P-5’-AATTCGGCAGCACCACTCGACGGGCACGTGGAGGC
CAGTAAGATAATCGACAGCGGCCCTGTTGCCTTCAACAT
TCCCCATCTCCCCAAGCTCATG-3’
primers for the pTrc300 B. suis virB constructs:
pTrc1+2-12:5’: 5’-GCGCGAGCTCAGAAGGAGACGATCCTATGGTGCCA-3’
pTrc1+2-12:3’ 5’-GCGCGAGCTCTTAGAAAACAACTACGCCGTCC-3’
VirBsuis2-5’:
5’-GATGCGGCAGAGCTCGACATAAGGAATAAAGATCATG
AAAAC-3’
VirBsuis6-3’:
5’-GACTGCGAGGTCTAGAAAGGCCCTAATCCCTGTTGAA
CTG-3’
primers for virB11 ortholog-encoding genes:
pVSBAD11suis5’: 5’-GCTACGTCATGATGTCCAACCGAAGTGACTTTATTG-3’
pVSBAD11suis3’: 5’-GCTACGTCTAGATTATAAATTTGTGCAGCATATGC-3’
pVSBAD11Agro5’: 5’-GCTACGCCATGGAGGTGGATCCGCAATTACGA-3’
pVSBAD11Agro3’: 5’-GCTACGTCTAGACTACTGCTGGTTAAGAAGATC-3’
VirB11suis>: 5’-GCGCGGTACCCATGATGTCCAACCGAAGTGAC-3’
T7-7VirB11suis3’: 5’-CGTCAGAAGCTTATAAATTTGTGCAGCATATGCGT-3’
TraG>: 5’-GCGCGGTACCCATGACTGATGCAGCTTTCTATC-3’
TraG<: 5’-CGCGCTGCAGTTACAGGCTCCCGTTCA-3’
TrwD>: 5’-GCGCGGTACCCATGTCTACAGTCTCGAAAGCAT-3’
TrwD<: 5’-GCGCCTGCAGCTAAGCCATCTTGGACTTGG-3’
HP0525>: 5’-GCGCGGTACCCATGACTGAAGACAGATTGGA-3’
Hp0525<: 5’-GCGCCTGCAGCTACCTGTGTTTGATATAAAAT-3’
B11C58Bsp1407I: 5’-GCTATGTACACATGGAGGTGGATCCGCAATTACGA-3’
T7-7VirB11Agro3’: 5’-GGCTGCCATGGAGGTGGATCCGCAA-3’
Restriction sites are underscored and Shine-Dalgarno motifs are in italics.
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3.2. Site-directed mutagenesis primers
Table 5. Site-directed mutagenesis primers
primer name sequence
523asiteMut: P-5’-ATCTCTATCGCTTTGTTAGCTAGCTCTCTAGGGTTGAACAAC-3’
VirB1suisMP: P-5’-GCAGCAATCGTGCAGGTCGCTAGCGGCTTCAATCCTTATGCA-3’
pTrc1+2-12Mut: P-5’-GTAGTTGTTTTCTAAGAATTCGCGCAAGGGCGAATTC-3’
B1M5: 5’-GCAGCGATCGCTCAGGTCGCTAGCCGCTTTGATCCGCTTGCT-3’
B1suisM5: 5’-GCAGCAATCGTGCAGGTCGCTAGCGGCTTCAATCCTTATGCA-3’
TraLM5: 5’-GCGTACATCGTCGGCCATGCTAGCTCAAATGGACCGTACAGG-3’
B1_deltaAA: P-5’-TACGTGCGAAAAGTTGAAACG/CAACAGCTCGTCCCCCCGTTA-3’
B1_1.Q>E: P-5’-AAAGTTGAAACGGCCGCTGAACAGCTCGTCCCCCCGTTAACC-3’
B1_2.Q>E: P-5’-GTTGAAACGGCCGCTCAAGAGCTCGTCCCCCCGTTAACCGCG-3’
B1_QQ>EE: P-5’-AAAGTTGAAACGGCCGCTGAAGAGCTCGTCCCCCCGTTAACC-3’
B1_+1P: P-5’-CGAAAAGTTGAAACGGCCCCGCAACAGCTCGTCCCCCCGTTA-3’
B1_1.A>D: P-5’-TACGTGCGAAAAGTTGAAACGGACGCTCAACAGCTCGTCCCC-3’
B1_ET>PW: P-5’-GGCTACGTGCGAAAAGTTCCGTGGGCCGCTCAACAGCTCGTC-3’
Shine-Dalgarno motifs are in italics and nucleotides that encode the mutation are in bold.
3.3. Specialized sequencing primers
Table 6. Specialized sequencing primers
name sequence application
12280>: 5’-CAGCACCTATTCGG-3’ sequencing of
pTrc300VirB2-12 and all
derived plasmids
11760>: 5’-CAGGACAAGCTCCTGG-3’ see above
10540>: 5’-CGGTTTCGATGGCACC-3’ see above
10020>: 5’-CTGGTAAAACTGTCC-3’ see above
9060>: 5’-CATCGTTCGCATGCG-3’ see above
9600>: 5’-GACCAGCTCGGCCGG-3’ see above
8500>: 5’-CGGGCGCTTCTGGCG-3’ see above
8440>: 5’-CCATGTTCATATTGCCGC-3’ see above
VirB1Check: 5’-ATCAAGGGAAACGGGTGGACGG-3’ sequencing of the B. suis
virB1 gene start region
T7-7 5’: 5’-TAATACGACTCACTATAGGGAGA-3’ sequencing of genes
inserted downstream of the
T7-promoter
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T7-Ter: 5’-GCTAGTTATTGCTCAGCG-3’ sequencing of genes
inserted upstream of the
T7-terminator (in pET21/24)
Trc5: 5’-GGGGAGATCTGACGCGCCCTGACG-3’ sequencing of genes
inserted downstream of the
pTrc 200/300 polylinker
region
Trc3: 5’-CCCCAGTACTTTAAAAGTGCTCATCATT-3’ sequencing of genes
inserted upstream of the
pTrc 200/300 polylinker
region
uni24: 5’-ACGACGTTGTAAAACGACGGCCAG-3’ sequencing of genes
inserted downstream of
pCR®2.1-TOPO insertion
site
rev24: 5’-TTCACACAGGAAACAGCTATGACC-3’ sequencing of genes
inserted upstream of
pCR®2.1-TOPO insertion
site
Trx3new: 5’-GCATTGGTAACTGTCAGACC-3’ sequencing of genes
inserted upstream of the
pT7-H6TrxFus polylinker
region
4. Growth media, supplements and antibiotics
4.1. Growth media
LB (Miller, 1972) 1% tryptone; 0.5% yeast extract; 0.5% NaCl
LBON (Bhandari, 1997) 1% tryptone; 0.5% yeast extract
YEB (Baron et al., 1997) 1% tryptone; 0.5% sucrose; 0.1%; 2 mM MgSO4
AB (Winans et al., 1988) 1% glucose; 0.39% MES; 1 mM Na-K-phosphate pH 5.5; 1
x AB salts (20 x AB salts: 20 g NH4Cl; 6 g MgSO4 x 7 H2O; 3
g KCl; 0.2 g CaCl2; 50 mg FeSO4 x 7 H2O per liter; pH 5.5)
TGE (Olsen, 1973) 1% tryptone; 0.5% yeast extract; 0.85% NaCl; 0.5%
glucose; 0.015% CaCl2
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4.2. Supplements, antibiotics and inhibitors
final concentration:supplements, antibiotics
or inhibitors
stock solution
E. coli A. tumefaciens
carb 100 mg/ml in H2O 100 µg/ml 150 µg/ml
str 50 mg/ml in H2O 50 µg/ml 100 µg/ml
spc 50 mg/ml in H2O 50 µg/ml 300 µg/ml
ery 50 mg/ml in methanol -- 150 µg/ml
kan 50 mg/ml in H2O 50 µg/ml --
tm 100 mg/ml in DMSO 20 µg/ml --
cm 50 mg/ml in methanol 20 µg/ml --
IPTG 0.5 M in H2O 0.5 mM 0.5 mM
AS 0.2 M in DMSO -- 0.2 mM in liquid culture,
agar plates; 0.5 mM for
conjugation assay
X-Gal 40 mg/ml in
dimethylformamide
40 µg/ml --
MTFPT 10 mM in DMSO various various
Oleic acid 10 mM in DMSO -- various
Linoleic acid 10 mM in DMSO -- various
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5. Buffers and solutions
Crosslink Buffer (CLB) 50 mM MES-KOH; 150 mM NaCl; 0.1 mM EDTA; pH 6.5
StrepII-Buffer (S2B) 300 mM NaCl; 100 mM Tris/HCl; 1 mM EDTA;
2 mM DTT; pH 7.0
PSB StrepII-Buffer with 50% glycerol
TAE 40 mM Tris/HCl; 20 mM acetic acid; 1 mM EDTA, pH 7.8
TBS 20 mM Tris/HCl; 137 mM NaCl; pH 8.0
TBS-T 20 mM Tris/HCl; 137 mM NaCl; 0.1% Tween-20; pH 8.0
PBS 137 mM NaCl; 2.7 mM KCl; 8 mM Na2HPO4;
1.7 mM KH2PO4
6. Growth conditions
6.1. Escherichia coli
For overnight cultures all E. coli strains were grown in LB or LBON under aerobic
conditions at 37°C using 20 ml tubes in a laboratory shaker (Modell Kühner, B.Braun
Melsungen) at 200 rpm. Day cultures were inoculated to an OD600 of 0.05 in vessels of
appropriate volume with the same media under vigorous shaking at 37°C (Certomat-R, B.
Braun Biotech International). The protein over-producing strain GJ1158 was induced at an
OD600 of 0.4-0.8 by addition of 5 M NaCl stock solution to a final concentration of 0.3 M.
Cultivation under aerobic conditions then proceeded at different temperatures for varying
amounts of time as given in table 7. Unless otherwise indicated, the total culture volume was
1 l in four 500 ml Erlenmeyer flasks filled with 250 ml LBON.
Table 7. Growth conditions for protein production with GJ1158
protein(s) optimal temperature cultivation time
VirB1 (C- or N-terminal tag) 26°C 4 h
VirB1/VirBX (bi-cistron) 26°C 6 h
(StrepII-)VirB4suis 26°C 18 h
H6Trx-HP0523 26°C 6 h
H6Trx -VirB7suis 37°C 6 h
(H6Trx or StrepII)-VirB8suis 37°C 4 h
(H6Trx or StrepII)-VirB9suis 37°C 4 h
(H6Trx or StrepII)-VirB10suis 27°C 6 h
(H6Trx or StrepII)-VirB11suis 27°C 18 h
(StrepII-)VirB11agro 20°C 18 h
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StrepII-HP0525 26°C 4 h
StrepII-TrwD 27°C 18 h
StrepII-TraG 27°C 18 h
6.2. Agrobacterium tumefaciens
A. tumefaciens  overnight cultures were grown in 20 ml tubes with YEB in a laboratory
shaker at 26°C. Day cultures were inoculated to an OD600 of 0.1 for experiments that aimed
at VirB protein analysis and to an OD600 of 0.25 for conjugation experiments in 100 ml
Erlenmeyer flasks containing AB at 20°C and 140 rpm (Gyrotory waterbath shaker Model
G76, New Brunswick Scientific Co., Inc.). For virulence gene induction A. tumefaciens cells
were either maintained in liquid culture at 20°C or plated on solid agar media as described
elsewhere (Schmidt-Eisenlohr et al., 1999a; Hapfelmeier et al., 2000).
7. Photometric methods
7.1. Optical density
The optical density of bacterial cultures was determined turbidometrically at 600 nm
wavelength with an U-1500 Spectrophotometer (Hitatchi)
7.2. Absorption
Protein concentration was measured according to Bradford at 595 nm wavelength.
Protein Assay Dye Reagent Concentrate (Bio-Rad) was used, and samples with 2-10 µg of
BSA gave the calibration standard (Bradford, 1976)
8. Molecular biology methods
8.1. PCR
DNA was amplified either with Pyrococcus furiosus (Pfu) or Thermus aquaticus (Taq)
DNA polymerase and appropriate buffer systems from different commercial and non-
commercial sources. Generally, 100 µl reactions contained 800 µM of the four dNTPs, 10
pmol of each primer, between 1 mM and 2 mM MgCl2 and approximately 1 ng of template
DNA. A “Gradient Thermocycler” (Biometra) was used to perform a 30 cycles program.
Times and temperatures of denaturation, annealing and elongation were moderately varied
to meet the special requirements of the polymerase and primer-template pairs used in
different experiments.
8.2. DNA isolation
E. coli or A. tumefaciens cells from 2 ml of an overnight culture were sedimented by
centrifugation and treated as described in the “JETquick Spin Column Technique” manual for
Materials and Methods
32
plasmid minipreparations. DNA fragments, which were generated by PCR or excised from
agarose gels were purified with the same system using the respective protocols. DNA was
precipitated with ethanol after elution from the column (Sambrook et al., 1989)
8.3. DNA in vitro modifications
8.3.1. Restriction cleavage and dephosphorylation
DNA was cleaved using restriction enzymes and buffers supplied by MBI Fermentas
and New England Biolabs (NEB) following manufacturers protocols. In the case of DNA
cleavage close to the end of a fragment, restriction digest proceeded over night. To avoid
religation, cleaved vector DNA was treated with Shrimp Alkaline Phosphatase (Roche
Diagnostics).
8.3.2. Removal of staggered ends
To create 5’-phosphorylated blunt ended DNA fragments ssDNA overhangs were
removed with Mung Bean Nuclease (NEB) according to the manufacturer’s protocol.
8.3.3. Ligation
Ligation of DNA fragments was conducted in 20 µl total volumes at room temperature
for two to 16 hours using T4 ligase (MBI Fermentas) and T4 ligase buffer (NEB). In most
cases linearized vector was incubated with a large excess of insert in order to obtain insert-
carrying clones.
8.4. Site-directed mutagenesis
Generation of site-directed mutations in genes was achieved following the protocol of
the “Gene editor TM site-directed mutagenesis system” (Promega). Since this requires the
presence of the bla gene on the respective vector, subcloning of genes into such a vector
had to be done in some cases.
8.5. DNA-sequencing
DNA sequences were determined with the chain termination method (Sanger et al.,
1977) using the BigDye® Terminator v1.1 cycle sequencing kit (Applied Biosystems), purified
vector DNA and 10 pmol of sequencing primer per reaction. The reaction was subsequently
processed as suggested by the manufacturer and analyzed by a capillary-sequencer (ABI
Prism R310, Applied Biosystems)
8.6. Transformation of plasmid DNA
Transformation of electrocompetent bacteria with plasmid DNA was achieved with a
Gene PulserTM –electroporation system (Bio-Rad) at 2000 V, 800 Ω and 25 µFaraday (Fiedler
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and Wirth, 1988). When chemically competent E. coli JM109, BMH71-18mutS (Promega) or
TOP10 (Invitrogen) were used, transformation was carried out as described by the supplier.
9. Biochemical methods
9.1. (d)NTPase assay
The standard reaction mixture (20 µl) consisted of ATPase buffer (50 mM Tris-HCl; 50
mM KCl; 2 mM MgCl2; 1 mM DTT; pH 7.5) and unless otherwise indicated, 1 mM of the
respective (d)NTP. For determination of the optimal pH value for the reaction, buffer A (50
mM Tris/HCl; 50 mM KCl; 2 mM MgCl2; 1 mM DTT; pH 7.0) and buffer B (50 mM
CHES/NaOH; 50 mM KCl; 2 mM MgCl2; 1 mM DTT; pH 9.5) were mixed in empirically
determined ratios to obtain the desired pH values. Two µl of an 10 x enzyme stock solution
(final concentrations of enzymes calculated based on active sites: 500 nM for StrepII-
VirB11B. suis, His-TrxVirB11B. suis and StrepII-HP0525; 5 µM for StrepII-TrwD and StrepII-
TraG; 1 µM for StrepII-VirB11A. tumefaciens) in PSB were pre-incubated with 16 µl buffer for
5 min, 2 µl of 10 mM (d)NTP stock solution (in H2O) were added to start the reaction, which
proceeded for 20 or 30 min. The (d)NTPase activity was determined based on Pi liberation
with the malachite-green assay (Cogan et al., 1999). The reaction was stopped either by
transfer of 20 µl aliquots of the mixture into vials containing an equal volume of 5 mM EDTA
on ice, or by direct detection of the Pi content. To that end H2O was added to a final volume
of 500 µl followed by addition of 172 µl Solution I (172 µl of 2.1 M H2SO4, 28 mM
ammoniumheptamolybdate) and 128 µl Solution II (0.35 % polyvinylalcohol, 0.76 mM
malachite green) as described by Cogan et al.. The formation of the blue phosphomolybdate-
malachite green complex was in linear relation to the amount of released Pi and was
determined through spectrophotometric measurement at 610 nm after 20 min incubation at
RT. For the standard curve 100 µM NaH2PO4 was prepared freshly from a 10 mM stock
solution and 0 to 60 µl (corresponding to [Pi] between 0 µM and 12 µM) were mixed with
water to a final volume of 500 µl. Solution I and Solution II were added and the OD610 was
determined. Concentration of Pi was plotted against the OD610 to determine the slope of the
standard curve. The velocity of the enzymatic reaction was either depicted as pmol Pi/min or
as the percentage of the maximum value that was observed under ideal conditions. To
analyze the impact of other StrepII-tagged VirB proteins from B. suis on the ATPase activity
of StrepII-VirB11, the standard reaction mix for each data point contained 14 µl of buffer, 2 µl
of 10 x enzyme stock solution (167 nM, VirB11suis hexamer) and 2 µl of VirB protein (1.67
µM, monomer). The reaction was started by addition of 2 µl 10 mM ATP. Negative controls
were performed with the potential interacting protein, which had been denatured by
incubation at 100°C for 5 min. Increase of the Pi concentration was measured as described
during 20 min and samples were taken every two minutes.
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9.2. Determination of protein-protein interactions
9.2.1. Strep-Tactin® Sepharose® pull-down assay
10 µl of purified StrepII-tagged proteins (5 pmol/µl in PSB) were incubated with 20 µl
Strep-Tactin® Sepharose ® (50% suspension in StrepII-buffer, IBA GmbH) for 15 min. 80 µl
S2B and 10 µl Trx-fusion protein (5 pmol/µl in PSB) were added next. After 15 min of
incubation at RT, the sepharose was sedimented (13.000 rpm, 2 min) and washed three
times with 200 µl-500 µl in the same buffer. Bound proteins were eluted with 35 µl 1 mM
biotin.
9.2.2. Chemical crosslinking with DSS
10 pmol/µl stock solutions of purified StrepII-tagged proteins in PSB were prepared. 5
µl of protein A was mixed with either 5 µl protein B, or 5 µl PSB as negative control. After 5
min, 90 µl CLB was added and the mixture was incubated for another 30 min.  Crosslinking
started by addition of 0.025 µl-1.25 µl 10 mM DSS, proceeded for 1 h and was stopped by
mixing with an equal volume of 2 x Lämmli SB (Lämmli, 1970). For the crosslinking of
StrepII-VirB11 (+/- inhibitor), 5 µl of 10 pmol/µl stock solution in PSB was mixed with 5 µl
PSB and 70 µl CLB was added. For the negative control 10 µl DMSO and 10 µl H2O were
added. In order to assay crosslinking with substrate alone, 10 µl DMSO and 10 µl ATP (10
mM in H20) was added. 10 µl MTFPT (10 mM in DMSO) and 10 µl ATP (10 mM in H20) was
added to assess inhibitor effect on multimerization. Incubation and crosslink proceeded as
described.
10. Electrophoretic methods
10.1. Electrophoretic separation of DNA
DNA was separated in horizontal TAE agarose gels. The agarose concentration was
0.5% to 1.5%, dependent on the fragment sizes of the sample; the ethidiumbromide
concentration in the gels was 0.4 µg/ml. Samples were mixed with 1/10 vol. of DNA SB (50%
glycerol, 0.05% bromophenolblue). For visualization of DNA the gel was placed on a UV-
screen (Eagle Eye, Stratagene)
10.2. Protein separation by SDS-PAGE
Depending on the size of the proteins of interest, two different methods were applied.
For proteins of a MW of >20 kDa, glycine-SDS-PAGE  (10%-15% acrylamide; Lämmli, 1970)
was performed. To separate proteins of a MW <20 kDa, tricine-SDS-PAGE was done (12%
acrylamide; Schägger and v. Jagow, 1987).  Gels were then either subjected to protein
transfer for Western-blot or directly stained with 0.2% Coomassie blue solution. Silver
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staining (Bloom et al., 1987) was performed when very low amounts of proteins had to be
visualized.
10.3. Electroelution
The purification of high quantities of unsoluble protein (500 µg-1 mg) for generation of
polyclonal antisera required elution from polyacrylamide gels, followed by precipitation and
immunization (Biogenes, Berlin). This was done with the “Biotrap”-system (Schleicher &
Schüll) according to the manufacturer’s description.
11. Chromatographic methods
Different chromatographic purification steps within one protein purification process were
performed in a uniform buffer at 4°C.
11.1. Immobilized metal chelate affinity chromatography (IMAC)
Sedimented bacterial cells were resuspended in 4-8 ml S2B  (no DTT; 0.5 mM PMSF)
and passed 3 x through a French Pressure Cell (Aminco) at 18,000 psi. The lysate was
subjected to centrifugation (SS34 rotor, 25 min, 13,000 rpm at 4°C) and the supernatant
applied to an HPLC-system (Äkta Purifier, Amersham Pharmacia Biotech) with a 5 ml Co2+-
charged IMAC column (Talon Superflow, Clontech). Hexa-His-tagged recombinant protein
was eluted according to a step-gradient protocol. At a flow rate of 0.5-1.0 ml/min the column
was first washed for 5 CV (column volumes). Then a stringent washing step with 20 mM
imidazole proceeded for 2.5 CV, before 150 mM imidazole was applied to the column for 2.5
CV. Both the stringent wash fractions and the elution fractions were collected in 2 ml
aliquots.
11.2. Strep-Tactin Sepharose chromatography
Cells were lysed in S2B (0.5mM PMSF) as described above. N-terminal StrepII-fusion
protein was purified from the supernatant with 1 ml Strep-Tactin® Sepharose® (IBA GmbH)
following the instructions given by the manufacturer.
11.3. Gel filtration
Samples generated by affinity chromatography (1 ml maximum) were loaded onto
Superdex 200 or Superdex 75 gel filtration columns in the same buffer and the flow rate
was 0.5 ml/min or 1.0 ml/min. To determine the MW of proteins, the columns were calibrated
with the “Gel filtration Calibration Kit” (Amersham Pharmacia Biotech), which uses proteins in
the range between 13.7 kDa and 669 kDa.
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11.4. Enrichment of proteins and dialysis
In order to concentrate protein samples after intermediate and final purification steps
centrifugal filter devices (Amicon® Ultra-15, Millipore) with either 10 kDa or 30 kDa nominal
molecular weight limit were used as described in the provided protocol. After concentration,
the samples were dialysed for >12 h against 1 l of PSB in a dialysis tubing (Visking, Roth) at
4°C. Samples were stored at –20°C until further use.
12. Bacteriological methods
12.1. Conjugation assay
12.1.1.  A. tumefaciens
For conjugation experiments A. tumefaciens donor and recipient were incubated at
20°C on AB minimal medium plates containing defined quantities of AS or IPTG inducers
following standard protocols (Bohne et al., 1998). In conjugation assays focussing on the
T4SS of the donor, the recipient strain (UIA143pTi, eryR) harboured the Ti-plasmid to ensure
formation of the receptor structure and efficient DNA-uptake. A donor strain of choice (A348
derivate harbouring pLS1, carbR) and the recipient strain were cultured under virulence-
inducing conditions and then mixed on an agar plate containing AS and for virulence gene
induction and IPTG for expression of plasmid-encoded genes. The conjugation then
proceeded for 2-3 days and cells were harvested, diluted to 10-8 in PBS and plated on YEB
medium containing ery and carb for selection of the transconjugands (UIA143pTi pLS1, eryR
carbR). The number of donor cells was determined and the transfer efficiency calculated as
number of transconjugand cells (TC) per output donor cells (D). Likewise, the assay was
performed to determine the state of the T4SS serving as the receptor structure for IncQ
uptake in the recipient. In this case the donor strain was always WT A348 pLS1 and after
dilution of the mating mixtures the number of transconjugands (TC) per recipient cells (R)
determined the transfer efficiency.
12.1.2. E. coli
Overnight cultures of donor and recipient bacteria were sedimented by centrifugation
and washed twice in an equal volume of LB to remove antibiotics. The pellet was suspended
in 100 µl of LB, the OD600 was determined and donor and recipient were plated in a one to
one ratio on 0.5 ml solid LB in a 24-well tissue culture plate (Becton Dickinson). Incubation at
37°C proceeded for 1 h. Cells were then washed off with 1 ml LB, subjected to a dilution
series from 100 to 10-6 and plated onto LB agar with selective antibiotics. For inhibitor
analysis, the donor was plated 1 h prior to addition of the recipient to permit inhibitor action
on T4SS function.
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12.2. Virulence assay
The virulence of A. tumefaciens was tested by inoculating fresh wound sites on
leaves of Kalanchoë daigremontiana with 10 µl of bacterial cell suspension OD600 = 0.25. In
addition, ten- and hundredfold dilutions were applied onto the lesions. Tumor formation was
analysed after four-six weeks.
12.3. Phage infection assay
Bacteriophage IKe was propagated and used to identify the amount of IncN-
determined conjugative pili. In this assay, stationary phase cultures of FM433 pKM101 were
mixed with the inhibitor and then preincubated with different titers of the IncN pilus-specific
bacteriophage IKe, which infects and lyses cells after binding to proteins of IncN-determined
pili. The mixture was subsequently poured into soft agar plates and plaque formation was
counted after incubation at 37°C overnight; plaque numbers from the control without MTFPT
was set to 100 %. Development of plaques is related to the status of the pilus in the
respective strain, because it roughly corresponds to the availability of IncN-pilus components
on the cell surface. Bacterial cultures were preincubated with MTFPT concentrations ranging
from 1 µM to 1000 µM by adding a 20 µl of a 10x stock solution, thus ensuring constant
DMSO content in all samples.
13. Immunological methods
13.1. Protein transfer
For detection of proteins by Western Blot, proteins were transferred onto a PVDF-
membrane (Immobilon-P, Millipore) in a vertical blot device (Trans Blot Cell, Bio-Rad; Blot
Buffer: 192 mM glycine, 25 mM Tris, 20% methanol) at 90 V for 1 h or 30 V for 16 h. Proteins
attached to peptide array membranes were transferred in a semi-dry blot device (Fast-Blot,
Biometra) following the protocol suggested by the company (Jerini AG). For each protein
transfer, a PVDF membrane, six pieces of Whatman paper of appropriate size and three
different transfer buffers were prepared (Cathode Buffer (CB): 25 mM Tris, 40 mM
6-aminohexanoic acid, 20 % methanol, pH 9.4; Anode Buffer I (AB I): 30 mM Tris, 20%
methanol, pH 10.4; Anode Buffer II (AB II): 300 mM Tris, 20 % methanol, pH 10.4). The
PVDF membrane was prepared by soaking it with methanol and incubation in Anode Buffer I
for 10 min. Pieces of Whatman paper were soaked with the different transfer buffers and
arranged on the semi-dry blot device in the following order.
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- cathode
2 x Whatman paper soaked in CB
peptide array membrane
PVDF membrane
2 x Whatman paper soaked in AB I
2 x Whatman paper soaked in AB II
+ anode
Protein transfer proceeded at 1 mA/cm2 for 2 h at 4°C. The PVDF membrane was subjected
to Western blot and the peptide array membrane was regenerated by washing it with water
(three times for 10 min), Regeneration Buffer I (62.5 mM Tris, 2% SDS, pH 6.7; four times for
30 min), 10x PBS (three times 20 min), TBS-T (three times 20 min) and finally TBS (three
times 10 min). In order to remove thightly bound protein, which might disturb subsequent
experiments with the peptide array membrane, it was placed in the semi-dry blot device as
described above and residual proteins were transferred at 1 mA/cm2 for 2 h at 4°C. Between
experiments, the membrane was stored in TBS-T at 4°C.
13.2. Western blot
Detection of proteins according to Harlow and Lane (1988) was achieved utilizing
“goat anti-rabbit IgG-HRP” (Bio-Rad), a chemiluminescence detection system (Western
Lightning, Perkin Elmer Life Sciences Inc. or Lumi LightPLUS, Roche Diagnostics) and blue
sensitive photographic film (B+, WicoREX ®).
13.3. Overlay assay
Approximately 1 µg of protein in SB was separated in a 12% glycine-SDS-PAGE and
transferred onto a PVDF membrane as described; the membrane was incubated in
regeneration buffer (10 mM Hepes pH 7.5; 10 mM MgCl2; 50 mM NaCl; 0.1 mM EDTA; 1 mM
DTT; 10% glycerol; Homann et al., 1990) for 24 to 48 h. The membrane was incubated with
TBS-T containing 5 % skimmed milk powder for 1 h in order to reduce unspecific adhesion of
protein and then incubated with approximately 5 µg/ml of the potentially interacting protein in
the same buffer at 4°C for 16 h. After washing the membrane, the protocol proceeded like
that of the standard Western-blot utilizing primary antibody to identify the overlaid protein.
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13.4. Peptide array experiments
The entire sequence of VirB1 from B. suis (Accession: NP_699276, see also Fig. 5)
without the signal peptide was displayed on a cellulose membrane as seventy 13-mers,
covalently bound at the C-terminus and with N-terminal acetylation, shifting three amino acid
positions each time:
peptide    1: AAIVQVESGFNPY
peptide    2:    VQVESGFNPYAIG
peptide    3:       ESGFNPYAIGVVG
peptide 4-68: defined by sequence and specification (see above)
peptide   69: TDAPPGKDNTDGV
peptide   70:    PPGKDNTDGVVVF
 The protocol for “Mapping of discontinuous epitopes“ from the supplier’s manual was
applied (Jerini AG). The peptide array membrane, which features all possible epitopes of
VirB1 was preincubated for 30 min in TBS-T, transferred into blocking solution (Roche
Diagnostics) for 1 h, washed again with TBS-T for 10 min and then incubated in blocking
solution containing 1-5 µg/ml of different proteins for 12 h at 4°C. Before transfer of the
attached proteins onto PVDF membranes with a semi-dry blot device (see 12.1), the peptide
array membrane was washed three times in TBS-T for 10 seconds.
13.5. Generation of polyclonal antisera
Soluble StrepII-VirB11 from B. suis was purified by affinity chromatography, whereas
StrepII-VirB1 was obtained from an inclusion body preparation, separated by SDS-PAGE,
excised from the gel and subjected to electroelution. Approximately 0.5 mg of each protein
was lyophilized and used for immunization of rabbits (BioGenes).
14. Data processing
14.1. Statistical and graphical data processing
To capture images of polyacrylamide gels, Western blots and plant leaves, an UMAX UTC-
6400 scanner was used. After first adjustments with Photoshop 6.0 (Adobe), the final images
were created with PowerPoint (Microsoft) or Canvas 7.0 (Deneba Systems). Statistical
analysis, curve fitting and imaging was done with Excel 98 and Prism 4 (trial-version,
GraphPad), using linear and nonlinear regression algorithms with standard parameters.
14.2. Protein sequence analysis
The ClustalW (version 1.82) algorithm for multiple sequence alignment (Higgins et al., 1994;
www.ebi.ac.uk/clustalw) or EMBOSS for alignment of two less conserved amino acid
sequences was applied (Smith and Waterman, 1981; Needleman and Wunsch, 1970;
www.ebi.ac.uk/emboss/align). Sequence information was processed with NORSp (Liu and
Rost, 2003; cubic.bioc.columbia.edu/services/NORSp) in order to discover long regions
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without regular secondary structure. Predictions of secondary structure were obtained with
the PHD-algorithm (Rost, 1996; www.embl-heidelberg.de/predictprotein). To create a
conservation plot of sequence alignment, the alignment data were transferred to the AMAS-
server (Barton and Livingstone, 1993; barton.ebi.ac.uk/servers/amas_server.html) using
standard default values. All structure images were generated with DINO 0.9.0 (Philippsen,
1998-2003; cobra.mih.unibas.ch/dino/intro.php).
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 Results
1. Characterization of structural and functional properties of VirB1
1.1. Display of conservation between the VirB1 SLT domain and its orthologs
LysG and Slt70
The murolytic enzyme hen egg white lysozyme (Gallus gallus LysC or HEWL) was
one of the first proteins whose structure was solved, which may be partly due to the
availability of large quantities of raw material for purification (Blake et al., 1965). The
nomenclature of the well-described enzyme is EC 3.2.1.17 or EC 3.2.1.14, the latter refering
to the chitinolytic activity that murolytic enzymes generally possess. Until now, the structures
of 18 lysozymes from different organisms have been solved. In addition, the three structures
of the lytic transglycosylases (EC 3.2.1.-) LaL from bacteriophage λ, Slt35 and Slt70 (both
from E. coli) are also available. The enzymatic action of lysozymes and soluble lytic
tranglycosylases (SLT) differs, but the protein fold is highly conserved (Mushegian et al.,
1996).
Sequence comparison of B. suis VirB1 with two murolytic enzymes, whose X-ray
structure was known, yielded interesting results. The SLT portion of the large donut-shaped
Slt70 from E. coli ranges from amino acid P494 to A620 and has a significant degree of
sequence similarity to B. suis VirB1 (ID: 23.1%; SIM: 38.1%; Gaps: 35.6%). Other proteins
like LysG from Anser anser (GEWL) (ID: 18.0% Sim: 33.1%; Gaps: 23.8%) and G. gallus Lys
C are less similar, although they were previously chosen to model the structure of a VirB1
ortholog (Mushegian et al., 1996). Structural superposition shows that despite an almost
identical tertiary structure of LysG and Slt70 (G. Koraimann, unpublished), their sequence
similarity (ID: 22.0%; SIM: 36.3%; Gaps: 32.7%) is less than that between Slt70 and VirB1. It
is therefore appropriate to use the surface model of Slt70 to visualize regions of VirB1-
interaction with other VirB proteins.
The AMAS algorithm was used to assign values expressing the degree of
conservation to all AA-positions in a multiple sequence alignment, ranging from A (identical)
to 8 (weakly conserved). One of the sequences in this alignment was a protein with known
tertiary structure (here: E. coli Slt70) and the other one was B. suis VirB1. The software
DINO was next applied to create a map of conserved residues on the surface of the known
3-dimensional model (Fig. 4). It is assumed that conserved patches on the surface are likely
to interact either with partner proteins or substrate(s).
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Following the modeling we found that many of the amino acids conserved between
VirB1 and Slt70 or LysG and Slt70 were not exposed on the surface but rather seem to
stabilize the structurally conserved lysozyme fold. The most prominent conserved surface
patch was the active site cleft with the catalytic E (Glu), which is ubiquitously found
throughout all lysozyme-like enzymes (Fig. 4). This model of the B. suis VirB1 structure was
instrumental for the analysis of its protein-protein interactions as outlined below.
Fig. 4. Prediction of conserved surface residues in different murein transglycosylases.   
Conserved amino acids between the SLT domain of B. suis VirB1 and E. coli Slt70 (A) or A. anser
LysG and E. coli Slt70 (B) are displayed on the surface of the Slt70 soluble lytic transglycosylase
domain. The results from an EMBOSS alignment were processed and submitted to the AMAS server
to validate the degrees of conservation. Identical residues in each of the two pairs are shown in dark
green (A+), high similarity (A) in green and lower similarity is in yellow (9) and light yellow (8). The
figure was prepared with DINO.
1.2. An in silico analysis of VirB1 ortholog conservation
VirB1 orthologs show significant similarity to the SLT domain of Slt70, and our
modeling suggests that the structure of these SLTs is also conserved. Nevertheless, we
noted differences, which may have interesting implications for the biology of these proteins.
One sequence stretch, that can be found in B.suis VirB1, A. tumefaciens VirB1 and also TraL
from pKM101, cannot be aligned to the sequences of Slt70, LysG or LysC whose structures
are known. According to the alignment and secondary structure prediction, this stretch may
form an α-helical region of about 17 AA N-terminal to the highly conserved GLMQ motif, and
this region could contribute to the distinct enzymatic features or the regulation of specialized
lytic transglycosylases. The respective region N-terminal to amino acid 517 in the E. coli
Slt70 (Fig. 5) sequence localizes within a loop region adjacent to the active site cleft. Apart
from this difference, many but not all SLT-like proteins from T4SS have long C-terminal
domain-like regions with interesting properties.
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Fig. 5. Alignment of the VirB1 orthologs investigated in this study. Residues identical to A.
tumefaciens VirB1 are shaded, conserved residues implicated in the enzymatic activity are indicated
by black frames. The putative active site Glu is labeled with a star, the cleavage site of A. tumefaciens
VirB1 is indicated with a black arrowhead. The alignment of the VirB1 orthologs was generated with
the MegAlign program, the SLT domain of E. coli Slt70 was aligned to B. suis VirB1 with EMBOSS
(Needle algorithm) and fit into the alignment. A dark blue arrow indicates the 17 amino acid stretch
characterizing VirB1 orthologs.
1.3. Secondary structure prediction of the VirB1 C-terminus
It has been shown earlier that VirB1 from A. tumefaciens undergoes posttranslational
processing and that the C-terminal part, denominated VirB1*, is released by proteolytic
processing (Baron et al., 1997). Although the SLT domain of VirB1 from A. tumefaciens is
completely located in the N-terminal half, both parts of the protein independently contribute to
tumorigenesis (Llosa et al., 2000). Since VirB1 from A. tumefaciens was found to interact
with other T4SS components in a yeast two-hybrid assay (Ward et al., 2002), it was
speculated that full-length VirB1 might undergo protein-protein interactions with other T4SS
components. This notion was strongly supported by the finding that VirB1* could be co-
immunoprecipitated with VirB9 following chemical crosslinking. VirB1* accumulated in
extracellular fractions, and it is possible that it exerts additional (non SLT-related) functions
for virulence, e.g. modifcation of the host membrane or participation in pilus formation. It was
also proposed that VirB1* could act as a chaperone, facilitating the correct folding of the
main pilus component VirB2. Alternatively, processing of VirB1 could be the first step of an
accelerated degradation process of the lytic protein in order to maintain the integrity of the
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cell wall. The fact that only full-length VirB1 or VirB1*, but not the N-terminus were detected
in Western blots after expression from the same promoter (C. Höppner and C. Baron,
unpublished data) also hints at a quick degradation of the SLT domain, whereas VirB1* was
stable and thus accumulated inside and outside of the cell.
.
Fig. 6. Features of the sequence of VirB1 orthologs. Predicted signal peptides are in grey and the
active site signature sequence of the orthologs is highlighted (Höppner et al., 2004; modified). The
NORS regions as predicted by NORSp are boxed, and their lenghts are shown on the right.
Sequence analyses of a number of VirB1 orthologs demonstrated special properties
of the C-terminal part. The sequences of VirB1* and also of the C-termini of B. suis VirB1
and pKM101 TraL were classified as NORS-regions (Fig. 6). These are regions of more than
70 AA length that show less than 12% secondary structure elements and an amino acid
composition different from loop regions. It was demonstrated that these very flexible regions
show similar degrees of conservation as other domains in similar proteins, and that they are
more abundant in proteins with functions as regulators or transcription factors than in those
with functions in biosynthesis or energy metabolism-related proteins (Liu et al., 2002). This
implicates important functional roles, most likely for transient protein-protein interactions with
different partners. Only 4% of all procaryotic proteins contain NORS regions, and within the
virB-operon of A. tumefaciens and B. suis, channel component VirB10, which is supposedly
involved in a high number of interactions (Cascales and Christie, 2003), is the only other
protein that possesses such a region.
1.4. Biochemical analysis of B. suis VirB1 interactions
1.4.1. Coproduction of VirB1 and other VirB proteins in bi-cistronic
expression vectors
Recombinant proteins produced in E. coli are often insoluble or improperly folded and
one reason for this is that their natural binding partners are absent. One method to
circumvent this problem of heterologous gene expression is the co-expression of the genes
encoding such proteins together with genes coding for potential interaction partners
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(Lutzmann et al., 2002). If the two proteins subsequently co-purify this constitutes strong
evidence for their interaction.
A)
B)
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Fig. 7 (preceding page). Graphical representation of the mono- and bi-cistronic vector
constructs used in this study. The first bi-cistronic vector based on pT7-StrepII was created by
inserting a virB8 fragment as defined by the primers VirB8-Strep 5’ and VirB8 3’ (Fig. 7A and table 4)
creating T7-StrepII-VirB1/VirB8 (A). Substitution of virB8 with other vir genes utilizing NotI/EcoRI-sites
to remove virB8 and to introduce the other genes via the same sites yielded all of the pT7-based bi-
cistronic constructs. Another lineage of bi-cistron vectors producing VirB1-His was created with
pET21b/pET24d. The depicted mono-cistronic vectors served as negative control in the experiments.
rbs: ribosomal binding site, Trc: Trc promoter, T7: T7 promoter
The potential interactions of VirB1 with other components of the B. suis T4SS were
tested by expression from vectors encoding either N- or C-terminally tagged VirB1 fusion
proteins and their putative interaction partners VirB8, VirB9, VirB10, VirB11 or VirB4. To this
end, a virB8 fragment with a ribosomal binding site was prepared with PstI/HindIII and
inserted into pT7-StrepII-VirB1 cleaved with the same enzymes. The insert was designed to
permit substitution of the virB8 fragment by excising it from the resulting vector pT7-StrepII-
VirB1/VirB8 with NotI/EcoRI and inserting fragments of virB9, virB10, virB11 and virB4 as
defined by the respective oligonucleotide primers (Table 4). Following this procedure, bi-
cistron constructs based on the T7-7 vector and co-expression of N-terminally StrepII-tagged
VirB1 and a putative interaction partner were created (Fig. 7).
In order to co-produce C-terminally His6-tagged VirB1 with putative interaction
partners, a vector based on pET21b/pET24d was modified to permit expression of bi-
cistronic mRNA (as in Lutzmann et al., 2002; vectors created by S. Höppner).  The first orf of
the pET21b-based vector series encodes the putative interaction partner and was created by
cleavage of the vector with NcoI/NotI and insertion of fragments of virB8, virB9 and virB10
treated with the same restriction endonucleases. Subsequently, virB1 was inserted by
cleavage and insertion with NheI/EcoRI, which placed virB1 in frame with the vector
sequence encoding the C-terminal His6-tag.
A series of constructs for the expression of non-tagged proteins was generated to serve as
controls, as these proteins did not bind avidly to affinity columns. Based on the pET21b-
based bicistron vectors, three constructs that served as negative controls were created by
excision of virB1 with SalI/XhoI and religation of the vector. Untagged VirB8, VirB9 or VirB10
were produced upon induction of expression from these vectors. The full-length virB4 gene
was inserted into pT7-7, that had been cleaved with NotI/EcoRI, in order to obtain a vector
for mono-cistronic production of VirB4. Insertion of the full-length virB11 gene into pTrc200
cleaved with BspHI/XbaI created a vector for mono-cistronic production of non-tagged
VirB11.
I decided to work with two different tags since the interactions of VirB1 with other
T4SS components might depend on regions of VirB1 that include either the C- or the N-
terminus. If expression from both vector types and subsequent analysis did not give any
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evidence for an interaction, this was not likely due to interference by the tags. It became
apparent, however, that in most cases low amounts of either C- or N-terminally tagged VirB1
and the co-produced putative interaction partner were retrieved from the affinity column,
which made it necessary to further analyse the interaction by gel filtration. In spite of the two-
step separation procedure, the untagged VirB proteins from both monocistronic and
bicistronic expression were detected in gel filtration eluates. As a consequence, if VirB1 and
the putative interaction partner are found in the same fractions after co-elution from the gel
filtration column, this does not automatically prove interaction. The two proteins might
possess a similar apparent MW that could not be resolved in the Superdex 200 column. In
order to decide between co-elution due to a similar MW and co-elution as an effect of
interaction, the elution of these putative interaction partners after expression from a bi-
cistronic expression vector was compared with the elution after expression from a mono-
cistronic expression vector. If no difference in elution of the untagged protein is observed in
the two cases, it indicates that there is no interaction between VirB1 and the second protein.
Monocistronic expression of the untagged putative interaction partner was therefore carried
out as a negative control in all experiments.
1.4.1.1. Purification of C- and N-terminally affinity-tagged VirB1
Fig. 8. Overproduction and purification of StrepII-VirB1 and VirB1-His6. Different steps of the
overproduction and purification from E. coli cells producing either StrepII-VirB1 (A) or VirB1-His6 (C)
were analyzed by Coomassie staining of SDS gels. Lanes as follows, 1: pre-induction, 2: harvest, 3:
insoluble fraction, 4: soluble fraction, 5: post-affinity chromatography. Samples from affinity
chromatography containing StrepII-VirB1 (B) and VirB1-His6 (D) were applied to a Superdex 200 gel
filtration column. Silverstain (B, D Top) or Western blot analysis (B, D Bottom) was performed to
detect recombinant VirB1.  Fraction numbers are indicated, starting with 1 (at 38 ml elution volume)
and they represent 2 ml fractions each. White arrowheads point to the expected size of monomeric
(M), dimeric (D) and tetrameric (T) protein. A dashed line marks the Superdex 200 void volume at
>600 kDa. Numbers on the left indicate reference proteins for SDS-PAGE. The names of the
respective expression vectors are given on the right. Black arrowheads indicate the elution of gel
filtration reference proteins with their associated MW from the Superdex 200 column.
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StrepII-VirB1 (Fig. 8 A, B): After expression at 27°C, the protein was purified from lysed
E. coli cells by affinity chromatography (Fig. 8 A). Gel filtration using a Superdex 200 column
was performed with the aim to further purify the protein. Analysis by silver staining and
Western blotting detected the major portion of StrepII-VirB1 in the void volume,
corresponding to a MW above 600 kDa. Faint VirB1-specific signals were detected only by
Western blotting in fractions 25, 22 and 16, which correspond to the monomeric, dimeric and
tetrameric form of StrepII-VirB1 (Fig. 8 B).
VirB1-His6 (Fig. 8 C, D): Purification with IMAC did not yield sufficient protein for detection in
a Coomassie-stained polyacrylamide gel (Fig. 8 C). The sample was subjected to gel
filtration and VirB1-His6 was detected in many elution fractions. Similar to the results
described above, a major portion of VirB1-His6 eluted in the void volume of the Superdex 200
column, but VirB1-specific signals were also found in fractions 24, 21 and 18, corresponding
to mono-, di-, and tetrameric assemblies (Fig. 8 D). An additional VirB1-specific signal was
detected in fractions 14 and 15 during the analysis of both N- and C-terminally tagged VirB1
proteins, which corresponds to a 160.5 kDa putative hexamer (Fig. 8 B, D).
The C-terminus of VirB1-His6 appeared to be inaccessible for binding to the affinity
column since only small amounts of this protein were purified by IMAC. Comparison of the
samples from affinity chromatography (Fig. 8 A and C, lanes 5) shows the lower amount of
His6-VirB1 that was retrieved as compared to StrepII-VirB1. In analogy to the process
observed in case of A. tumefaciens VirB1 (Baron et al., 1997), the C-terminus may have
been proteolytically removed after production in E. coli. Since no notable signals indicating
such a processing product were detected (Fig. 8 B, D), cleavage of the C-terminal part is
probably not a good explanation for the low amounts of VirB1-His6. In spite of its presence in
strongly reduced amounts, the Western blot signal of VirB1-His6 (Fig. 8 D) appears stronger
than for StrepII-VirB1 (Fig. 8 B), but this is due to the fact that the chemoluminogramm was
exposed to X-ray film twenty times longer.
Unpublished results from G. Koraimann’s laboratory (Graz, Austria) showed the
association of E. coli chaperone GroEL with the C-terminus of some VirB1 orthologs.  The
possibility that GroEL binds to VirB1 was therefore assessed by Western blot analysis of the
samples eluted from the gel filtration column using VirB1- and GroEL-specific antisera.
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Fig. 9. Elution of B. suis VirB1 and E. coli GroEL. Samples of StrepII-VirB1 purified by affinity
chromatography were separated with a Superdex 200 gel filtration column. SDS-PAGE and Western
blot analysis with VirB1- and GroEL-specific antisera was performed. Fraction numbers are indicated,
starting with 1 (38 ml elution volume) and representing 2 ml fractions. A dashed line marks Superdex
200 void volume at >600 kDa. Numbers on the left indicate reference proteins for SDS-PAGE. Name
of the vector used for expression is given on the right. Black arrowheads indicate elution of reference
proteins and the associated numbers show the MW.
This analysis revealed that GroEL co-eluted from the gel filtration column with StrepII-
VirB1 (Fig. 9). GroEL may bind to VirB1, which would explain the detection of VirB1
predominantly in high MW complexes. GroEL and VirB1 were both detected in fraction 2 and
3, and in addition GroEL was present in fractions 6 to 8, as indicated by the signal appearing
at approximately 60 kDa.
Subsequent experiments aimed at elucidating the influence of other T4SS
components on the molecular mass of VirB1, as determined by co-purification during affinity
chromatography followed by analytical gel filtration. The amounts of VirB1 and its interaction
partners obtained from 1 l of E. coli overproduction cultures did not permit the detection of
the proteins by Coomassie or silver staining, and it was therefore necessary to use specific
antisera. One additional concern during these studies was that small amounts of untagged
VirB proteins also bound to and eluted from the affinity columns. In order to establish
interactions it was therefore necessary to verify the interaction by gel filtration. The results of
the separation co-expressed proteins were compared with the elution of untagged VirB
proteins expressed from mono-cistronic vectors. If they differed from those obtained with co-
expressed proteins, it was taken as evidence for an interaction.
Fig. 10. (next page) Coelution of VirB1 with other T4SS components. Samples containing StrepII-
VirB1 + VirB8 (AI) and VirB1-His6 + VirB8 (AII), StrepII-VirB1 + VirB9 (BI) and VirB1-His6 + VirB9 (BII),
StrepII-VirB1 + VirB10 (CI) and VirB1-His6 + VirB10 (CII), StrepII-VirB1 + VirB11 (D) and StrepII-VirB1
+ VirB4 (E) were separated with a Superdex 200 gel filtration column. Silver staining or Western blot
analyses were performed to detect recombinant VirB proteins. Fraction numbers are indicated, starting
with 1 (38 ml elution volume) and representing 2 ml of elution volume each. White arrowheads point to
the expected size of monomeric (M), dimeric (D) and tetrameric (T) protein. The dashed line marks the
column void volume at >600 kDa. Numbers on the left indicate reference proteins for SDS-PAGE.
Black arrowheads indicate the elution of gel filtration reference proteins with the associated MW from
the Superdex 200 column. Name of the vector used for expression is on the right of each panel; single
virB genes were expressed from mono-cistronic vectors as negative controls (bottom of each panel).
All experiments were performed up to three times and gave similar results.
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1.4.1.2. Analysis of VirB1-VirB8 bicistron products
StrepII-VirB1+VirB8 (Fig. 10 AI): StrepII-VirB1 forms high MW complexes that elute from the
gel filtration column in the void volume. In addition, small amounts of StrepII-VirB1 were
detected in fractions 24, 20 and 16 to 18 corresponding to the mono-, di- and tetrameric
form. Irrespective of the expression of virB8 from mono- or bicistronic vectors, the protein
predominantly eluted in fractions 24 to 28, indicating monomeric protein and co-expression
had no effect on the elution of VirB1. Some VirB8 eluted in the void volume indicating
aggregate formation.
VirB1-His6+VirB8 (Fig. 10 AII): VirB8 eluted as a monomer in fractions 24 to 28, but the
elution of VirB1-His6 differed from that of StrepII-VirB1. The relative amount of high MW
complexes was strongly reduced and the protein eluted in fractions 17 to 21, supposedly the
tetrameric and dimeric form. Co-expression with virB8 had no apparent effect on the elution
of VirB1-His6.
1.4.1.3. Analysis of VirB1-VirB9 bicistron products
StrepII-VirB1+VirB9 (Fig. 10 BI): StrepII-VirB1 eluted as a high MW complex in the void
volume and in fractions 17 and 18, indicating a MW of about 100 kDa. In contrast to other
bicistron expression experiments, the presence of VirB9 in the void fraction could even be
visualized in a silver-stained polyacrylamide gel, indicating relatively high amounts of the
protein. VirB9 was detected predominantly in the void volume, but minor amounts were
detected in fractions corresponding to the monomer, dimer and, like StrepII-VirB1, in fraction
17 and 18. When VirB9 was produced from a mono-cistronic vector, the protein could be
detected by Western blot only in the void volume and in the fraction corresponding to the
monomer.
VirB1-His6+VirB9 (Fig. 10 BII): VirB1-His6 eluted from the column in three different forms.
First, in fractions 6, 7, 8 and 9, representing a high MW complex that had a lower MW than
that of VirB1-His6 when it was expressed from a mono-cistronic vector (Fig. 8). Second, in
fractions 15, 16 and 17, corresponding to a MW of approximately 160 kDa and third, in
fractions number 21, 22 and 23, corresponding to a size intermediate to the dimer and
tetramer. VirB9 eluted in fractions 6 to 9 and 15 to 17 but the largest portion of the protein
was monomeric. In contrast, when VirB9 was expressed from a mono-cistronic vector, it
predominantly eluted in fractions 22 to 25, which corresponds to the supposed monomer.
1.4.1.4. Analysis of VirB1-VirB10 bicistron products
StrepII-VirB1+VirB10 (Fig. 10 CI): StrepII-VirB1 formed high MW complexes that eluted from
the gel filtration column in the void volume, and VirB10 was not detected in these
experiments. VirB10 produced from a mono-cistronic vector eluted in the void volume and in
fractions 16 to 18, indicating a MW intermediate to dimeric and tetrameric VirB10.
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VirB1-His6+VirB10 (Fig. 10 CII): VirB1-His6 eluted in the void volume and in fractions 17, 18
and 19, which corresponds to a MW expected for the VirB1-His6-tetramer. VirB10 produced
in a strain carrying the mono-cistronic vector eluted in the void volume and in fractions 17 to
19, indicating a MW between the dimeric and tetrameric from. The elution of VirB10 co-
expressed with VirB1-His6 and VirB10 produced from mono-cistronic mRNA was
indistinguishable, and therefore gave no indication of an intercation.
1.4.1.5. Analysis of VirB1-VirB11 bicistron products
StrepII-VirB1+VirB11 (Fig. 10 D): StrepII-VirB1 formed high MW complexes that eluted from
the gel filtration column in the void volume and it was also detected in fractions 24, 20, 19, 17
and 16, corresponding to the mono-, di- and tetrameric form. VirB11 was detected in the void
volume and in fractions 12 to 14, corresponding to the hexameric form of the protein (see
chapter 2.2.1). VirB11 produced from a mono-cistronic vector eluted in similar fractions from
the gel filtration column. However, the amount of proteins produced in the cells was reduced
indicating that VirB1 may interact with VirB11 and thereby stabilize it.
1.4.1.6. Analysis of VirB1-VirB4 bicistron products
StrepII-VirB1+VirB4 (Fig. 10 E): StrepII-VirB1 formed high MW complexes that eluted from
the gel filtration column in the void volume, but small amounts of the protein were detected
across all the analyzed fractions. As a B. suis VirB4-specific antiserum was not available, the
protein was visualized in a silver-stained gel in fractions 16 and 17 (monomer) and 13 and 14
(dimer). Co-elution of StrepII-VirB1 and VirB4 was apparent in these fractions. VirB4 was
also expressed from a mono-cistron vector and it may unspecifically attach to the Strep-
Tactin Sepharose affinity column. However, it could not be visualized by silver staining in the
eluates from the subsequent gel filtration column, suggesting that binding of the non-tagged
protein to the column can not account for the results observed after co-expression of StrepII-
VirB1 and VirB4. The co-elution therefore indicates an interaction.
1.4.2. Strep-Tactin® Sepharose® pull-down assay
An alternative way to demonstrate protein-protein interactions is a pull-down assay
that exploits the affinity of the StrepII-tag to the Strep-Tactin Sepharose affinity matrix. The
VirB proteins that were tested for their capacity to bind VirB1 were affinity purified as His6-
tagged thioredoxin-fusions (here: His-Trx-) to achieve high solubility and their co-precipitation
with StrepII-tagged VirB1 bound to the affinity matrix was determined. The results are shown
in Fig. 11.
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Fig. 11. Strep-Tactin Sepharose pull down assay with StrepII-VirB1. StrepII-VirB1 was
preincubated with the Strep-Tactin matrix before addition of the indicated His-Trx-VirB proteins. After
three times washing with S2B, proteins were eluted from the matrix with 1 mM biotin, and analysed by
SDS-Page and subsequent Western blot. Lanes 1 show the negative control where only His-Trx-VirB
was incubated with the matrix, lanes 2 show the pull-down assay. Experiments were repeated five
times and representative results are shown here.
His-Trx-VirB7 and also His-Trx-VirB10 did not co-precipitate with StrepII-VirB1,
showing that they do not interact in this assay. This result also demonstrates that the His6-
thioredoxin per se has no affinity for the matrix utilized here, which is an important negative
control. A very different observation was made in case of His-Trx-VirB8, which bound to the
matrix irrespective of the presence of StrepII-VirB1. Since even extensive washing could not
remove the protein from the Strep-Tactin matrix, it was impossible to use this method to
assess the VirB8-VirB1 interaction. Co-fractionation (=likely interactions) with StrepII-VirB1
were demonstrated in case of His-Trx-VirB9 and His-Trx-VirB11. Observations from the bi-
cistronic expression experiments had already provided some evidence for an interaction
between VirB1 and VirB9 and VirB1 and VirB11 (1.4.1.5), and those were further
substantiated here.
1.4.3. Crosslinking of purified VirB1 to other VirB proteins
The reagent DSS was used to crosslink potentially interacting proteins in solution as
described in chapter 9.2.2 of the Materials and Methods section. The samples were
subsequently separated by SDS-PAGE and subjected to Western blotting.
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Fig. 12. Crosslinking of StrepII-VirB1 with other StrepII-tagged VirB proteins. The panels have a
uniform organization. StrepII-VirB1 alone (left), a mixture of StrepII-VirB1 and the indicated StrepII-
VirB protein (center) or StrepII-VirB protein alone (right) were incubated with concentrations of DSS
ranging from 0 µM to 100 µM. The specific antisera used for detection are shown on the right side of
each panel. Numbers on the left indicate reference proteins. Arrows point to signals that appeared
exclusively after crosslinking of the protein mixture. A box in the panels with the results from the
StrepII-VirB1/StrepII-VirB9 crosslink shows the part of panel that has been magnified in order to show
more detail (below).
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VirB1: Upon treatment of StrepII-VirB1 with increasing concentrations of the
crosslinking reagent, a VirB1-specific signal appeared in the Western blot that corresponds
to a StrepII-VirB1-dimer (Fig. 12, left column, left panel-side). More diffuse signals were
observed at approximately 100 kDa and larger, indicating the formation of StrepII-VirB1
tetramers and of even higher molecular mass oligomeric states. The signal patterns of other
StrepII-VirB proteins on Western blots detected with specific antisera were also altered by
the addition of DSS (Fig. 12, right column, right panel-side). VirB8: VirB8-specific signals
appeared at molecular masses corresponding to the mono-, di-, tri-, and tetramer of the
protein. VirB9: Similarly, StrepII-VirB9 may form monomers, dimers and tetramers in solution
since specific signals corresponding to the respective molecular masses were detected in the
experiment after inclusion of DSS. VirB10: A weak VirB10-crossreactive signal was detected
at approximately 100 kDa after addition of DSS, which may indicate the formation of StrepII-
VirB10 dimers. VirB11: The VirB11-specific signals that appeared on a Western blot
featuring StrepII-VirB11 incubated with DSS confirm the formation of many clearly defined
oligomeric states of the protein, with the hexamer being the signal with the highest MW.
The analysis of crosslinking products formed after incubation of mixtures of the
StrepII-tagged T4SS components in the presence of DSS led in some cases to the
identification of new products identified with both antisera. This was taken as evidence for an
interaction of the co-incubated proteins. (Fig. 12, both columns, center-panel). VirB1/VirB8:
When StrepII-VirB1 and StrepII-VirB8 were incubated together with DSS a new product was
detected both with the VirB1- and VirB8- specific antisera. The MW of this product is 55 kDa,
which matches precisely the sum of the two individual proteins. VirB1/VirB9: Two faint new
signals were observed on a chemoluminogramm analyzing crosslink formation of a mix of
StrepII-VirB1 and StrepII-VirB9 in the presence of DSS. These two distinct signals at 70 kDa
and 140 kDa were detected with VirB1- and VirB9-specific antisera, and they were not
detected when the proteins alone were incubated with DSS. VirB1/VirB10: In contrast to the
other protein combinations, there was no evidence for the formation of unique crosslink
products between StrepII-VirB1 and StrepII-VirB10. VirB1/VirB11: In contrast, a large
number of novel VirB1-specific signals appeared on a Western blot following co-incubation of
a mix of StrepII-VirB1 and StrepII-VirB11 in the presence of DSS. In contrast, VirB11-specific
antisera did not detect all of these products, but signals likely corresponding to crosslink
products were detected at 70 kDa and 97 kDa with both antisera.
It is apparent that StrepII-VirB1 interacts with VirB9 and VirB11, as suggested by the
formation of detectable crosslinked products after addition of DSS. In contrast to the previous
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experiments there is also a clear indication that VirB8 and StrepII-VirB1 interact. Since
different approaches pursued here gave evidence for interactions of VirB1 with VirB9 and
VirB11, and VirB8 may also interact with VirB1, the putative interaction partners were
subjected to peptide array experiments with a VirB1 membrane (Material and Methods, 13.4)
to identify the binding site(s).
1.4.4. Peptide-array analysis of VirB1 interactions
Peptide array experiments were conducted in order to assess the interactions of
VirB1 that were suggested by the experiments outlined above and to narrow down the
binding site on VirB1. Proteins StrepII-VirB8, StrepII-VirB9 and StrepII-VirB11 of B. suis were
assayed for interaction with VirB1 peptides displayed on a membrane, which represents the
entire sequence of the processed form of VirB1. Three identical membranes were used to
analyze parallel experiments, and the membranes retained VirB protein in every case.
Fig. 13. Method of peptide array evaluation. Signals from the Western blot (here: detail from the
VirB1 membrane incubated with VirB9) are categorized by eye, the intensity value (1=weak,
2=intermediate, 3=strong, 4=very strong) corresponds to a certain peptide number and color. By
alignment, a sequence stretch responsible for the observed signal pattern can be identified. In the
case of “RYNLPKY” the most intense signal is categorized as 4 (very strong), so this value and the
corresponding color (red) are assigned to the whole sequence stretch.
 Western blots from five independent experiments, which determined the binding of
an interaction partner to specific peptides, were graphically superimposed to obtain a
representative mean result. The intensity of the signal for each spot was categorized from 1
(weak) to 4 (very strong) by eye. By aligning the sequences of the binding peptides, it was
possible to identify domains of VirB1 that bind the respective VirB protein. When more than
one spot defined an interacting domain in the sequence, the highest value of signal intensity
present was assigned to the entire domain (Fig. 13).
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Fig. 14. Patterns of VirB8-, VirB9- and VirB11-specific signals on the VirB1 peptide array
membranes. The signal patterns for the interactions of VirB8 (A), VirB9 (B) and VirB11 (C) with the
VirB1 membrane represents the results of five independent experiments, which were graphically
superimposed. A color code is used to indicate the intensity of VirB protein binding (= interaction) for
every stretch of the VirB1 sequence. Secondary structure elements and the proposed signal peptide of
VirB1 as predicted by the PhD-algorithm (Rost, 1996) are shown.
The three assessed proteins StrepII-VirB8, StrepII-VirB9 and StrepII-VirB11 bound to
different regions of VirB1 and the binding strengths were different. StrepII-VirB9 bound to the
highest number of VirB1 peptides, but StrepII-VirB8 and StrepII-VirB11 also bond to a
defined set of VirB1 peptides. Since interacting amino acids are often found in external loop
regions, a prediction of the VirB1 secondary structure was done with the PhD algorithm and
the proposed secondary structure is also shown in Fig. 14.
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Weak binding of VirB8 occurred to a region C-terminal of the catalytic E27, which is
predicted to be a loop/β-sheet region. VirB8 strongly interacted with another loop region N-
terminal to the predicted NORS region (Fig. 14 A).
StrepII-VirB9 bound different amino acid stretches throughout the entire sequence of
VirB1. Interactions of intermediate strength occurred with three parts of the VirB1 sequence
that are only three amino acids long. StrepII-VirB9 bound to the first three amino acids
following the predicted signal peptide of VirB1, a loop region C-terminal to a short β-sheet
and N-terminal to the conserved GIAQ motif, which is characteristic to all SLTs. An extended
domain bound with intermediate strenght by StrepII-VirB9 was localized to in the part of
VirB1 classified as NORS region. Strong interactions to the amino acids CYY were observed,
which are predicted to participate in the formation of an α-helix N-terminal to the NORS
region. Very strong binding to a loop region shortly after the GIAQ motif and N-terminal to the
start of the NORS region was detected. In addition, two long amino acid sequence stretches
in the NORS region were strongly recognized by StrepII-VirB9 (Fig. 14 B).
Similar to StrepII-VirB8, StrepII-VirB11 bound only to a limited set of peptides on the
VirB11 array membrane. A weak interaction of StrepII-VirB11 with the VirB1 sequence is
apparent in a loop/β-sheet region C-terminal to the catalytic E27. Strong binding to an α-
helix/loop region and a loop region in the amino acid sequence constituting the second half
of the SLT domain were detected.  A Very strong interaction of StrepII-VirB11 was observed
with a short loop region C-terminal from the GIAQ motif (Fig. 14 C).
The interactions of VirB1 with VirB8, VirB9 and VirB11, which had been suggested by
previous experiments, were further substantiated with this method. Most interacting amino
acids stretches identified here constitute loop or NORS regions, which are especially suited
for establishing transient protein-protein interactions, suggesting that the interaction sites
may be biologically relevant.
1.5. Heterologous expression of the B. suis virB operon in A. tumefaciens
A multitude of studies on the T4SS of A. tumefaciens have provided information about
VirB1. By analyzing the VirB1 ortholog from B. suis in the context of its native T4SS it should
be possible to assess, whether the characteristic properties defined for VirB1 also apply to
the ortholog in B. suis. Since experiments with the biosafety level 3 (BL 3) pathogen B. suis
require specialized resource- and time-consuming safety measures, an alternative approach
to analyze the significance of VirB1 in the B. suis T4SS was pursued here.
 It was demonstrated before that the A. tumefaciens T4SS is not only able to transfer
T-DNA into plant cells but also to effect transfer of non-self transmissible IncQ plasmids into
other A. tumefaciens cells in a VirB-dependent manner (Stahl et al., 1998).  The transfer
efficiency of IncQ plasmids like pLS1 (carbR) was significantly increased when the recipient
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strain displayed a T4SS that probably served as a receptor structure for the donor (Bohne et
al., 1998). This assay permits to assess the requirement of VirB proteins for efficient plasmid
transfer in the recipient or in the donor strain. It was demonstrated that other T4SS like the
ComB system from H. pylori serve as natural competence systems and mediate DNA-uptake
(Hofreuter et al., 2001). The ComB system only consists of orthologs to a subset of the VirB
proteins, similar to A. tumefaciens, in which expression of a subset of the virB operon in the
recipient already enhanced IncQ plasmid uptake (Binns et al., 1998; Liu and Binns, 2003).
According to this, the requirements for the formation of a transfer-promoting receptor
structure seem to be less stringent than for formation of a functional T4SS on the donor side,
as not all VirB proteins are essential for a the T4SS receptor. Recipient strains devoid of
VirB3, VirB4 or one the putative transmembrane channel components (VirB7-VirB10) are
more severely attenuated than other VirB mutants. Expression of various virB operon
subsets demonstrated that expression of virB1-virB5 or virB6-virB11 on the recipient side
results in strains attenuated between 100- and 1000-fold. In contrast to that there is a
stringent requirement for VirB2 through VirB11 on the donor side, and VirB1 mutants are
strongly attenuated. Therefore, functional assembly of the B. suis T4SS was tested on the
recipient side using an InQ plasmid conjugation assay. Functional assembly of the B. suis
T4SS in the A. tumefaciens membrane was tested after expression of the B. suis virB genes
in the recipient strain.
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Fig. 15. Construction of the pTrc300VirBX-B12 vectors. The organization the virB operon in the
created vector family is shown here. Different parts of the virB operon together with their restriction
sites are shown in yellow (virB1), purple (virB2/virB3-virB6) and light blue (virB7-virB12). Arrows show
the operations and the rounded boxes show the molecular biology techniques that were used to obtain
the new constructs. All sites that feature a directed or spontaneous mutation are marked with an X.
(Topo) refers to Topoisomerase-directed insertion of a Taq-generated PCR product into vector
pCR®2.1-TOPO (Topo-Cloning, Invitrogen). pCR®2.1-TOPO-VirB1: virB1 fragment with rbs inserted
into the vector, pCR®2.1-TOPO-VirB1-II: pCR®2.1-TOPO-VirB1 with its SacI site was mutated to NheI
by site directed mutagenesis, pCR®2.1-TOPO-VirB1 E27A: pCR®2.1-TOPO-VirB1 with the catalytic
E27 changed to A by site directed mutagenesis.
Previous experiments indicated that pTrc300VirB2-B12 created by Q. Yuan could
indeed raise the transfer efficiency in a conjugation assay when the vector was present in the
recipient, and it was suspected that VirB1 could further improve this. In the course of the
analysis of the role of VirB1 in the B. suis T4SS, several vectors encoding different subsets
of the virB operon were created. The most promising experiment was to analyze properties
of a vector that expressed virB1 in addition to virB2-virB12, and this vector was constructed
by insertion of a virB1 fragment excised with SacI pCR®2.1-TOPO-VirB1 (Fig. 15, 2) into
pTrc300VirB2-12. Routine sequencing of this vector yielded two unanticipated findings. First,
the original vectors pTrc300VirB2-12 and pTrc300VirB2-6 were found to have a missense
mutation in the start codon of the virB2 gene, which had previously not been noticed
although the virB operon sequence was determined. Tests for virB2 expression in strains
harbouring these vectors showed absence of the protein from cell lysates, but this had been
explained previously with the low amount of VirB2 in the cells or a low sensitivity of the
VirB2-specific antiserum. The vectors pTrc300VirB2-B12 and pTrc300VirB2-B6 were
accordingly renamed to pTrc300VirB3-B6 and pTrc300VirB3-B12. Second, it was found that
during the insertion of virB1 into pTrc300VirB3-B12, a 56 bp fragment had been accidentally
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inserted between virB1 and the mutated virB2 gene. The fragment derived from pCR®2.1-
TOPO-VirB1 was inserted most likely due to an incomplete SacI excision of virB1. The
resulting vector was hence named pTrc300VirB1+B3-B12. To assess whether production of
VirB2 increased the efficiency of pLS1 transfer into the recipient UIA143 the vector
pTrc300VirB2-12 was created by cleavage of the virB2-B6 fragment from a new PCR
amplification with SacI/XbaI and insertion into pTrc300VirB7-B12 linearized with the same
two enzymes. Subsequently pTrc300VirB2-12 was cleaved with SacI and the virB1 fragment
excised from pCR®2.1-TOPO-VirB1 with SacI was inserted, creating pTrc300VirB1-B12 (Fig.
15). Initial tests demonstrated that UIA143 pTrc300VirB1+B3-B12 was a better recipient than
UIA143 pTrc300VirB1-B12. To rule out that the difference between the transfer efficiencies
was related to the “extra” 56 bp fragment inserted after virB1, another vector for expression
of virB1-12 including the extra 56 bp named pTrc300VirB1+B2-B12 was created. To this end,
the virB1 gene encoded on pCR®2.1-TOPO-VirB1 was subjected to site-directed
mutagenesis. The aim was to change the SacI site of pCR®2.1-TOPO-VirB1 that was
accidentally let uncleaved during the creation of pTrc300VirB1+B3-B12 into NheI (creating
pCR®2.1-TOPO-VirB1-II; Fig. 15.3). This permitted controlled SacI-excision and insertion of
virB1+56bp into pTrc300VirB2-B12 and hence creation of pTrc300VirB1+B2-B12 (Fig. 15).
Similar, pCR®2.1-TOPO-VirB1 was subjected to site directed mutagenesis creating
pCR®2.1-TOPO-VirB1E27A  (Fig. 15, 4), encoding virB1 with a mutation of the catalytic E27.
This fragment was subsequently excised from pCR®2.1-TOPO-VirB1E27A with S a cI and
inserted into pTrc300VirB2-B12, creating pTrc300VirB1E27A-B12 (Fig. 15). The newly created
vectors were transferred into UIA143 and their ability to stimulate pLS1 transfer was tested
and compared to that of the original vector pTrc300VirB3-B12 with the mutation in virB2.
1.5.1. Heterologous expression of different subsets of the virB operon
To reproduce the observation that pTrc300VirB3-12 causes an increased transfer
efficiency in a conjugation assay, the experiment was repeated focussing on different
subsets of the virB operon from B. suis. Moreover, it was interesting to learn whether this
effect is also caused by the tra region of pKM101, which encodes a structurally related T4SS.
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Fig. 16. Conjugation assay with recipient strains expressing subsets of either the B. suis virB
operon (A) or the pKM101 tra operon (B). The indicated strains were used as recipients in
conjugation assays to measure the efficiency of pLS1 transfer from donor strain A348 pLS1. The
experiments were conducted either under virulence inducing (+AS) or non-inducing (-AS) conditions.
To test the effect of heterologous gene expression in recipient cells, the experiments were carried out
in the presence or absence of IPTG, which is required to induce expression of pTrc300-encoded
genes. Standard deviation of three independent experiments is shown.
A. tumefaciens conjugation assays with a recipient (UIA143, eryR) expressing subsets
of the B. suis virB genes demonstrated that expression of the virB3-virB12 genes led to a
significant increase of pLS1 uptake, whereas expression of virB3-virB6 or virB7-virB12 did
not elevate transfer efficiency as compared to the negative controls UIA143 and UIA143
pTrc300 (Fig. 16 A). Similarly, expression of the tra region from IncN-plasmid pKM101 did
not impact pLS1 uptake efficiency (Fig. 16 B). After the confirmation of previous results with
pTrc300VirB3-B12, the other strains expressing subsets of the virB operon were analyzed in
conjugation assays.
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Fig. 17. Conjugation assay with recipients expressing the virB operon +/- the virB1- and/or
virB2 gene. The indicated A. tumefaciens strains were used as recipient in a conjugation assay
measuring the efficiency of pLS1 transfer by donor strain A348 pLS1 under virulence-inducing (+AS)
conditions and in the presence of IPTG. Transfer efficiency (transconjugand per recipient; TC/R) into
induced UIA143pTi (WT) was set to 100 %. Standard deviation of three independent experiments is
shown.
Transfer of pLS1 into the recipient strain bearing pTrc300VirB1+B3-B12 had the
highest efficiency of almost 50% of the level of acetosyringone-induced A. tumefaciens wild
type, whereas transfer into UIA143 pTrc300VirB3-B12 had 10% efficiency as compared to
the wild type (Fig. 17). Transfer of pLS1 into recipients carrying pTrc300VirB1-B12 and
pTrc300VirB2-B12 was not detected. To rule out that the difference between the transfer
efficiencies into UIA143 carrying pTrc300VirB1+B3-B12 and pTrc300VirB1-B12 was related
to the “extra” 56 bp fragment inserted after virB1, another vector for expression of virB1-B12
including the “extra“ 56 bp named pTrc300VirB1+B2-B12 was created as described (Fig. 15).
However, pLS1 transfer into UIA143 pTrc300VirB1+B2-B12 was not detected showing that
the presence of an intact virB2 gene had a strong negative effect on the transfer (Fig. 17). To
study the molecular basis for these surprising findings, we next studies VirB protein levels in
UIA143 carrying the different constructs.
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Fig. 18. VirB protein levels in pTrc300VirBX-B12-bearing strains. Production of virulence proteins
in A. tumefaciens strain UIA143 harbouring pTrc300-constructs was monitored after culture of the
indicated strains under virulence-inducing (+AS) conditions as described (Baron et al., 1997). IPTG
was added to induce gene expression from the trc promotor. Cell lysates were subjected to SDS-
PAGE, followed by Western blot analysis with B. suis VirB-specific antisera. The experiments were
performed twice with consistent results. The black arrowheads point to the VirB-specific signals and
numbers on the left indicate reference proteins.
VirB-specific antisera were used to analyze the VirB protein levels of UIA143 cells
harbouring pTrc300, pTrc300VirB3-B12, pTrc300VirB1+B3-B12, pTrc300VirB2-B12,
pTrc300VirB1-B12 and pTrc300VirB1+B2-B12. These strains were cultivated for 16 h at
20°C (see Materials and Methods 6.2), harvested, lysed and the cell lysates were seperated
with polyacrylamide gels.  Western blot analysis demonstrated that the cellular levels of
many VirB proteins differed significantly between the different strains, depending on the
organization of the virB operon (Fig. 18). The VirB1 levels in strains UIA143 pTrc300VirB1-
B12 and UIA143 pTrc300VirB1+B2-B12 were drastically reduced as compared to UIA143
pTrc300VirB1+B3-B12. This obervation was unanticipated since the sequences of
pTrc300VirB1+B3-B12 and pTrc300VirB1+B2-B12 only differ by one nucleotide in the virB2
start codon. Similar observations were made in case of other VirB-proteins. The VirB2 level
in UIA143 pTrc300VirB2-B12 was higher than in UIA143 carrying pTrc300VirB1-B12 or in
UIA143 pTrc300VirB1+B2-B12. The VirB8 and VirB10 levels in UIA143 expressing virB3-
virB12, virB1+B3-virB12 or virB2-virB12 were higher than in UIA143 carrying pTrc300VirB1-
B12 or UIA143 pTrc300VirB1+B2-B12. Thus, the expression of the virB1 gene negatively
impacted VirB2 protein levels and expression of virB2 reduced the amount of detectable
VirB1. Whereas the expression of virB1 did not have an apparent impact on the steady state
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level of other T4SS components, the simultaneous expression of virB1 and virB2 had a
negative effect on the steady state levels of VirB8, VirB10 and VirB11. Finally, virB2 alone
exerted no negative influence on the steady state levels of other VirB-proteins, and only the
level of VirB10 was slightly reduced in UIA143 carrying pTrc300VirB2-B12 as compared to
UIA143 carrying pTrc300VirB3-B12. Since differences in the vector sequences are very
minor, it is presently not clear what leads to the substantial differences in the accumulation of
different VirB proteins.
Western blot analysis with VirB1-specific antiserum revealed another interesting
detail. In addition to VirB1 (27 KDa) cell lysates from UIA143 pTrc300VirB1+B3-B12 featured
another cross-reactive protein at 20 KDa. This putative cleavage or degradation product of
VirB1 may also have been present in the other virB1-expressing strains but was not detected
due to the lower level of VirB1 protein. VirB1 may therefore undergo cleavage similar to its
ortholog from A. tumefaciens.
Taken together, These results suggest that VirB2 exerted a negative influence both
on transfer efficiency, as determined by conjugation assays and, together with VirB1, on the
levels of VirB proteins inside A. tumefaciens cells. Production of VirB1 in UIA143
pTrc300VirB1+B3-B12 apparently was an important factor for functional assembly of the
heterologously expressed T4SS, as it strongly increased plasmid transfer into the recipient
as compared to UIA143 pTrc300VirB3-B12
1.5.2. Heterologous expression of the virB operon encoding a VirB1 protein
variant
Since it is known that introduction of a non-polar virB1  deletion into the
A. tumefaciens virB operon causes a drastic reduction of the incorporation of the major pilus-
component VirB2 into T-pili, it is reasonable to assume that a likewise effect might be
observed for the B. suis virB operon. In order to analyze the importance of VirB1 and of its
active site for the incorporation of VirB2 and VirB5 into exocellular high molecular mass
structures, a mutation was introduced into the virB1 gene by site-directed mutagenesis,
changing the putative catalytic E residue into A (VirB1E27A). The levels of VirB proteins in cell
lysates and in fractions of exocellular high molecular mass appendages were determined for
strain UIA143 pTrc300, UIA143 pTrc300VirB2-B12, UIA143 pTrc300VirB1-B12 and UIA143
pTrc300VirB1E27A-B12 after 24 h incubation under virB-inducing conditions. Exocellular high
molecular weight structures were removed from the cell by shearing and ultracentrifugation
as described previously and analyzed by SDS-PAGE and a subsequent Western blot
(Schmidt-Eisenlohr et al., 1999b).
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Fig. 19. Levels of VirB proteins in cells and exocellular high molecular weight structures from
UIA143 carrying pTrc300VirB2-B12, pTrc300VirB1-B12 and pTrc300VirB1E27A-B12. Production of
VirB proteins was monitored after cultivation under virulence-inducing (+AS) conditions (Baron et al.,
1997) and IPTG was added to effect gene expression from the trc promotor. Cell lysates (A) and
exocellular high MW appendages (B) were subjected to SDS-PAGE, followed by Western blotting with
B. suis VirB-specific antisera. Experiments were performed twice with consistent results. The black
arrowheads point to the VirB-specific signals and numbers on the left indicate reference proteins.
Whereas the levels of VirB proteins in cell lysates did not differ between strains
expressing the full virB operons with or without the active-site mutation (VirB1 and VirB1E27A),
the level of some VirB proteins in cell lysates was significantly higher in UIA143
pTrc300VirB2-B12, (see also 1.5.1). No VirB protein was detected in lysates from the
negative control strain UIA143 pTrc300 (Fig. 19 A). Western blot analysis confirmed that the
amount of the putative minor pilus component VirB5 found in fractions of exocellular
appendages was comparable between strains carrying either pTrc300VirB2-B12 or
pTrc300VirB1-B12. Interestingly, no VirB5-specific signal was detected in the sample from
strain UIA143 pTrc300VirB1E27A-B12, indicating the absence of a virB gene-determined pilus-
like structure (Fig. 19 B). This result suggests that the active site of VirB1 contributes to the
functionality of the B. suis T4SS in A. tumefaciens. The putative major pilus component VirB2
was never detected in fractions of exocellular appendages, confirming the observations
made in a more detailed analysis of this particular topic (Carle, 2004).
1.6. Genetic analysis of A. tumefaciens VirB1
1.6.1. Heterologous complementation of the virB1 deletion mutant PC1001
VirB1 orthologs in T4SS share limited sequence similarity and were identified due to
their conserved localization in the virB-like operons and their active site signatures. To test
the hypothesis that these proteins are interchangeable between different T4SS, a selection
of VirB1 orthologs was used (VirB1 from A. tumefaciens C58, VirB1s from B. suis, TraL from
the IncN plasmid pKM101, the protein encoded by the F-plasmid orf169 gene (F169) and
HP0523 from H. pylori). A schematic representation of these proteins and their active site
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signatures is shown in Fig. 6.  The sequence identity to A. tumefaciens C58 VirB1 is 27% for
B. suis VirB1s, 31% for TraL, 19% for H. pylori HP0523 and only 17% for the F169 protein.
The genes were PCR-amplified with specific oligonucleotide primers (Table 4), the
overhanging ends were cleaved with NcoI/ScaI and cloned into similarly restricted broad host
range expression vector pTrc200. In addition to these constructs, the regions in the genes
encoding the conserved G residues from the active sites of A. tumefaciens VirB1, B. suis
VirB1 and TraL were changed to A with the aim to distinguish between enzymatic functions
and other tasks that VirB1 orthologs fulfill in T4SS. This required subcloning of the respective
genes into pT7-7, since the site-directed mutagenesis system (Promega) requires presence
of a β-lactamase resistance gene.
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Fig. 20. Cleavage of the active site mutation and complementation of T-pilus formation by
strain PC1001 expressing virB1 orthologs. Processing of VirB1 (A) and secretion of VirB1* (B) was
monitored by culturing the indicated strains under virulence inducing (+AS) or non-inducing (-AS)
conditions as described (Baron et al., 1997). IPTG was added to effect gene expression from the trc
promotor. Cell lysates (A) and precipitated supernatant (B) were subjected to SDS-PAGE.
Subsequently, a Western bloting and detection with C58 VirB1-specific antiserum was done.
Exocellular high-molecular mass T-pilus fractions (C) and cell lysates (D) were separated by SDS-
PAGE followed by Western blotting with VirB2 and VirB8-specific antisera. Experiments were
performed three times, the arrows point to signals of VirB2 in exocellular fractions that were detected
in at least two out of three experiments. Numbers on the left indicate reference proteins.
The plasmids were transformed into A. tumefaciens A348 virB1 deletion strain
PC1001, followed by growth under virulence gene-inducing conditions and analysis of VirB
protein content in subcellular fractions (cell lysate, supernatant and pilus fraction). Whereas
in the induced wildtype A348 the VirB1 cleavage product VirB1* was neither detected in the
cell lysate nor in the supernatant fraction, it was clearly visible in PC1001 producing VirB1
and VirB1E->A.(Fig. 20 A, B). This can likely be explained by the specificity of the antisera for
strain C58 VirB1. Processing of VirB1 and export of VirB1* into the extra-cellular space was
not affected by the active site mutation since equal levels of full length VirB1 in cell lysates
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(Fig. 20 A), and secreted VirB1* (Fig. 20 B) were detected in samples from PC1001 carrying
either pTrcB1 or pTrcB1E->A.
 VirB1 is known to be required for pilus formation in A348 (Schmidt-
Eisenlohr et al., 1999b), which emphasizes its necessity for T4SS assembly. To test for
complementation, the A348 WT and PC1001 carrying pTrc200 with or without VirB1
ortholog-encoding genes were grown on AB plates under virulence gene inducing conditions,
followed by subcellular fractionation (cell lysate and pilus fraction) and analysis of VirB8 and
VirB2 content with specific antisera.
Cellular VirB2 and VirB8 protein levels of the analyzed strains grown under virulence-
inducing conditions were similar. The presence or absence of VirB1 did not affect the cellular
accumulation of T-pilus component VirB2 or T4SS core component VirB8 (Fig. 20 D).
Surface-exposed high molecular mass structures were removed from the cell by shearing
and ultracentrifugation as described (Schmidt-Eisenlohr et al., 1999b). No significant
amounts of VirB2 could be detected in exocellular fractions of PC1001, but T-pilus formation
was restored to near wildtype levels by introduction of pTrcB1 and pTrcB1s. A weak
restoration of extracellular VirB2 levels was observed in PC1001 pTrcTraL only in two of
three experiments, but pTrcF169 and pTrcHP0523 repeatedly failed to complement pilus
formation. The active site variants of VirB1, VirB1s and TraL did not complement T-pilus
formation, proving the requirement of the active site E residue (Fig. 20 C).
Fig. 21. Complementation of pLS1 donor activity of strain PC1001. The indicated strains were
used in a conjugation assay to measure the efficiency of pLS1 transfer. The experiment was done
either under virulence inducing (+AS) or non-inducing (-AS) conditions. Bars indicate transfer
efficiency (in % of induced A348pLS1). To test the effect of VirB1 ortholog production the experiments
were carried out in the presence (grey bars) or absence (dark grey bars) of IPTG. Standard deviation
of three independent experiments is shown (black lines).
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Since pilus isolation efficacy is inherently difficult to quantify and would probably not
permit the detection of a very low degree of complementation, conjugation assays were
conducted in order to analyze the transfer capabilities pf pLS1-carrying strains. IncQ plasmid
pLS1 can be transferred to recipient A. tumefaciens cells in a VirBdependent manner, relying
on the recognition of relaxosome complexes by the A. tumefaciens T4SS (Stahl et al., 1998).
Since this plasmid confers carbenicillin-resistance, the transfer efficiency can be easily
quantified. Plasmid pLS1 was introduced in A348 and PC1001 harbouring pTrc200 with or
without genes encoding virB1 orthologous proteins. After incubation of these strains with
UIA143 pTiA6, the transfer efficiency was quantified by assessing the number of output
donor (D) and transconjugands (TC) on selective media. As expected from previous
observations (Bohne et al., 1998), the transfer efficiency of PC1001 was only 10% of the WT
value. The introduction of pTrcB1 almost completely restored transfer, pTrcB1s bearing
donor obtained transfer efficiency of 50% and a small increase could also be assigned to the
presence of pTrcTraL. Interestingly, pTrcB1E->A also conferred the ability to modestly raise
the transfer efficiency of PC1001 to almost 20% of the WT. The other donor strains were
unable to transfer pLS1 to recipient cells (Fig. 21).
When the experiment was conducted without addition of IPTG to the conjugation
assay, similar but reduced effects of the different constructs were observed, showing that the
trc promotor determined a significant level of expression even under non-inducing conditions
(Fig. 21). This observation was confirmed by Western blot analysis of trc-controlled proteins,
showing that low levels were produced even in the absence of IPTG (not shown).
An additional set of experiments was carried by Dr. A. Binns and Dr. Z. Liu from the
University of Pennsylvania (Philadelphia, USA) in the context of this collaborative work. The
effects of VirB1-orthologs on the complementation of tumor formation by A. tumefaciens
PC1001 on N. tabacum leaf discs and transfer efficiency upon expression of virB1 genes on
the recipient side of conjugation experiments yielded results, which were consistent with our
findings and therefore supported the findings presented here (Höppner et al., 2004). VirB1
orthologs that have a C-terminal NORS region like VirB1s and TraL are therefore able to
complement VirB1, whereas “short” VirB1 orthologs like HP0523 and F169 are unable to do
so. The fact that VirB1E->A has residual complementing ability suggests two different
contributions of VirB1 to virulence.
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1.6.2. Mutational analysis of the VirB1 processing-site
The importance of the C-terminal domain-like region of VirB1 for its biological activity
has been stressed before (Llosa et al., 1998; Baron et al., 1998). However, it is still unknown
what importance correct and efficient cleavage of VirB1 and subsequent secretion of VirB1*
has for the T4SS.
Fig. 22. The VirB1 cleavage site sequence. The following AA-substitutions and deletions
surrounding the cleavage site (arrow) of VirB1* were created by site-directed mutagenesis 1:
VirB1ΔAA172 2: VirB1 A172D 3: VirB1 Q174E    4: VirB1 Q175E 5: VirB1Q174E/Q175E 6: VirB1
A173P 7: VirB1 E170P/T171W
To shed light on this particular question, directed mutations were introduced in the
region encoding the vicinity of the A. tumefaciens C58 VirB1 cleavage site (Fig. 22). By
introduction of amino acid substitutions and deletions (deletion of A172 and A173;
substitution of A172 with D; substitution of Q174, Q175 or both residues with E; substitution
of A173 with P; substitution of E170 with P and T171 with W) it was attempted to affect
cleavage of VirB1. In order to do that, the virB1 gene from pTrcB1 was subcloned into pT7-7
and a site-directed mutagenesis system (Promega) was used according to manufacturer’s
protocol, utilizing the site-directed mutagenesis primers listed in Table 5. After confirmation of
the correct sequence, mutagenized virB1 fragments were re-inserted into pTrc200 with
NcoI/ScaI and the vector-based production and processing of VirB1 and the secretion of
VirB1* in A. tumefaciens strain PC1001 was analyzed by cultivation of the cells under
virulence gene-inducing conditions and subsequent analysis of VirB protein content in
subcellular fractions (cell lysate, supernatant and pilus fraction).
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Fig. 23. Effects of cleavage site alterations on VirB1 processing, VirB1* export and assembly of
the pilus. The production and processing of VirB1 and secretion of VirB1* were monitored by
cultivation of the indicated strains under virulence-inducing conditions in the presence of IPTG. Cell
lysates (A) and precipitated supernatant (B) were subjected to SDS-PAGE. Subsequently Western
blotting with C58 VirB1-specific antiserum was performed. Exocellular high-molecular mass T-pilus
fractions (C) and cell lysates (D) were separated by SDS-PAGE followed by Western blotting with
VirB2-, VirB8-, VirB9- and VirB10-specific antisera. The white arrowhead points to the signal of VirB2
in the exocellular fraction of PC1001pTrcB1A->D. Numbers on the left indicate reference proteins.
Experiments were repeated five times with consistent results.
Some of the virB1-mutants were affected in VirB1 processing and VirB1* secretion.
Although the cellular levels of VirB1 did not notably differ between all the analysed strains,
changes affecting the amount and MW of VirB1* in cell lysates (Fig. 23 A) and culture
supernatants (Fig. 23 B) were observed. While the VirB1 proteins carrying mutations of Q174
or Q175 (Fig. 23 A, B; lane 3,4) were processed similar to the WT, the changes affecting the
A172 or A173 (Fig. 23 A, B; lane 1,2,6) had different phenotypes. Processing products of
VirB1ΔAA and VirB1A->D were detectable in the cell lysate, though the latter only at a reduced
level. More strikingly, there was no signal indicating the presence of VirB1* of WT MW in
culture supernatants of PC1001 producing these two variants. Instead, the molecular masses
of signals indicate the generation of one or more aberrant VirB1 processing products. VirB1A-
>P was not processed to a product different from VirB1*, and high amounts of it were detected
in the cell lysate (Fig. 23 A; lane 6), while aberrant signals were detected in culture
supernatants (Fig. 23 B; lane 6). The absence of VirB1* from cell supernatants was also
observed in PC1001 producing VirB1Q1->E/Q2->E although its cellular level was normal.
VirB1E->P/T->W was processed to yield aberrantly sized VirB1*, and relatively large amounts
much of this cleavage product were detected in the supernatant (Fig. 23 A, B; lane 7).
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Exocellular high MW T-pilus fractions were isolated to analyze effects of the VirB1
protein variants on T-pilus formation. While cellular accumulation of T4SS components VirB2
and VirB8 was equal in PC1001 producing either VirB1 or VirB1 variants (Fig. 23 D), the
level of VirB2 in the pilus fractions from strain PC1001 pTrcB1ΔAA and PC1001 pTrcB1A->D
was notably reduced (Fig. 23 C).
It is apparent that some of the amino acid substitutions inserted into the vicinity of the
VirB1 cleavage site had effects on the processing of VirB1, and a modest effect on T-pilus
formation was observed in two cases. This leads to the question if aberrant cleavage of
VirB1 is associated with a reduction of T4SS function. To assess whether non-wildtype-like
processing and secretion of VirB1 has an effect on the plasmid donor efficiency, conjugation
assays were performed. After incubation of PC1001 pLS1 (carbR) expressing virB1 and its
mutants with the recipient strain UIA143 pTiA6 (eryR), the transfer efficiency was quantified
on selective media.
Fig. 24. Complementation of pLS1 donor activity of strain PC1001 with cleavage site variants of
VirB1. The indicated strains carrying pTrc200 expressing virB1 active site variant constructs were
used in a conjugation assay to measure the efficiency of pLS1 transfer. The experiment was
conducted under virulence inducing (+AS) conditions and in the presence of IPTG. Grey bars indicate
transfer efficiency (in % of PC1001 pTrcB1) and the standard deviation of four independent
experiments is shown for each value (black lines).
The pLS1 transfer efficiency of strains PC1001 pTrcB1A->D and PC1001 pTrcB1Q1->E/Q2->E
moderately differed from the WT (Fig. 24). Dr. A. Binns and G. Nair from the University of
Pennsylvania (Philadelphia, USA) performed a different functional assay of these two strains,
determining tumor formation on N. tabacum leaf discs. The reduced efficiency of
PC1001pTrcB1A->D was confirmed, but PC1001pTrcB1Q1->E/Q2->E was indistinguishable from
Results
73
the WT. To reveal possible differences in the production, processing and accumulation of
VirB1* in cell lysates, time-course studies were conducted next.
After 6-8 hours of pre-incubation in AB medium, virulence protein production in the
strains A348, PC1001 pTrc200, PC1001 pTrcB1 and PC1001 pTrcB1A->D was induced with
AS and IPTG. Samples were taken at 1, 3, 5 and 20 h in order to observe the production and
processing of VirB1 in cell lysates by Western blot analysis.
Fig. 25. Time course of VirB1 production and processing in A. tumefaciens strains under
virulence-inducing conditions. White arrowheads point to VirB1-specific signals that only appear in
the Western blot with samples from PC1001pTrcVirB1A->D. Black arrowheads point to signals of VirB1
and VirB1*. Numbers on the left indicate reference proteins.
In A348 only weak signals of its native VirB1 and no VirB1* were detected after 20 h
of induction. This is likely due to the VirB1-specific antiserum used in these studies, which
had beenraised against VirB1 of A. tumefaciens C58 (Höppner et al., 2004). As expected,
the Western blot with samples from PC1001 pTrc200 was devoid of inducible VirB1-specific
signals. Strong VirB1-specific signals were detected in PC1001 expressing virB1 or virB1A->D
before induction with IPTG and the protein levels increased after addition of IPTG. Analysis
of the lower molecular mass processing products showed that in contrast to PC1001 pTrcB1
additional VirB1-specific signals were detected after induction of strain PC1001 pTrcB1A->D.
These signals appeared 1 h post-induction and their number and intensity increased, and a
ladder of decreasing molecular masses was apparent. After 20 h, however, the VirB1-
specific signals in cell lysates of PC1001 pTrcB1A->D were almost indistinguishable from
those in PC1001 pTrc200VirB1 (Fig. 25).
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Taken together, mutants of the VirB1 cleavage site were created and cellular processing of
the mutant proteins differed from the WT-protein in some cases. The cleavage site variation
of VirB1A->D obviously affected the kinetics and specificity of VirB1 processing and it was
secreted with reduced efficiency, but a VirB1*-like product was still formed in PC1001
pTrcB1A->D.
1.6.3. Effect of the heterologous production of an HP0523-VirB1*-hybrid in
PC1001.
Heterologous complementation of a virB1 mutant either with different VirB1 orthologs
or mutant VirB1 protein showed that the VirB1 C-terminus fulfills an important though not
essential function for the A. tumefaciens T4SS. Some VirB1-orthologs such as F169 and
HP0523 could not complement the lack of VirB1. This might be an effect of a missing C-
terminal appendage (NORS region), since all orthologs that functionally complemented the
virB1 defect possessed this characteristic region. The following experiment was conducted
with the aim to obtain direct evidence for the role of HP0523 as a lytic transglycosylase and
to shed light on the importance of the VirB1 C-terminus. A number of hybrid proteins
consisting of parts of HP0523 and VirB1 were created and tested for processing and their
ability to complement pLS1 transfer and pilus formation in PC1001.
Fig. 26. Domain organization of hybrid VirB1 protein used for complementation of PC1001. The
predicted signal peptide of A. tumefaciens VirB1 is in hatched grey, of that of HP0523 in grey. The
active site signature sequences of the two orthologous SLT domains (Bayer et al., 1995) are
highlighted in red. The hatched box indicates VirB1*. Genes encoding all these protein variants were
inserted into pTrc200.
 pTrc200 constructs expressing genes for VirB1, VirB1* and HP0523 were already
available from previous studies, and vectors producing hybrid proteins HP0523-VirB1* and
SP-HP0523-VirB1* were created next. To this end, hp0523 and virB1* fragments were
produced by PCR amplification from H. pylori genomic DNA and pGK217 (Material and
Methods, 2) using specific primers (Tab. 4).   The ends of the hp0523 fragment were cleaved
with EcoRI and NcoI, of those of virB1* with NcoI and Acc65I. The processed fragments
were mixed in a ratio 1:1 and added in excess to pTrc200 cleaved with EcoRI and Acc65I
and then ligated to create pTrcHP0523-B1*. As the predicted signal peptide of HP0523 did
not correspond to the consensus sequence, it was a possibility that the A. tumefaciens
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protein export machinery may not recognize it. To ensure proper subcellular localization of
the hybrid protein, a vector for production of the HP0523-B1* fusion protein with the VirB1 SP
was created next. pTrcHP0523-B1* was used to create pTrcSP-HP0523-B1* by insertion of
the fragment encoding the virB1 signal peptide (annealed oligos SPVirB1-5’ and SPVirB1-3’,
Tab. 4) into the EcoRI site. Vectors producing the VirB1 constructs listed in Fig. 26 were
transformed into A. tumefaciens A348 virB1 deletion strain PC1001, followed by growth
under virulence gene-inducing conditions and analysis of VirB protein content in subcellular
fractions (cell lysate and pilus fraction).
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Fig. 27.  Production and processing of HP0523-VirB1*-hybrid protein with and without the VirB1
signal peptide and the effect on pilus production. Processing of VirB1 or HP0523-VirB1*-hybrid
protein and secretion of VirB1* was monitored by culture of the indicated strains under virulence
inducing (+AS) or non-inducing (-AS) conditions as described (Baron et al., 1997). IPTG was added to
effect gene expression from the trc promotor. Cell lysates were subjected to SDS-PAGE and Western
blotting, followed by detection with VirB1-specific antiserum (A). White arrowheads point to the VirB1-
specific signal, framed white arrowheads point to signals of the HP0523-VirB1 hybrid protein, black
arrowhead indicates VIrB1*. To analyse the complementation of T-pilus formation, the WT strain A348
and PC1001 (ΔvirB1) carrying the indicated constructs were cultured under virulence-inducing or non-
inducing conditions with IPTG. Exocellular high-molecular mass T-pilus fractions (B) were separated
by SDS-PAGE followed by Western blotting with VirB2-, VirB5- and VirB8-specific antisera.
Experiments were performed twice and gave consistant results.  The arrowheads point to signals of
VirB2, VirB5 and VirB8 detected in exocellular fractions. Numbers on the left indicate reference
proteins.
VirB1 and VirB1* were heterologously produced in PC1001 and processing of the
proteins yielded VirB1*, which was detected in a Western blot with VirB1-specific antiserum.
No signal was detected in the lane with a sample from strain PC1001 producing HP0523,
and a specific antiserum was not available. A signal at the expected MW of 27 kDa was
detected in the lane with samples from PC1001 producing HP0523-VirB1* and was even
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stronger when SP-HP0523-VirB1* was produced. The signals were probably due to the
recognition of the VirB1* C-terminus by the A. tumefaciens VirB1-specific antiserum.
Interestingly, no processing of the hybrid-protein without the VirB1 signal peptide was
observed, but a low amount of VirB1* was detected in cells producing SP-HP0523-VirB1*.
This indicates that VirB1* is produced in dependence of a functional signal
peptide (Fig. 27 A).
Surface-exposed high molecular mass structures were isolated from the cell by
shearing and subsequent ultracentrifugation as described (Schmidtt-Eisenlohr et al., 1999b).
No significant amounts of VirB2 pilin were detected in exocellular fractions of PC1001 but T-
pilus formation was restored to near-wildtype levels by the introduction of pTrcB1. pTrcB1*,
pTrcHP0523 and pTrcHP0523-B1* failed to complement pilus formation. However,
heterologous production of the hybrid protein SP-HP0523-VirB1* resulted in partial
complementation of T-pilus formation as monitored by the detection of VirB2 in exocelluar
high molecular mass fractions. The minor pilus component VirB5 was only detected in
samples from induced A348 WT, PC1001 expressing virB1 and PC1001 pTrcSP-HP0523-
B1* (Fig. 27 B). These results lead to the conclusion that HP0523 can functionally substitute
for the SLT domain of VirB1, but the observation that trace amounts of VirB8 were repeatedly
detected in the exocellular high MW fractions from PC1001 pTrcSP-HP0523-B1* contests
this notion. Since VirB8 was only detected in excellular high molecular mass fractions from
this strain, the effect may be due to a toxic effect of the H. pylori VirB1 ortholog on PC1001,
which led to limited cell lysis.
To quantify the complementation of plasmids producing HP0523 fusions, conjugation
assays with donor strain PC1001 pLS1 (carbR) carrying the constructs pTrc200, pTrcB1,
pTrcB1*, pTrcHP0523, pTrcHP0523-B1* and pTrcSP-HP0523-B1* and the recipient strain
UIA143pTiA6 (eryR) were performed as described in 1.5 and 1.6.1.
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Fig. 28. Complementation of pLS1 donor activity of strain PC1001 expressing different parts of
virB1 and hp0523. The indicated strains carrying pTrc200 and virB1-hp0523-hybrid constructs were
used in conjugation assays to measure the efficiency of pLS1 transfer. Bars indicate transfer efficiency
(in % of induced A348pLS1).  The experiment was done under virulence-inducing (+AS) conditions
and in the presence of IPTG. Standard deviation of three independent experiments is shown.
Expression of virB1 in PC1001 restored pLS1 transfer efficiency to WT-level. I n
contrast, neither production of VirB1* nor that of any of the HP0523-hybrid proteins led to an
increase of pLS1 transfer beyond background levels (Fig. 28). This result is in contrast to
observations from the analysis of T-pilus formation, where the hybrid protein SP-HP0523-
VirB1* partially complemented pilus formation. Production of SP-HP0523-B1* in PC1001 led
to detection of VirB2 protein in the exocellular fraction but complementation of IncQ transfer
was not observed. Moreover, PC1001 pTrcSP-HP0523-VirB1* was unable to incite tumor
formation on leaves of K. daigremontiana (not shown). The complementation of pLS1
transfer by SP-HP0523-VirB1* may be too low to be detected in the conjugation assay.
Alternatively, the production of the hybrid protein may complement certain functions of VirB1,
creating a phenotype where pilus biogenesis and T-DNA/IncQ transfer ability are uncoupled.
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2. In silico, in vitro and in vivo analysis of T4SS traffic-(d)NTPase
orthologs
Orthologs of the traffic-(d)NTPase VirB11 are essential components of T4SS in a
number of different proteobacteria. They not only are an interesting subject for functional
studies but also potential targets for anti-infective drugs, that might affect cessation of
(d)NTP hydrolysis. We tried to assess general properties of some VirB11 orthologs with in
silico, in vitro and in vivo methods. This task was supported by the use of a compound with a
specific inhibitory effect on HP0525, the VirB11 ortholog from H. pylori. While an in silco
analysis helps to discover conserved features of this enzyme family, in vitro assays were
necessary to determine enzyme properties and the effect of inhibitors. Finallly, in vivo assays
were conducted in order to analyze whether inhibition of VirB11 is reflected by a decreased
efficiency of T4SS functions.
2.1. Sequence conservation among the studied VirB11 orthologs
The VirB11 ATPases are a subclass of the VirB11-PulE family of (d)NTPases, which
are required for the functionality of T4SS and T2SS. These (d)NTPases are indispensable for
substrate secretion and assembly of the secretion system, and several amino acids are
conserved, most of them involved in enzymatic activity. To further dissect common features
of some representative members of this protein family, the full-length sequence of protein
TrwD from IncW-plasmid pR388, TraG from IncN-plasmid pKM101, VirB11 of A .
tumefaciens, VirB11 of B. suis and HP0525 from H. pylori, were subjected to a multiple
sequence alignment using the ClustalW server.
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Fig. 29. Sequence conservation of the VirB11 orthologs. A sequence alignment of B. suis VirB11,
pKM101 TraG, pR388 TrwD, VirB11 from A. tumefaciens C58 and H. pylori HP0525 was calculated
with the ClustalW-algorithm. Labels as follows: (*) identical AA in all five sequences, (:) marks a high
and (.) a lower degree of AA conservation at the respective aligned position. Protein names are given
on the left side, last AA-position in the respectiive line on the right side. Red boxes indicate all AAs
involved in the active site pocket and catalytic activity in HP0525 (Savvides et al., 2003); shaded box
indicates the linker region between the N- and C-terminus; A: Walker A nucleotide binding motif.
The analysis aligns amino acid residues that are implied in the catalytic activity like
the Walker A box and the two conserved E residues at HP0525 position 209 and 248
(Savvides et al., 2003). Other amino acids throughout the sequence are also highly
conserved (Fig. 29). The amino acid sequence identities for pairs of VirB11 orthologs were
as follows: HP0525/VirB11suis: 30%; HP0525/VirB11Agro: 22%; HP0525/TraG: 16%;
HP0525/TrwD: 24%; VirB11suis/VirB11Agro: 33%; VirB11Agro/TraG: 37%;
VirB11Agro/TraG: 30%; TrwD/TraG: 38%. As structural data are available for the ADP-bound
form of HP0525 it was possible to display the information from the VirB11 sequence
alignment as a conservation map on the surface structure of HP0525. The results from the
ClustalW-alignment (Fig. 29) were processed and submitted to the AMAS-server to further
validate the degrees of amino acid conservation. These data were displayed on the surface
of the HP0525 structure (see also Results, 1.1).
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Fig. 30. Structural conservation among VirB11 orthologs displayed on the surface of HP0525.
Predicted surface of the monomer (A) and, in a different orientation, the holoenzyme (B) of HP0525. In
(A) the NTD is on top, the larger CTD on the bottom of the panel. In the “front” image of the
holoenzyme NTDs are facing the observer, in the “rear” image the CTDs. Identical residues in all five
proteins are marked in dark green (A+), high similarity in green (A) and lower similarities are in yellow
(9) and light yellow (8). The figure was prepared with DINO (cobra.mih.unibas.ch/dino).
Many of the conserved amino acid residues in the N-terminal domains (NTD) and C-
terminal domain (CTD) of HP0525 are not exposed to the surface, implying a highly
conserved tertiary structure fold. Surface-exposed conserved amino acids are of special
interest in the context of this work, as they may be binding sites for inhibitors. The surface
area with the largest coherent area of identical AA-residues in all five proteins was formed by
amino acids of the active site pocket and in close vicinity to the (d)NTPs γ-phosphate (Fig. 30
A, front). The residues located close to the nucleotide purine/pyrimidine were not conserved,
which may be explained by different substrate preferences (Fig. 30 A, rear). The region of
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highly conserved AA-residues in the active site was not visible in images of the hexameric
protein, because it is located in a solvent-accessible position buried inside the hexameric
structure of VirB11 (Fig. 30 B). Apart from this region, the surfaces of the studied VirB11
orthologs did not exhibit further conserved patches. The hexameric holoprotein could be
viewed either from the putative periplasmatic side (Fig. 30 B, front), showing conservation of
the NTD, or form the opposite side  (Fig. 30 B, rear) displaying the CTD part of the HP0525
hexamer, which is supposedly inserted into the inner membrane (Yeo and Waksman, 2004).
2.2. Purification and characterization of VirB11 orthologs from different T4SS
2.2.1. Purification of VirB11 orthologs
After analysis of the structure of HP0525 (Yeo et al., 2000), a purification strategy for
the VirB11 orthologs was developed. The N-terminus of the HP0525 monomer was not in
close contact with parts of the protein that are involved in hexamer formation or catalytic
activity. Based on this observation, N-terminal modifications should not affect protein
structure and function, and a number of N-terminal StrepII-fusions of VirB11 orthologs were
generated accordingly.
Plasmids for recombinant over-expression of VirB11 orthologs were created by PCR
amplification of DNA fragments using templates pUC18VirB (B. suis virB11), H. pylori
genomic DNA, pR388 (trwD), pKM101 (traG) and pGK217 (A. tumefaciens virB11). Specific
primers are listed in Table 4. Ends of the fragments were treated with restriction
endonucleases (specified in Table 3) and inserted into similary treated vector pT7-StrepII or
pT7-H6TrxFus. The vectors were transformed into E. coli GJ1158 cells and protein
production was performed as described (Materials and Methods, 6.1 and Table 7). After
recombinant expression of the virB11 genes, the cleared cell lysates were subjected to
Strep-Tactin® Sepharose® affinity purification. The eluates from this step were applied to a
protein solution concentration device with 30 kDa molecular mass cutoff, to remove low
molecular mass cellular proteins, and they were then loaded onto a Superdex 200 gel
filtration column to isolate the enzymatically active hexameric proteins. The fractions were
subsequently concentrated and dialysed in PSB for long-term storage.
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Fig. 31. Coomassie-stained polyacrylamide gels monitoring the purification of VirB11
orthologs. The N-terminally StrepII-tagged VirB11 orthologs were purified from E. coli strain GJ1158.
Samples were loaded onto a 12% glycine-SDS polyacrylamide gel. Lanes represent: 1:pre-induction,
2:harvest, 3:Eluate I (post-affinity chromatography), 4:Eluate II (post-gel filtration, hexamer). White
arrowhead points to purified A. tumefaciens StrepII-VirB11. Numbers on the left indicate reference
proteins.
SDS-PAGE monitoring the different steps of the purification procedures (cell lysates
from pre-induction and harvest, affinity chromatography eluate, gel filtration eluate) of all
VirB11 orthologs was performed and the polyacrylamide gels were stained with Coomassie
to analyze the purity of the proteins (Fig. 31). The purification of most VirB11 orthologs was
efficient, and only the amount of A. tumefaciens StrepII-VirB11 was relatively low. Protein
concentrations were determined with the Bradford assay (StrepII-VirB11suis: 467 µg/ml;
StrepII-HP0525: 1234 µg/ml; StrepII-TrwD: 7100 µg/ml; StrepII-TraG: 3462 µg/ml; StrepII-
VirB11Agro: 1238 µg/ml; HisTrxVirB11suis: 3310 µg/ml). A stock solution for the (d)NTPase
assay was prepared for each protein by dilution with PSB.
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2.2.2. General Properties of the (d)NTPases
To set up NTPase enzyme assays for inhibitor studies, the general properties of the
five purified VirB11 orthologs were characterized frist. The pH-dependency of enzymatic
activity was analyzed at different values (pH 9.2, 8.6, 8.2, 7.9, 7.5 and 7.0), with ATP as
substrate and Pi release was determined with the malachite green test in 20 µl total volume
(Materials and Methods, 9.1).
A)
        pH
B)
Fig. 32. pH-optimum and substrate preferences of StrepII-tagged VirB11 orthologs. The purified
enzymes were tested for their optimal pH value and preferred substrate. The pH-value was tested in
the range between 7.0 and 9.2, the activities are given as the percentage of the maximal activity
observed (A). Substrate preferences were assayed with ATP and the four dNTPs, applying the
indicated enzyme concentrations.
All the tested StrepII-tagged VirB11 orthologs had their highest enzyme activity at pH
7.5, and the activities were much lower under more acidic or basic conditions (Fig. 32 A).
The only exception was TrwD, which had a second activity maximum at more basidic
conditions of pH 8.6. The substrate preferences were assessed with ATP or one of the four
(d)NTPs at a pH value of 7.2 for 20 min. Almost all proteins had high enzymatic activities with
ATP, and only HP0525 preferred dATP as a substrate. Limited hydrolysis of all the dNTPs
was also observed, although with generally reduced velocities (Fig. 32 B). For all ATPase
assays conducted in the following, standard parameters were pH 7.5 with the substrate ATP
(dATP in the case of HP0525).
The kinetics of ATP and dATP hydrolysis by the VirB11 orthologs were analyzed in a
series of parallel experiments with different substrate concentrations. For analysis, the
substrate concentration was plotted against the velocity of Pi-liberation.
Results
84
Fig. 33. Enzyme kinetic analysis NTP hydrolysis by VirB11 orthologs. In order to determine the
K0.5 and VMAX/2, a set of different ATP or dATP concentrations was used in the (d)NTPase assay. The
enzyme concentration was 0.5 µM for StrepII-VirB11 B. suis, 1.0 µM for StrepII-HP0525 and 5.0 µM
for StrepII-TrwD and StrepII-TraG. In the case of StrepII-VirB11suis and StrepII-HP0525 experiments
were repeated at least three times.
The sigmoidal shape of the curves depicting (d)ATPase velocities in relation to
substrate concentration indicated cooperativity in case of the enzymes from B. suis and
H. pylori. As a consequence of the cooperativity, no KM-value could be assigned to those two
enzymes. Instead, the substrate concentration corresponding to the VMAX/2-value was
denominated K0.5. A similar observation was made in case of StrepII-TrwD, but those
experiments were repeated only twice and therefore it was impossible to make a definite
statement. StrepII-TraG had very low enzymatic activity and a sigmoidal shape of the course
was not observed (Fig. 33).
The enzymatic properties of the analyzed StrepII-tagged VirB11 orthologs are
summarized in Table 8.
Table 8. Enzymatic properties of N-terminally StrepII-tagged VirB11 orthologs
Protein c (µM) optimal pH substrate K0.5 (µM) VMAX (pmol Pi/min)
StrepII-VirB11 B. suis 0.5 7.5 ATP 200 185
StrepII-HP0525 H. pylori 1.0 7.5 dATP 250 320
StrepII-TrwD pR388 5.0 7.5 ATP 3750 120
StrepII-TraG pKM101 5.0 7.5 ATP 200 16
StrepII-VirB11 A. tumefaciens 0.5 7.5 ATP ND ND
ND: not determined
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2.2.3. B. suis StrepII-VirB11 ATPase activity in the presence of other VirB
proteins
The role and mode of action of VirB11-like proteins is still largely speculative, but
some data suggest the importance of at least transient interactions of this protein with other
T4SS components (Ward et al., 2002). Due to the higher solubility of B. suis virB-encoded
proteins, as compared to those from A. tumefaciens, it was possible to directly analyze the
impact of putative channel and pilus components on the velocity of VirB11-mediated ATP
hydrolysis. Equal volumes of StrepII-tagged VirB5, VirB8 and VirB9 in PSB (provided by A.
Carle and L. Krall) were added to the standard ATPase-assay in ten-fold excess respective
to the VirB11 hexamer.
Fig. 34. Impact of StrepII-VirB5, StrepII-VirB8 and StrepII-VirB9 on the ATPase activity of B. suis
StrepII-VirB11. Liberation of Pi was measured over 20 min in different reactions with either only
VirB11, VirB11 + other StrepII-VirB-protein or VirB11 + other denatured StrepII-VirB-protein. The
concentration of the ATPase hexamer was 16.7 nM and the concentration of the interacting
monomeric proteins was 167 nM.  A linear regression algorithm was applied to interpret the data
points (Prism4).
The addition of other T4SS components did not cause notable changes of the initial
rates of ATP hydrolysis by B. suis StrepII-VirB11 (Fig. 34).
VirB11 acts within a T4SS that is localized in the bacterial membrane (2-dimensional
matrix) and composed of VirB proteins that form a network of interactions among each other.
This ensures a high local concentration of potential interaction partners of VirB11, which may
increase its enzyme activity. The assays performed here were conducted with soluble
proteins (3-dimensional matrix) and this may decrease the likelihood VirB11 protein-protein
interactions so that we could not mimick the in vivo situation.
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2.3. Studies with VirB11-specific inhibitors
2.3.1. In vitro studies of the effect of MTFPT
The company CHIRON, one of the collaborators in the EU frame program 5, which
funded this project, applied the native VirB11 ortholog HP0525 from H. pylori to a high-
throughput screen for inhibitors of the ATPase activity in a combinatorial library. The high-
throughput screen using a malachite-green based assay for Pi liberation identified three
compounds that drastically reduced ATPase activity, and one of them was commercially
available (Maybridge Inc.). Since the identity of the other two novel compounds remained
proprietary by the company, those could not be characterized further. I tested the substance
4-methyl-2-[4-(trifluoromethoxy)phenyl]-1,2,4-thiadiazolane-3,5-dion (MTFPT), which was
originally named CHIR-1 (Fig. 35), has a molecular mass of 292.23 g/mol and is insoluble in
water. Initial tests showed not only inhibition of HP0525, but also an inhibitory effect on H.
pylori virulence (CHIRON, unpublished data).
As a first step to analyze MTFPT with respect to
its effect on a set of purified VirB11-ortholgs, in
vitro ATPase assays were performed. The N-
terminally StrepII-tagged VirB11 orthologs were
incubated with increasing concentrations of the
potential inhibitor and the velocities of the enzyme-
catalyzed ATP hydrolysis was measured as
described. The standard reaction mixes contained
14 µl of buffer, 2 µl of enzyme stock solutions and
2 µl of DMSO with different MTFPT concentrations
ranging from 1 µM to 1 mM. The mixtures were preincubated for 5 min on ice and the
reaction was started by addition of the respective substrates and continued for 20 min. In
order to determine the mode of inhibition, parallel experiments were conducted with different
substrate concentrations.
Fig. 35. 4-methyl-2-[4-(trifluoromethoxy)-
phenyl]1,2,4-thiadiazolane-3,5-dione
(MTFPT)
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Fig. 36. Effect of MTFPT on StrepII-VirB11B. suis and StrepII-HP0525. The inhibitor concentration
in log-scale is plotted against the velocity of NTP hydrolysis (A, D) using nonlinear regression
(sigmoidal dose-response, variable slope). The plots of inhibitor concentration against 1/v (B, E) and
of inhibitor concentration against S/v (C, F) are calculated for the same data points as shown in A and
D. Linear regression was applied in B, C, E and F. Lines represent substrate concentrations of 600 µM
(A) or 1000 µM (D); dashed lines represent 200 µM and 250 µM (A) or 100 µM (D). The results from
three independent experiments are shown.
The data for StrepII-VirB11 from B. suis indicated a clear reduction of enzyme velocity
at increasing inhibitor concentrations and the IC50 value was determined to be 242 µM
(inhibitor concentration causing a 50% reduction of velocity, also known as i0,5 ). Parallel
experiments showed that the IC50 value was not impacted by changes of the ATP substrate
concentration (Fig. 36 A), which permitted conclusions on the mode of inhibition. In the case
of competitive inhibition, substrate and inhibitor compete for the same binding site of the
enzyme, and increases of the substrate concentration increase the IC50 value. This was not
observed here, and therefore competitive inhibition was ruled out. However, it still remained
unclear whether the mode of inhibition was non- or un-competitive.  To address this question
the data were plotted in a different way, applying the Dixon plot of 1/v against [Inhibitor] (Fig.
36 B, E) and the Cornish-Bowden plot of [S]/v against [Inhibitor] (Fig. 36 C, F). If a plot of
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[S]/v or 1/v against [Inhibitor] gives a straight line, and IC50 is the value of [Inhibitor] that gives
a value of [S]/v or 1/v that is double the value of [S]/v or 1/v at [Inhibitor] = 0 (i.e. v = 0.5
vMAX), then the intercept of the line on the abscissa is equal to –IC50. This follows from
elementary principles of geometry. In pure non-competitive inhibition, the IC50 is independent
of [S], so the common intersection point of lines depicting different substrate concentrations
lies on the abscissa axis in both plots. This case is the least commonly observed in studies
with natural enzymes (Cortés et al., 2001). Here, the slopes of lines and the position of a
common intersection point in Fig. 36 B and C suggests mixed-uncompetitive inhibition in the
case of MTFPT-action on StrepII-VirB11, a type of inhibition that has features of both non-
competitive and un-competitive inhibition.
In order to understand this finding, it is important to know that in Competitive
Inhibition substrate and inhibitor compete for the free form of an enzyme. Therefore the
inhibitory effect decreases upon increase of the substrate concentration. At low substrate
concentrations the IC50 is therefore low. In Un-competitive Inhibition the inhibitor
exclusively binds to the enzyme-substrate complex. At low substrate concentrations there is
little formation of the enzyme-substrate complex, causing a high IC50. Non-competitive
Inhibition describes a situation where an inhibitor either binds to the free form of the enzyme
or the enzyme-substrate complex. Dependent on the substrate concentration, such an
inhibitor either acts competitive or un-competitiv, and the inhibitory effect is independent from
the substrate concentration. The three modes of inhibition explained here possess an infinite
number of intermediate forms that will commonly be observed in kinetic measurements
(reviewed by Burlingham and Widlanski, 2003).
The same experimental setup and data processing was done with StrepII-HP0525.
Again, the enzyme reaction velocity decreased with increasing MTFPT concentrations
(IC50=189 µM), and the inhibition was not impacted by the variation of substrate
concentration (Fig. 36 D). Similar to B. suis VirB11 this suggested non-competitive or mixed-
uncompetitive inhibition of StrepII-HP0525 by the compound. Since the inhibitor was
discovered through its effect on HP0525 activity, the effect of MTFPT was not surprising, still
IC50 was considerably lower in the initial tests with the native enzyme (Chiron, unpublished).
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Fig. 37. Effect of MTFPT on StrepII-TrwD, StrepII-TraG and A. tumefaciens StrepII-VirB11. The
inhibitor concentration in log-scale is plotted against the velocity using nonlinear regression (sigmoidal
dose-response, variable slope). For StrepII-TrwD the experiment was performed three times, for
StrepII-TraG and A. tumefaciens VirB11 two times with similar results.
The same experimental setup was used to analyse the effect of MTFPT on the other
StrepII-tagged VirB11-like proteins. Due to their lower enzymatic activity and limited amounts
of the proteins, inhibitor tests were performed with only one substrate concentration. The
results indicate an inhibitory effect MTFPT on all orthologs with IC50 values of 8.1 µM for
StrepII-TrwD, 176 µM for StrepII-TraG and 38 µM for StrepII-VirB11Agro (Fig. 37). The
results from all inhibitor studies are summarized up in Table 9.
Obviously, the inhibitor MTFPT did not compete for the active site with the substrate,
suggesting that the compound bound to the VirB11 orthologs at different sites. Although
(d)ATPase activity and hexamer formation can be dissociated in HP0525, it was a possibility
that MTFPT bound to a region of the protein which is important for the formation of the
hexameric scaffold or the allosteric interaction between its subunits. To analyze this
possibility, a chemical crosslinking experiment of StrepII-VirB11 B. suis alone and together
either with substrate or substrate plus inhibitor was performed. The samples were analyzed
by separation with a polyacrylamide gel followed by Western blotting with VirB11-specific
antisera.
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Fig. 38. Crosslinking of StrepII-VirB11B. suis in the presence of substrate and inhibitor. StrepII-
VirB11 B. suis was incubated with concentrations of DSS ranging from 0 µM to 100 µM. The
concentration of the substrate ATP and the inhibitor MTFPT was 1000 µM each. The samples were
separated by SDS-PAGE followed by Western blotting with VirB11-specific antiserum. Numbers on
the left indicate reference proteins. Arrowheads point to signals appearing exclusively after
crosslinking the protein sample.
 When StrepIIVirB11 was incubated with DSS, higher molecular mass complexes of
different sizes were formed, which is in line with the homo-oligomeric nature of the protein.
The analysis revealed no differences between the samples, which had been crosslinked with
or without ATP and MTFPT, suggesting that the inhibitor did not cause major conformational
changes of the hexameric ATPase (Fig. 38).
Taken together, the results suggest that MTFPT exerted an effect on all five tested
(d)ATPases. In the case of B. suis StrepII-VirB11and StrepII-HP0525, MTFPT likely bound to
the enzyme and the enzyme-substrate complex as defined for non-competitive inhibition.
Since the mixed-uncompetitive inhibition observed here is an intermediate between non-
competitive and uncompetitive inhibition, it can be assumed that the inhibitor bound both the
free enzyme and the enzyme-substrate complex (as it is the case in non-competitive
inhibition), but has a slight preference for the latter. This suggests binding of MTFPT to a
conserved region close to, but not at the active site. The inhibitor did not interfere with
hexamer formation, which further supports this idea.
2.3.2. In vivo studies of the MTFPT inhibitory effect
An inhibitory effect of MTFPT on a number of VirB11-like proteins was established in
vitro, and in the context of future drug development, it was necessary to assess whether it
also inhibits VirB11 activities in vivo.
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2.3.2.1. Effect of MTFPT on the A. tumefaciens T4SS
As first assay, we determined its effect on the A. tumefaciens T4SS. Inhibition of A.
tumefaciens VirB11 should decrease transfer of IncQ plasmid pLS1 to recipient cells (UIA143
pTiA6), since (d)NTP-hydrolysis of VirB11 is essential for this process. To address this
question, an A. tumefaciens conjugation assay with donor strain A348 pLS1 and UIA143
pTiA6 as recipient was conducted in the presence of MTFPT in concentrations ranging from
1 µM to 1 mM.
A. tumefaciens A348
0 1 2 3 4
0.0
2.5
5.0
7.5
10.0 ( + AS)
( -  AS)
Log [Inhibitor] (µM)
Fig. 39. A348 output donor numbers at
different MTFPT concentrations. The
inhibitor concentration (Log[Inhibitor]) in µM is
plotted against the output donor number (Log
(D)) from the conjugation assay (both in log-
scale). Black triangles and the interconnecting
dashed lines correspond to cells cultured in
the absence of AS (- AS), black squares and
interconnecting lines correspond to cells
cultured in the presence of AS (+AS).
A. tumefaciens donor and recipient were co-incubated for two days, followed by
quantification of the numbers of exconjugants, donors and recipients. This quantification
revealed a negative effect of MTFPT on bacterial growth or survival, beginning at 100 µM
MTFPT, and no output donor A348 pLS1 was recovered at 1 mM MTFPT (Fig. 39). The
number of transconjugants was almost constant independent of the MTFPT concentration,
but due to the toxic effect on the donor, it was not possible to use this assay to quantify
plasmid transfer. This toxic effect was also apparent when donor and recipient were cultured
under non-inducing conditions (Fig.39, -AS), although the number of output donors was
generally higher.
 When the capacity of A348 to incite tumor formation in the presence of different
MTFPT concentrations was analyzed, it was found that the presence of DMSO in an infected
plant wound inhibited the development of tumors (not shown). Since both the inhibitor
MTFPT and its solvent DMSO unspecifically interfered with the assays of T4SS functionality
described above, the impact of MTFPT on the cellular levels of T4SS components and on
pilus formation was determined next.
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Fig. 40. Effect of MTFPT on the cellular levels of T4SS components and pilus. T4SS components
from high MW fractions (A, C) and cell lysates (B, D) of the indicated strains were separated on 15%
tricine-SDS-polyacrylamide gels, subjected to Western blotting and analyzed with specific antisera.
Black arrowheads point at signals of the indicated proteins. VirBXA refers to proteins from A.
tumefaciens  and VirBXs to the orthologs from B. suis. Unless otherwise indicated, UIA143
pTrc300VirB1-B12 was induced with 0.5 µM IPTG and A348 pTiA6 with 200 µM AS. Lanes are: 1:
uninduced, no MTFPT; 2:  no MTFPT; 3: 100 nM MTFPT; 4: 1 µM MTFPT; 5: 10 µM MTFPT.
Numbers on the left indicate reference proteins.
Production of the pTiA6-encoded A. tumefaciens T4SS and of the recombinant B.
suis T4SS as determined by pTrc300VirB1-B12 were induced and exocellular high MW
structures were isolated and analysed as described (Schmidt-Eisenlohr et al., 1999b). DMSO
in a concentration of 10%, which was required to dissolve MTFPT, neither affected growth of
strain A348 pTiA6 nor of UIA143 pTrc300VirB1-B12 (not shown). However, growth of both
strains was strongly inhibited by MTFPT concentrations of 100 µM and 10 µM, but lower
concentrations had no significant effect. The highest concentration used in these assays was
therefore 10 µM MTFPT.The accumulation of VirB proteins in cell lysates and in exocellular
high MW fractions was analyzed by SDS-PAGE and Western blotting with specific antisera.
B. suis VirB5 was detected in pilus fraction from of UIA143 pTrcVirB1-B12 cultured in the
presence of IPTG irrespective of the presence of MTFPT, whereas a weak VirB2-specific
signal was only detected when the strains were cultured in the presence of IPTG and MTFPT
(Fig. 40 A, lane 3-5). Cell lysis caused by the inhibitor may be an explanation for this
phenomenom, but this is not likely since VirB8 was not detected in the pilus fractions (Fig. 40
A).  The levels of VirB2, VirB5, VirB8 and VirB11 in IPTG-induced UIA143 pTrcVirB1-B12
were not impacted by the concentration of MTFPT  (Fig. 40 B).
In virulence-induced A. tumefaciens A348, equal levels of VirB2 and VirB5 were
detected in the pilus fraction of all strains cultured in the presence of different MTFPT
concentrations. VirB8 was not detected in the excocellular fractions, which rules out that the
inhibitor caused significant cell lysis under these conditions (Fig. 40 C). Similarly, MTFPT
had no effect on the cell levels of VirB2, VirB5, VirB8 and VirB11 in induced A348.
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In both strains, the inhibitor up to a concentration of 10 µM did not influence the
amount of cellular VirB11 and of any other VirB protein. This suggests that drastic
conformational changes or disassembly of the hexamer were not caused by MTFPT, which
was already suggested by the results of the crosslink analysis (Fig. 38). Thus, the inhibitory
effect observed on the ATPase activities of VirB11 from A. tumefaciens and B. suis did not
impact the levels of VirB proteins in the cells or the formation of high MW exocellular
appendages under these conditions. At present it is not clear what caused the inhibition of
the growth of A. tumefaciens by MTFPT, but this effect obscured the use of this model for the
analysis of the impact of T4SS function(s). As alternative in vivo assays, T4SS models in E.
coli were analysed next.
2.3.2.2. Effect of MTFPT on conjugative transfer of broad host range
plasmids
The In vivo effect of MTFPT on the VirB11 orthologs of T4SS involved in transfer of
the conjugative plasmids pR388, pKM101 and pRP4 to recipient cells was analyzed in
conjugation assays. E. coli donor strain FM433 (spcR) harbouring the broad host range
plasmids pR388 (tmR), pKM101 (carbR) and pRP4 (kanR) was mated to the recipient strain
WL400 (cmR, strR) as described (Materials and Methods, 12.1.2). Concentrations of MTFPT
during the conjugation assay ranged from 10 nM to 1000 µM, and the DMSO concentration
was always 10%. After serial dilution, the output donor cell number was determined by
plating on LB (spc). Transconjugands resulting from pR388 transfer were selected on LB cm/
tm, from pKM101 transfer on LB cm/ carb and from pRP4 transfer on LB cm/ kan. The
transfer efficiency was measured as the number of transconjugands (TC) per donor cells (D)
and set to 100 % in the positve control (no MTFPT). The toxicity of MTFPT was assessed by
comparision of the output donor numbers of one series of experiments with different inhibitor
concentrations.
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Fig. 41. MTFPT effect on conjugation and survival of IncN, -P, -W plasmid bearing cells. E. coli
FM433 carrying the indicated plamids was incubated with different concentrations of MTFPT and the
efficiency of plasmid transfer to E. coli WL400 was measured. The value of transconjugand per donor
(TC/D) of the uninhibited strains was set to 100% (A). The effect of MTFPT on growth of E. coli cells
was assessed, and total output donor numbers in dependence of inhibitor concentration is shown (B).
Standard deviation is from three independent experiments.
A negative effect of the inhibitor on transfer efficiency of the three plasmids was
already observed at a concentration of 100 nM, which leads to a plasmid transfer efficiency
of approximately 60 % of the positive control. At a MTFPT concentration of 1000 µM, a very
strong inhibitory effect on the transfer of all the plasmids strains to 30% of the level without
inhibitor was observed. Inhibitor concentrations between 100 nM and 1000 µM had
intermediate effects, but there was no apparent linear relation between MTFPT concentration
and inhibition of plasmid transfer (Fig. 41 A). Analysis of numbers of output donors showed
that MTFPT had no toxic effect on E. coli at concentrations up to 1000 µM (Fig. 41 B),
showing that the inhibition of conjugative transfer was likely due to a direct effect on the
plasmid-determined T4SS.
2.3.2.3. Effect of MTFPT on IncN pilus formation
An alternative assay for T4SS function in broad host range plasmids is the formation
of extracellular pili, which are used by bacteriophages as entry sites. Phage infection can
therefore be applied to quantify pilus formation. E. coli strain FM433 was used to assay
effects of the inhibitor on the formation ofthe IncN pilus.
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Fig. 42. Efficiency of IKe infection of an IncN plasmid-determined pilus structure. Inhibitor
concentrations in µM are shown (abscissa). The plaque numbers for FM433 pKM101 incubated
without MTFPT (uninhibited control) acts as a reference value and was set to 100% (ordinate).
Standard deviation of three independent experiments is shown (black lines).
Pre-incubation with MTFPT affected the ability of IKe to infect FM433 pKM101. At a
MTFPT concentration of 100 µM a reduction to 70% of the positive control was observed,
and at a concentration of 1000 µM MTFPT the plaque number was reduced to 50% of the
positive control value (Fig. 42). Obviously, incubation with MTFPT led to a change in quality
and/or quantity of the primary IKe receptor on the bacterial cell surface.
2.3.3. Effects of oleic and linoleic acid on VirB11 activity
It was demonstrated by others that certain phospholipids stimulated the activity of
some VirB11 orthologs (Krause et al., 2000). Moreover, it could be shown that unsaturated
fatty acids such as linoleic acid and oleic acid exerted an inhibitory effect on TrwD (Machon
C, unpublished). The fact that fatty acids influenced the activity of at least some VirB11
orthologs raised the question whether this effect could also be observed in case of the N-
terminally StrepII-tagged VirB11 orthologs.
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Fig. 43. The in vitro effect of oleic- and linoleic acid on the VirB11 orthologs. The inhibitor
concentration in logarithmic scale on the abscissa is plotted against the velocity of the enzyme on the
ordinate. The inhibitory effect of either oleic- or linoleic acid was determined. Lines were either drawn
by hand or calculated with nonlinear regression (sigmoidal dose-response, variable slope).
Experiments were performed three times with similar results.
Table 9. IC50 value of different inhibitory compound’s action on VirB11 orthologs
Protein MTFPT
IC50 (µM)
Oleic acid
IC50 (µM)
Linoleic acid
IC50 (µM)
StrepII-HP0525 H. pylori 189 12 25
StrepII-VirB11B.suis 242 - -
StrepII-TrwD (pR388) 8,1 99 79
StrepII-TraG (pKM101) 176 - -
StrepII-B11A.tumefaciens (38) ND ND
ND: not determined; -: no inhibition
(d)ATPase assays were conducted with N-terminally StrepII-tagged B. suis VirB11,
H. pylori HP0525, TrwD (pR388) and TraG (pKM101) as described (2.3.1), in the presence of
different concentrations of linoleic acid and oleic acid. The two compounds acted similarly
when acting on the same enzyme, but between VirB11 orthologs the effect of these fatty
acids varied. Whereas the ATPase activity of StrepII-VirB11 from B. suis remained almost
constant irrespective of the fatty acid concentration, StrepII-TraG activity increased two-fold
upon addition of the fatty acids. In contrast, StrepII-TrwD was inhibited in the same way as
native TrwD (Machon C, unpublished), with a 6-fold reduction of activity in the presence of 1
mM linoleic or oleic acid. Interestingly, the same effect could also be observed in case of
StrepII-HP0525. In the presence of 100 µM of both fatty acids Pi liberation from dATP was
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strongly inhibited, and the IC50 values were the lowest observed in the context of this work.
The IC50 values in the presence of fatty acids are shown in Table 9 and compared to those of
MTFPT.
2.4. Complementation of an A. tumefaciens VirB11 mutant
In order to gain insights into the protein-protein interactions required for VirB11
functions it was tried to reconstitute a functional T4SS by heterologous complementation of
the virB11 deletion mutant PC1011 with pTrc200 expressing either A. tumefaciens C58
virB11 or B. suis virB11. Ends of PCR fragments encoding full-length virB11 were generated
with the restriction enzymes BspHI and XbaI and inserted into vector pTrc200 treated with
NcoI and XbaI. The resulting vectors pTrc200, pTrcB11 and pTrcB11s were transformed into
PC1011, followed by growth under virulence gene-inducing conditions and analysis of VirB
protein content in subcellular fractions (cell lysate and pilus fraction).
Fig. 44. Complementation of T-pilus formation and virulence by strain PC1011 expressing
virB11 orthologs. The indicated strains were cultured under virulence inducing (+AS) or non-inducing
(-AS) conditions. trc-driven gene expression was induced with IPTG. Exocellular high-molecular mass
T-pilus fractions (A) and cell lysates (B) were separated by SDS-PAGE followed by Western blotting
with VirB2-, VirB11s- and VirB11A-specific antisera. Numbers on the left indicate reference proteins.
Lesions on leaves of K. diagremontiana were inoculated with the indicated strains and tumor formation
was monitored (C).
VirB11 and VirB11s in cell lysates were detected in Western blots with the respective VirB11-
specific antisera, and we observed cross-reaction of the Agrobacterium VirB11-specific
antiserum with the Brucella VirB11 ortholog (Fig. 44 B). Brucella VirB11 was apparently
produced at high levels and overproduction was visible in Coomassie-stained gels (not
shown). The level of VirB2 in cell lysates did not vary  (Fig. 44 B), but in the pilus fractions
VirB2 was only detected in the samples from A348 and PC1011 pTrcB11 cultured under
virulence-inducing conditions (Fig. 44 A).  Consistent with this observation, only these two
strains were able to incite tumor formation in lesions of K. diagremontiana leaves (Fig. 44 C),
showing that Brucella VirB11 did not complement the virB11 defect of PC1011. A348 and
PC1011 pTrcB11 were then transformed with pLS1 and their ability to transfer the IncQ-
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plasmid was monitored in conjugation assays with A348 pLS1, PC1011 pTrcB11 pLS1 and
PC1011 pTrcB11 spLS1 (all carbR) as donors and UIA143 pTiA6 (eryR) as recipient.
Surprisingly, only the induced WT strain A348 was able to transfer pLS1 (not shown).This
finding may be explained by the fact that PC1011 pTrcB11 did not express the virB11 gene
from the octopine-type A. tumefaciens A348, but the ortholog from nopaline-type A.
tumefaciens C58. In any case, the B. suis VirB11 ortholog did not complement the genetic
defect of PC1011 suggesting that the requirements for protein-protein interactions preclude
the heterologous exchange of these two enzymes. To gain further insights into this questions
VirB11 protein interactions with VirB5 were next assessed with purified proteins.
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2.5. Protein-protein interactions of VirB11
2.5.1. Strep-Tactin® Sepharose® pull-down assay
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Fig. 45. B. suis VirB11 binds to matrix-bound StrepII-VirB5. StrepII-VirB5 was preincubated with
the Strep-Tactin matrix before addition of His-Trx-VirB11. After washing, proteins were eluted from the
matrix with 1 mM biotin, and analysed by SDS-PAGE and subsequent Western blot with the specific
antisera indicated on the right. Lane 1: negative control where only His-Trx-VirB11 was incubated with
the matrix; Lane 2: pull-down assay. White arrowhead points at the faint VirB11-specific signal.
Experiments were repeated three times with consistant results.
A pull-down assay as described in 1.4.2 was performed to analyse a potential protein-
protein interaction between VirB11 and the minor pilus component VirB5. Interactions of the
orthologs from A. tumefaciens had previously been suggested by a different experimental
approach (Krall, 1999). Matrix-bound B. suis StrepII-VirB5 (provided by A. Carle) was
incubated with His-Trx-VirB11. After washing and elution, the sample was subjected to
Western blot analysis with VirB11- and VirB5-specific antisera. The analysis revealed
specific attachment of the recombinant ATPase to the Sepharose-matrix that displays non-
covalently bound StrepII-VirB5. An implication of this result is that VirB5 may interact with
VirB11 in order to be localized to the nascent pilus structure.
2.5.2. Overlay assay of VirB11 and VirB5 orthologs
L. Krall had previously observed an interaction of A. tumefaciens VirB11 and VirB5
using an overlay-assay. In order to reproduce this result and detect similar interactions with
the different orthologs used in this work, overlay assays were performed.
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Fig. 46. Overlay-assay of PVDF-bound VirB11 orthologs with soluble VirB5 orthologs.
Coomassie-stained SDS-polyacrylamide gel (A) shows the amount of VirB11 orthologs blotted onto
PVDF membranes for the overlay assays. 1: VirB11 (A. tumefaciens); 2: StrepII-VirB11 (B. suis); 3:
StrepII-TraG (pKM101); 4: StrepII-TrwD (pR388); 5: StrepII-HP0525 (H. pylori). Subsequently, these
membranes were incubated with or without the indicated proteins and, only in the case of incubation
with A. tumefaciens VirB5, with or without 1 mM ATP. Black bars indicate the specific antisera that
were applied to detect bound VirB5 proteins. White arrowheads point to the detection of an A.
tumefaciens VirB5-specific signal at a MW corresponding to the A. tumefaciens VirB11 monomer.
Reference proteins are indicated on the left.
As our previous work had shown that it was difficult to obtain substantial amounts of
the A. tumefaciens VirB11 ortholog in soluble form, the proteins for this assay were produced
as inclusion bodies. E. coli strains GJ1158 harbouring pT7-StrepII-VirB11 B. suis, pT7-
StrepII-TraG, pT7-StrepII-TrwD or pT7-VirB11 A. tumefaciens were cultured to an OD600 of
0.4-0.8 and induced by addition of 5 M NaCl to final concentrations of 0.3 M. After cultivation
at 37°C for 16 h, the cells were sedimented by centrifugation, suspended in PBS and lysed
by passage through a French Press. After sedimentation of the lysate, large amounts (≥ 1
mg) of insoluble VirB11 orthologs were retrieved from the sedimented inclusion bodies.
Proteins were boiled for 5 min in 1 ml protein sample buffer and diluted in order to separate
equal amounts by SDS-PAGE (Fig. 46 A). The proteins were transferred to PVDF
membranes, followed by renaturation, incubation with the putative interaction partners
Agrobacterium StrepII-VirB5 (in the absence and in the presence of 1 mM ATP), Brucella
StrepIIVirB5 and pKM101 TraC.  The bound proteins were detected by Western blotting and
specific signals were only detected on the membrane incubated with A. tumefaciens StrepII-
VirB5 in the presence or absence of 1 mM ATP. The position of the VirB5-specific signal on
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the blot corresponded to that of A. tumefaciens StrepII-VirB11. Binding to renatured VirB11
orthologs was not observed in case of Brucella StrepIIVirB5 (Fig. 46 B).
The overlay assay conduced here therefore reproduced the previous observation that
VirB11 and VirB5 from A. tumefaciens interact. However, further evidence that this
interaction occurs in other T4SS could not be provided, but data from the pull-down assay
(2.5.1) demonstrated that this interaction might at least be conserved in the T4SS of B. suis.
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 Discussion
1. Interactions of VirB1 with other T4SS components
1.1. Common features of VirB1 from B. suis and A. tumefaciens
The α-proteobacteria A. tumefaciens and B. suis both live in close interaction with
eukaryotes. They utilize an inducible macromolecular translocation system coined T4SS,
which spans both the inner and outer membrane of the cell envelope, to support this life
style. Though host characteristics and the overall way of life of both pathogens differ
substantially, the virB operons encoding the T4SS in both organisms show a high degree of
structural conservation. This becomes even more evident when single proteins of the
systems are compared.
Algorithms suited for the prediction of subcellular sorting signals show that the VirB1
orthologs from A. tumefaciens and B. suis both possess N-terminal signal peptides, an
observation supported by experimental evidence in the case of A. tumefaciens VirB1 (Llosa
et al., 2000). The characteristic active site signature of transglycosylase is found in both
proteins. Predictions of the secondary structure show a high degree of conservation, not
anticipated by the 27% identical amino acid residues in both sequences (Höppner et al.,
2004). The sequence that was identified as the cleavage site of A. tumefaciens VirB1 also
shows limited conservation between the two proteins. One very interesting feature of VirB1 is
that the entire C-terminal domain following the cleavage site is classified as a NORS-region.
NORS-regions are likely unordered and may receive their structure through interactions with
other proteins (Liu et al., 2002), possibly located in the periplasma in the case of VirB1. It
was previously shown that this part, denominated VirB1*, accumulates in the supernatant of
virulence-induced A. tumefaciens cells (Baron et al., 1998), and observations from this work
(Fig. 17) suggest that similar processing might also occur in B. suis VirB1. Analysis of the
efficiency of conjugative transfer into A. tumefaciens carrying the B. suis T4SS with and
without VirB1 showed that this protein is non-essential but required for high-efficiency
function. The finding that B. suis VirB1 partly complemented its A. tumefaciens ortholog
(Höppner et al., 2004) further emphasizes the similarity of the two proteins.
1.2. Interactions of VirB1 with other VirB proteins
A role of VirB1 as nucleation center was suggested before, but the many interactions
with T4SS components had until now only been demonstrated in the yeast dihybrid assay
(Ward et al., 2002). The B. suis T4SS is more amenable to investigation with biochemical
methods than the Agrobacterium T4SS. Many of its components are relatively easy to purify,
because in contrast to those from A. tumefaciens, they can be overexpressed in a soluble
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form with high yield, followed by affinity purification. This feature was exploited to conduct
biochemical experiments to assess the suggested interactions. Overproduction of VirB1 with
a C- or N-terminal affinity-tag resulted in a protein that was bound to GroEL, which may be
due to improper folding in the cytoplasm. The C-terminally His6-tagged variant of VirB1 could
not be efficiently affinity purified with an IMAC column, suggesting that the C-terminus was
inaccessible. It is likely that the chaperone GroEL bound to the NORS region of the
recombinant protein. The resulting multimeric protein complex (or aggregate) had a MW
larger than 600 kDa and thus eluted in the void volume of a Superdex 200 gel filtration
column. Apart from that, recombinant VirB1 was mainly present in the dimeric, tetrameric and
hexameric state. The above findings were demonstrated in case of VirB1-His6 but not in case
of StrepII-VirB1. The difference is probably due to a minor portion GroEL-free VirB1-His6 in
the cell lysate that is getting specifically enriched in affinity purification, since it preferentially
binds to the IMAC column. In contrast to this situation StrepII-VirB1 was predominantly
affinity-purified in complex with GroEL since the tag is accessible. This inhibited its protein-
protein interactions.
Nevertheless, chemical crosslinking of enriched recombinant StrepII-VirB1 showed
that dimeric and presumably also tetrameric forms of VirB1 exist. An attempt to map self-
interacting domains of VirB1 using Peptide Array experiments was not successful, since
strong binding to all VirB1-derived peptides displayed on the membrane occurred (not
shown). The available data suggest that VirB1 forms homo-multimeric assemblies, probably
dimers and tetramers. The molecular sieving effect of the murein layer prohibits diffusion of
globular proteins or protein assemblies larger than 55 kDa. Since the permeation of the
murein layer might be important for the function of lytic transglycosidase in the periplasm, the
formation of dimers (approximately 50 kDa) appears to be more plausible in the natural
biological context than the formation of tetramers (approximately 100 kDa), which may not
permeate the murein layer.
Using a co-elution assay of proteins co-expressed from bicistron vectors we did not
get any evidence for an interaction between VirB1 and VirB8, which was predicted from a
previous yeast two-hybrid study (Ward et al., 2002). However, this may be due to the buffer
conditions used in this specific assay. Whereas the proteins did not elute from the gel
filtration column together, we observed reduced amounts of supposedly GroEL-bound VirB1-
His6 in high MW assemblies. This might be explained by an interaction between VirB1 and
VirB8, which may have prevented or competed with GroEL binding, but this interaction may
not be stable enough to sustain cell lysis and further fractionation. In a pull-down assay with
matrix-bound StrepII-VirB1 His-Trx-VirB8 was found to bind to the matrix in a non-specific
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way so that this method was not suited to analyse the interaction. In contrast, chemical
crosslinking of the two proteins gave evidence for interaction in a 1:1 stoichiometry. Data
from the Peptide Array experiment further suggested that a set of VirB1 peptides interacts
with VirB8, which supports the notion that VirB1 and VirB8 interact. The evidence is not as
substantial as that in case of VirB9 discussed below, suggesting that the interaction is
weaker and/or may need additional interaction partners.
The interaction between VirB1 and VirB9 was demonstrated using a pull-down assay
and by chemical crosslinking of the two proteins in solution. Co-elution of the two proteins
following their co-expression in a bi-cistron construct was also demonstrated with a gel
filtration assay. During this experiment we also noted a reduction of the amount of high MW
StrepII-VirB1 in the void volume of the gel filtration column, which further substantiates the
notion that VirB9 impacts the oligomeric state of VirB1. Peptide array experiments identified
VirB9-interacting peptides throughout the VirB1 sequence, and a considerable portion of
them was in the C-terminus. According to the molecular masses of the co-eluting VirB1-VirB9
complexes and of the crosslinked products, VirB1:VirB9 stoichiometries of both 2:1 (80 kDa)
and 2:2 (110 kDa) are likely. These data are consistent with the results of a previous study,
which pursued a biochemical approach to demonstrate the interaction of the VirB1 C-
terminus with VirB9 in A. tumefaciens orthologs (Baron et al., 1997).
An interaction between VirB10 and VirB1 could neither be demonstrated with the pull-
down assay nor by gel filtration. When the two proteins were subjected to cross-linking in
solution no specific new products were observed. Tests of the interaction of VirB10 with a
VirB1 displayed on a peptide array were therefore not conducted and we do not consider it
likely that the two purified proteins interact.
In contrast to the entirely negative results in case of VirB10 some evidence for an
interaction of the hexameric ATPase VirB11 with VirB1 was obtained. A pull-down assay
demonstrated specific binding of His-Trx-VirB11 to StrepII-VirB1, and results of crosslinking
experiments further supported this finding. However, we did not observe co-elution of the two
proteins from a gel filtration column. Nevertheless, VirB11 production was enhanced upon
co-expression with VirB1, which indicates an interaction and VirB11 specifically bound to
certain VirB1 peptides in array experiments.
Due to the lack of VirB4-specific antisera, the interaction of the ATPase VirB4 could
only be assessed in a co-elution assay following bi-cistronic expression of strepII-virB1 and
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virB4. Significant amounts of VirB4 co-eluted with StrepII-VirB1, indicating an interaction
between the two proteins.
Taken together, the results suggest that VirB1 is a self-interacting protein that establishes
transient contacts with other VirB proteins. In the course of biogenesis of the T4SS, VirB1
might interact with the ATPases VirB11 and VirB4, with the transmembrane channel
component VirB8 and VirB9. The interaction of VirB1 and VirB10 that was postulated by a
dihybrid screen (Ward et al., 2002), was not observed in the experiments conducted here.
Table 10. Suggested and proven interactions of VirB1.
Biochemical methodProtein localization
(Cascales and Christie,
2003)
dihybrid  screen
(Ward et al., 2002) pull-down
assay
chemical
crosslink
Co-elution peptide array
VirB1 Periplasm + ND + + ND
VirB8 IM + ND + - +
VirB9 OM + + + + +
VirB10 IM + - - - ND
VirB11 IM + + + - +
VirB4 IM + ND ND + ND
The data for VirB-protein localization and interactions detected with dihybrid-assays are from other
publications and refer to the A.tumefaciens T4SS. IM: inner membrane; OM: outer membrane; ND: not
defined
To assess whether the sequence stretches of VirB1 that interact with other proteins
are spatially clustered or not, E. coli Slt70 was used as a model to approximate the structure
of VirB1 (Fig. 4). The amino acid residues of E. coli Slt70 that correspond to amino acids
from VirB1 interacting with other VirB proteins are shown in Fig. 47. The peptide array
experiment yielded signals of different intensity corresponding to peptides featuring parts of
the VirB1 sequence. The corresponding sequences were aligned and defined regions of
interaction. For each interacting region, the intensity of the signals constituting it was
categorized into four classes, from “weak” to “very strong”. This classification did not
compare signal intensities between peptide array experiments with different proteins and
therefore, a “strong” interaction of VirB1 peptides with VirB8 might be classified as
“intermediate” in a peptide array with VirB9. The studies are therefore semi-quantitative and
need to be followed up by more quantitative methods in future. VirB8 and VirB9 apparently
interacted with loop regions of VirB1 that are most likely situated on different sides of the
protein, and VirB11 may bind to a part of the protein that connects these two. There was no
apparent interference with the active site cleft, and the amino acids identified here are not
involved in the stabilization of the tertiary structure of the protein. Amino acids important for
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interactions are expected to localize on the surface of a protein and this is observed here,
adding credibility to the model. Most of the proposed interactions between VirB1 and VirB9
could not be visualized in this model since they map to the C-terminal part of VirB1, which
lacks a counterpart in Slt70. A model, which integrates the postulated interactions with
results from functional studies with A. tumefaciens, will be shown below (Fig. 48).
Fig. 47.  Regions of B. suis VirB1 that are bound by VirB proteins in peptide array experiments.
View of the E. coli Slt70 SLT domain surface structure like that shown in Fig. 4; regions of VirB1
interacting with VirB8, VirB9 and VirB11 as defined by the peptide array experiments are shown. Grey
colour indicates no significant interaction, orange color indicates strong and red color very strong
interaction with the different VirB proteins.
Our experiments did not provide any evidence for a direct interaction between VirB1
and VirB10. An interaction between these proteins was suggested by the finding that in Ti-
plasmid-free A. tumefaciens expressing virB7-virB10 the correct membrane localization of
VirB10 could be achieved by expression of virB1-virB3 but not of virB2-virB4 (Liu and Binns,
2003). This could be explained by a direct interaction of VirB1 with VirB10 or an indirect
interaction via correct localization of VirB9, which then interacts with VirB10 (Das and Xie,
2000). Alternatively, the correct localization of VirB10 could be achieved through localized
cell wall lysis mediated by the transglycosylase activity of VirB1, which does not require a
direct interaction. In contrast to our findings data supporting a direct interaction between
VirB1 and VirB10 were obtained in a dihybrid assay (Ward et al., 2002), but the results of our
work did not substantiate these findings.
1.3. VirB1 is an important component of the B. suis T4SS
It was previously demonstrated that VirB1 orthologs play an important role in the
T4SS of A. tumefaciens and E. coli strains harbouring pKM101; the efficiency of substrate
transfer was reduced 10- to 1000-fold upon non-polar deletion of the encoding genes (Berger
and Christie, 1994). An infection assay with signature tagged B. abortus mutants
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demonstrated that mutagenesis of the virB1 gene causes attenuation of virulence (Hong et
al., 2000). A more recent study demonstrated that survival of B. abortus in macrophage cell
cultures was strongly attenuated in strains carrying a non-polar virB1 mutation (Hartigh et al.,
2004). Taken together, the deletion of genes encoding VirB1 orthologs generally has an
attenuating effect on T4SS related functions. One way to assess this effect in greater detail
was enabled by the finding that VirB1 is also important for T4SS-mediated DNA uptake in A.
tumefaciens (Liu and Binns, 2003).
Conjugation experiments proved that expression of B. suis virB3-virB12 in A .
tumefaciens facilitated plasmid transfer into these cells, indicating at least partly functional
assembly of the heterologous T4SS. When the virB1 gene was added to this subset of the
virB operon, the recipient efficiency increased approximately 8-fold, which underscores the
very important role of VirB1 for T4SS function. Surprisingly, the levels of VirB proteins were
decreased as compared to virB3-virB12 when B. suis virB1-virB12 were expressed in A.
tumefaciens and the recipient efficiency was drastically reduced. Analysis of VirB1 and VirB2
protein levels in this strain suggests that the two proteins exerted a reciprocal negative effect
on each other’s level in the cell. The reduced level of VirB1 in UIA143 pTrc300VirB1-B12
may be a cause for the low recipient efficiency. VirB2 from the A. tumefaciens T4SS requires
a specific post-translational processing reaction, which leads to the formation of a 74 amino
acid long cyclic peptide (Lai et al., 2002). It is conceivable that similar processing of B. suis
VirB2 may not have occurred in A. tumefaciens due to the substrate specificity of the
involved proteases (Lanka and Haase, 1997). High amounts of improperly processed and
probably misfolded VirB2 may inhibit the correct assembly of the T4SS in the A. tumefaciens
membranes and this may explain the fact that virB2-expressing strains cannot serve as pLS1
recipients. This conclusion is in accord with the results of a study using crosslinking to
assess VirB protein interactions in UIA143 pTrc300VirB1-B12. VirB-specific signals that
corresponded to defined crosslinking products were decreased in samples from UIA143
pTrc300VirB1-B12, as compared to samples from UIA143 pTrc300VirB1-B3-B12 (Carle,
2004), suggesting major differences of T4SS assembly.
If misfolded VirB2 was responsible for impaired T4SS assembly, this could also
explain the observation that UIA143 pTrc300VirB3-B12 was a much better recipient for
conjugative pLS1 transfer than UIA143 pTrc300VirB1-12. An alternative explanation is that
contact-promoting structures on the A. tumefaciens donor cell are blocked by B. suis VirB2
on the recipient cell. However, this possibility appears not very likely since B. suis VirB2 was
not detected in fractions of exocellular high MW structures, whereas the putative minor pilus
component VirB5 could easily be detected. This observation was exploited in another
experiment, which underscored the importance of VirB1. It was shown that the active site E
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residue of VirB1 was required to ensure the presence of VirB5 in exocellular high MW
fractions, suggesting that the enzymatic activity of the lytic transglycosylase is necessary for
pilus biogenesis of the B. suis T4SS.
1.4. Structure-function analysis of VirB1
Comparative analyses of structure and sequence of the soluble lytic
transglycosylases Slt70 and Slt35 from E. coli identified general active site requirements of
this enzyme family (van Asselt et al., 2000). The definition of a sequence motif consisting of
three significantly conserved amino acid stretches led to the identification of genes encoding
lytic transglycosylases, which contribute to a variety of macromolecular secretion systems
(Koraimann, 2003). In contrast to other genes from the A. tumefaciens virB operon or its
orthologs, deletion of virB1 genes has just an attenuating effect on substrate secretion in
most cases. It was speculated that the localized lysis of the cell wall catalyzed by these
proteins might be partly complemented by other murein-metabolizing enzymes. In spite of
suggestive evidence for a role of VirB1-like proteins in murein metabolism, direct evidence
for their enzymatic activity was not provided until now. The most convincing line of evidence
was that overproduction of P19, the putative lytic transglycosylase from IncP plasmid RI, led
to perforation of the bacterial cell envelope (Bayer et al., 2001). Moreover, mutation of the
active site E residues of P19 and VirB1 essentially abolished their abilities to complement the
defects in their respective T4SS (Mushegian et al., 1996). The notion that VirB1-like proteins
likely act on the conserved murein substrate led to the hypothesis that, in contrast to other
T4SS components, the exchange between different VirB1 orthologs might be possible
(Koraiman, 2003).
I have applied a variety of different assays, such as T-pilus formation and IncQ-
plasmid transfer, to demonstrate that despite limited sequence similarities B. suis VirB1 and
TraL (pKM101) complemented the virB1 defect in A. tumefaciens PC1001. In contrast,
production of other orthologs such as F169 and HP0523 did not restore T4SS function in
PC1001. Interestingly, the complementing VirB1 orthologs share a C-terminal extension,
which is absent in the non-complementing proteins. In A. tumefaciens, this C-terminal
extension (VirB1*) is removed by proteolytic processing and it exerts an important role, since
its production alone partially complemented virB1 defects (Llosa et al., 2000). We suggest
that the presence of a C-terminal domain in B. suis VirB1 and TraL (pKM101) was
responsible for the outcome of the experiment. In addition, mutations were introduced into
the genes at a position encoding the putative active site E residues and this abolished the
complementation of TraL and B. suis VirB1. In contrast, A. tumefaciens
VirB1E->A retained residual activity, which further underscored the functional importance of
VirB1*. Changes of the active site did not interfere with processing and secretion of VirB1*,
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ruling out an autocatalytic cleavage impacted by the enzyme’s transglycosylase active site
(Höppner et al., 2004).
Since the interaction of VirB1* with other T4SS components such as VirB9 was
demonstrated in vivo (Baron et al., 1997), it was relevant to further dissect the processing
reaction by the creation of VirB1 variants with alterations of the cleavage site sequence.
Seven variants surrounding this A-rich sequence motif were tested for their ability to
complement strain PC1001. The amounts and molecular masses of processing products
differed from VirB1* wild type in most cases. The strongest effects were observed in case of
VirB1ΔAA, VirB1A->D and VirB1A->P where alternative processing and changes of the quantities
and  molecular masses of the secreted products were obvious. The effect was most
pronounced for VirB1A->D, which altered the –1 residue respective to the cleavage site. This
change had a weak but significant effect on the complementation of PC1001 T-pilus
formation, IncQ-transfer and tumor formation (G. Nair, personal communication). When a
Western blot using VirB1-specific antisera was performed with samples from a time course
expression of VirB1A->D, a number of processing products were detected, which are not
commonly observed in case of the WT VirB1. Since the N-terminal SLT domain of VirB1 was
never detected in Western blots (Baron et al., 1997), it is reasonable to assume that these
VirB1-specific signals are caused by aberrantly processed VirB1A->D. Moreover, these
aberrant VirB1* forms were not detected in culture supernatants of cells producing VirB1A->D,
indicating that efficient cleavage and secretion are likely linked.
These findings may constitute an analogy to those reported in the case of major pilus
component VirB2, which is processed at a triple-A motif. The resulting C-terminal part of the
protein is denominated the VirB2 pilin and it is translocated to the cell exterior and
assembled into the T-pilus (Lai and Kado, 1998). Since the cleavage sites of VirB1 and VirB2
are very similar, and the cleavage products VirB1* and VirB2 pilin have the same length (73
versus 74 amino acids), it is reasonable to assume that processing occurs by the same as of
yet unidentified protease. Changes of the first A of the VirB2 cleavage site to D led to a loss
of pilus incorporation, detection of VirB2 propilin in cell lysates and significantly reduced
virulence (Lai et al, 2002). The phenotypes of such a strain and a non-polar virB1 deletion
mutant are basically identical since VirB1 is required for T-pilus formation (Lai et al, 2000).
Thus, the effect of a VirB1 cleavage site variant could be explained by interference of the
unprocessd protein with T4SS biogenesis. Propeptides from other processed and secreted
virulence factors like elastase and subtilisin assist folding of the protease before they are
proteolytically removed (McIver et al., 1995). VirB1* might exert a similar function on the
VirB1 SLT domain and/or VirB2.
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The results of the analysis of cleavage site variants support the notion that F169 and
HP0523 did not complement PC1001 because they do not possess a VirB1*-like region. To
test this hypothesis, a hybrid protein was created comprising the A. tumefaciens VirB1 signal
peptide, the SLT domain of HP0523 and C-terminal VirB1*. SP-HP0523-VirB1* was
processed to yield VirB1* and partially complemented pilus formation. However, pilus
fractions from strains expressing sp-hp0523-virB1* contained trace amounts of VirB8, which
suggests lysis of the cells upon production of the hybrid protein. This leaves the possibility
that the extracellular localization of VirB2 may be caused by limited cell lysis and not by pilus
assembly. In contrast to pilus formation, other bioassays performed with PC1001 pTrcSP-
HP0523-B1 delivered no evidence for functional complementation. Taken together, the
results suggest that the hybrid protein may be able to complement pilus biogenesis, but not
the full T4SS function.
 An overview of the properties of A. tumefaciens strains expressing different
virB1constructs is shown in Table 10.
Table 10. Relative efficiency of PC1001 complementation by different VirB1 variants.
Strain: PC1001
1)
PC1001
pTrcB1
1)
PC1001
pTrcB1
E->A
 
1)
PC1001
pTrcB1-N
(SLT)
PC1001
pTrcB1
A->D 1)
PC1001
pTrcB1*
virB1-genotype: ΔvirB1 WT virB1 E60A virB1Δ173-252 virB1 A172D virB1Δ29-172
Transfer efficiency
(%):
9,4 +/-
4,7
100 +/-47 18,8 +/- 9,4 8,2 +/- 2,4 
3) 40 +/- 20 14 +/- 2,4
3)
Tumor formation: + +++ ++ ++
2) +++ ++
2)
T-pilus: - +++ - -
3) ++ -
3)
The relative efficiency of the indicated donor strain to transfer IncQ-plasmid pLS1 to UIA143 pTiA6
was determined in at least three independent experiments. SLT: soluble lytic transglycosylase domain;
+++: strong, ++: significant, +: weak, -: absent. Data are taken from: this work 1); (Llosa et al, 2000) 2);
(Höppner, 2000) 3)
1.5. Multiple roles of VirB1
A large amount of information on the role of VirB1 was collected in previous studies.
Together with this analysis of protein interactions of VirB1 from the B. suis T4SS and the
results from functional studies conducted with both the A. tumefaciens and B. suis T4SS, a
model can be designed describing the function(s) of VirB1 as follows.
Upon expression of the virB operon, all VirB proteins possessing a N-terminal signal
peptide are exported into the periplasm or partially traverse the inner membrane. By self-
interaction of its C-terminal NORS-region, VirB1 forms a 50 kDa homo-dimer, which may
render the active site inaccessible. The predicted pore size of the peptidoglycan layer
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permits diffusion of globular proteins larger than 55 kDa (Dijkstra and Keck, 1996), and
therefore, VirB9, VirB7, VirB5, VirB2 and the VirB1 dimer freely diffuse in the periplasm (Fig.
48a). The contact between VirB1 and VirB9 is mediated via the C-terminus of VirB1 and
leads to activation of the lytic transglycosylase activity of VirB9-bound VirB1. This step may
lead to a conformational change, followed by processing of VirB1 at its VirB1* cleavage site
by signal peptidase I (SPI), which also cleaves the VirB2 propilin. Interactions with inner
membrane proteins such as the NTPases VirB11 and VirB4 may localize subunits of the
T4SS to the site of peptidoglycan degradation (Fig. 48b). Assembly of VirB7 and VirB9,
which subsequently recruit other channel components such as VirB10 and VirB8,
accompanies the opening of the cell wall. Next, VirB10 exerts its proposed role to bridge the
periplasm between the NTPases of the inner membrane and the VirB9-VirB7 subassembly.
The N-terminal part of VirB1 is subsequently degraded in order to protect cellular integrity,
whereas the C-terminal domain remains attached to VirB9 (Fig. 48c). The VirB2 pilin may
next interact with VirB1*, which may facilitate correct folding and/or passage to the
exocellular space through the nascent pilus channel. This scenario is supported by results
from a chemical crosslinking assay with isolated Ti-pili, which showed interaction of VirB2
and full-length VirB1 (Krall, 2004). In addition, in a non-polar virB1-mutant decreased level of
VirB2 was detected in the cell whereas deletions of all other virB genes did not have such an
effect (Lai et al., 2000), which further supports a functional interaction between the two
proteins. While interactions between the other VirB proteins promote T4SS assembly (Fig.
48d), VirB2/VirB1* and VirB5 are translocated to the exterior of the cell, VirB1* is released,
triggering assembly of the pilus components (Fig. 48e). VirB1* may exert an additional
function in host cell recognition, but the model proposed here accounts for its contribution to
T4SS assembly and its accumulation in the extracellular space.
Fig. 48. Model of T4SS assembly emphasizing the role of VirB1. The model is based on all the
data available on T4SS subunit contacts and assembly (Cascales and Christie, 2003). The VirB1 SLT
domain is labeled in grey, the unordered C-terminal NORS region in red. Red arrowheads symbolize
action of a protease, possibly signal peptidase I (SPI). The VirB proteins are indicated by their
respective numbers in the A. tumefaciens or B. suis virB operon. Bottom: cytoplasmatic side, Sec:
machinery of the general secretion pathway.
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VirB1 orthologs are not present in all T4SS, but they obviously play an important role.
T4SS without VirB1-like components may benefit from coordinated induction of the virB
genes with the up-regulation of genes responsible for peptidoglycan metabolism, which
ensures the formation of openings in the cell wall. This would require coordinated expression
of genes located at different positions in the genome and an example of this principle is
Caulobacter crescentus. This organism possesses a lytic transglycosylase, which permits
assembly of the flagellar basal body hook complex at the cell pole of swarmer cells. The
protein PleA is transcriptionally autonomous and upregulated only for a short time period in
the predivisional cell when this activity is needed (Viollier and Shapiro, 2003). Taken
together, it is evident that the localized lysis of the murein layer is important for the efficient
assembly of the T4SS. In many systems this is achieved through coordinated expression of
the lytic transglycosylase genes with those of the components of the membrane spanning
structure. However, the presence of naturally occurring openings in the murein layer or the
activity of cell wall metabolic enzymes may be sufficient to allow limited assembly of
functional T4SS. This explains the severely attenuated phenotype of virB1 mutants, which
might not be able to assembly sufficient amounts of T4SSs for wildtype-like effector
secretion.
2. VirB11, the hexameric traffic (d)NTPase from T4SS
2.1. Structural conservation in diverse systems
VirB11 orthologs are indispensable for correct assembly and function of T4SS. Five
different orthologs from well-characterized T4SS were analyzed in the context of this work to
gain insights into their structure, biochemical properties and inhibition by different small
molecules. The VirB11 ortholog from H. pylori consists of two domains with approximately
equal length and both are comprised of extended central β sheets (Savvides et al., 2003).
The connecting linker region close to residue I134 is in close structural proximity to the
Walker A motif, which is responsible for nucleotide binding and hydrolysis. A notable feature
discovered upon alignment of sequences of VirB11 orthologs is that conserved residues are
not evenly distributed in the N- or C-terminal domain. The HP0525 N-terminal domain
comprises 133 amino acids, which constitutes 40.3% of the entire protein. Only 25.7% of the
amino acids, which are identical among the five analyzed VirB11 orthologs, and only 24.8%
of all amino acids scored from 7 to A in an AMAS alignment (indicating high conservation),
localize in this domain. The conservation of amino acids is therefore much higher in the C-
terminus of the proteins. The significance of this finding is evident knowing that the more rigid
C-terminus of this inner membrane protein was suggested to be inserted in the inner
membrane and to mediate the oligomerization (Yeo and Waksman, 2004). In contrast, the
more flexible N-terminus may be in contact with the periplasm and may be involved in
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diverse protein-protein interactions as suggested by dihybrid analysis with the A. tumefaciens
ortholog (Ward et al., 2002). Two prominent stretches in the N-terminal part of VirB11
ortholog do not contain any conserved residues. They correspond to the HP0525 residues
M1 to L35, which constitute an α-helical region, and E64 to R80, which constitutes an
extended loop region. Together, these domains form structurally adjacent parts of the N-
terminus that likely face the periplasm. The lower degree of conservation can be explained
assuming that the N-terminal part interacts with T4SS components that vary between the
different organisms using these secretion machineries. In contrast to that, the highest degree
of sequence conservation was found in case of amino acids that are parts of the substrate
binding cleft or contribute to catalytic activity, tertiary structure and homomultimer formation.
Those features of VirB11 are presumably more conserved between the orthologs.
2.2. Similar enzymology of VirB11 orthologs from T4SS
 The hexameric VirB11 orthologs were purified as N-terminally StrepII-tagged proteins
from E. coli cell lysates. The enzymologies of all proteins were very similar, and they had a
strong preference for ATP or dATP hydrolysis at the pH value of 7.5. In a previous study, the
native proteins VirB11 from A. tumefaciens and TrwD from plasmid pR388 were analyzed
with a different assay relying on Phosphoimager/storage phosphor technology, utilizing
radioactively labeled NTPs and a competition assay to establish substrate preference
(Krause et al., 2000). The results of the present study differ from the previous one
concerning the optimal pH value, the utilized substrates and vMAX. These differences may be
a result of the different assay methods, buffer conditions and protein purification protocols,
but many results were entirely consistent in both studies.
For example, the formation of hexamers, the requirement for divalent cations, the
substrate preference for ATP and dATP and the inefficient utilization of dTTP and dCTP were
observed in both studies (Krause et al., 2000). In Krause et al., the pH value promoting
maximum substrate turnover was found to be 9.5 for HP0525 and TrbB, the latter having a
second maximum at pH 7.5. In this work pH 7.5 was found to be the optimal pH for all VirB11
orthologs and the activity of StrepII-HP0525 was higher than the activity described for native
HP0525. The results of this work therefore prove that the addition of N-terminal StrepII and
TrxA tags did not impair hexamer formation of the VirB11 orthologs, and the tags have
greatly facilitated protein purification. The high degree of conservation of the active site
region was reflected by similar substrate requirements. One observation that had not been
described until now is the positive cooperativity of substrate conversion, which was indicated
by the sigmoidal shape of the curve when substrate concentration was plotted versus the
enzyme velocity. This is a characteristic feature of cooperative enzymes whose kinetics
cannot be described by the classic Michaelis-Menten equation (Stryer, 1997).
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2.3. Inhibitors act on all VirB11 orthologs
The in vitro effect of the novel inhibitory compound MTFPT, originally denominated
CHIR-1, was not specific although the molecule was identified in a high-throughput-screen
for inhibitors of the native hexameric HP0525 (Chiron Diagnostics, unpublished). I showed
here that this effect extends to a number of orthologs from different T4SS. The potency of
MTFPT was analyzed in vivo in a H. pylori tissue culture infection model and with purified
HP0525 without an N-terminal tag. The inhibition occured at significantly lower
concentrations than those found in this study (this work; W. Pansegrau, Chiron personal
communication). In spite of the quantitative differences, the data presented here are
qualitatively similar to those obtained by our collaborators. In addition, the results are very
similar in case of the two VirB11 orthologs analyzed in most detail, H. pylori StrepII-HP0525
and B. suis StrepII-VirB11.
For both enzymes very similar IC50 values were determined, and the fact that
changes of the substrate concentration did not alter this value constitutes convincing
evidence against a competitive mode of inhibition. The data were analyzed using a Dixon
plot, which is a plot of 1/v against [Inhibitor] and a Cornish-Bowden plot of S/v against
[Inhibitor], and the results strongly suggest a non-competitive or mixed-uncompetitive mode
of inhibition in case of both enzymes (Cortés et al., 2001). This type of analysis was not
carried out for the other VirB11 orthologs, but inhibitory effects were observed and the IC50-
values were within the same range of 10 to 200 micromolar.
It was reported previously that phospholipids such as cardiolipin and
phosphatidylglycerol stimulate the ATPase activity of VirB11 orthologs (Krause et al., 2000).
Others reported that unsaturated fatty acids inhibit the enzymatic activity of TrwD in a non-
competitive manner (C. Machón, unpublished). This question was analyzed here and to this
end, oleic acid and linoleic acid were added to the ATPase assays with VirB11 orthologs.
The effect of both fatty acids on TrwD was confirmed since the activity of StrepII-TrwD
decreased similar to previous reports. In contrast, StrepII-TraG and StrepII-VirB11 were not
inhibited. Remarkably, a strong negative effect of both oleic and linoleic acid on the activity of
the H. pylori ortholog was observed and these results suggest interesting follow-up work.
Oleic and linoleic acid are non-toxic and water-insoluble components found in plants and
they are not only utilized in a number of processes in the food industry but also are enriched
in many products such as cottonseed or olive oil. We suggest that the search for a non-toxic
pharmaceutical product to cure Helicobacter infections should be viewed in the light of the
ability of oleic and linoleic acid to disable the Cag-PAI via HP0525 inhibition. In any case,
good pharmacokinetic properties of biologically active compounds are important for its further
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development and in the case of MTFPT the in vitro effect had to be assessed in a number of
suitable in vivo assays.
When conjugation assays with A. tumefaciens were conducted to assess the effect of
MTFPT, it became apparent that it has a bacteriostatic or even bactericidal effect on
Agrobacterium cells at concentrations higher than 10 µM under these conditions. Therefore,
we could not assess the effect on the T4SS in this organism. The growth inhibition of
Agrobacterium was only tested on minimal media since this is required for virB induction.
MTFPT may have no effect on Agrobacterium when is cultured on rich media, but this was
not tested. Instead, we exploited the ability of MTFPT to inhibit IncP, -W and -N conjugation
between E. coli cells. The inhibitor did not have toxic effects on this organism at
concentrations up to 1 mM. For all tested plasmids, the T4SS-mediated conjugative transfer
was significantly reduced in the presence of more than 100 µM MTFPT, which confirmed the
results of the in vivo analysis. The pKM101-determined pilus serves as receptor for the lytic
bacteriophage IKe. I conducted an assay exploiting this fact and showed that decreased
conjugation efficiency correlated with decreased availability of the pilus phage receptor. The
data obtained in vitro were thus confirmed by the in vivo experiments. Inhibition of the
ATPase had the consequence that the tra operon-determined T4SS could not elaborate a
pilus structure, and MTFPT had similar effects on the secretion machineries encoded on
pR388 and pRP4. Major obstacles that became apparent in the course of these experiments
are the insolubility of MTFPT in water and the high concentrations that were needed to cause
an effect. It is nevertheless reasonable to assume that this component may serve as a lead
compound for development in a medicinal chemistry program, which may lead to potent
broad-spectrum T4SS-inhibitors.
3. Complementation of a VirB11 mutant
The observation that VirB proteins from different T4SSs complement each other’s
function was encouragement to perform a complementation experiment with the VirB11
orthologs from A. tumefaciens and B. suis. However, expression of the virB11 gene from
B.suis did not complement the virB11 defect in A. tumefaciens PC1011. The amino acid
identity between the proteins is only 33%, and many of the conserved residues are likely part
of the active site pocket and homo-multimerization domain. The protein interface responsible
for interactions with other T4SS components such as VirB9, VirB10 and VirB4
(Ward et al., 2002; Zhou and Christie, 1997), seems to be more variable, which explains why
complementation was not observed in this case.
In contrast to that, it was a very unexpected finding that VirB11 from A. tumefaciens
strain C58 did not complement IncQ plasmid transfer in the A. tumefaciens strain A348
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derivative PC1011. In contrast to that, tumor development following infection of K .
diagremontiana leaves and the amount of Ti-pili were undistinguishable between the
complemented strain and the WT. These observations are reminiscent of previous reports
showing that heterologous production of VirB11 from A. tumefaciens strain A348 with certain
amino acid substitutions uncoupled pilus production from the ability to transfer T-DNA and
IncQ plasmids (Sagulenko et al., 2001).
VirB11 from A. tumefaciens strains C58 and A348 have an overall amino acid identity
of 90%, and all but one of the residues, which were proven to be important for the
complementation of PC1011 in previous studies (Sagulenko et al., 2001), were identical.
Earlier, it was shown that expression of strain A348 virB11Q135E in PC1011 complemented
pilus production and T-DNA transfer, while IncQ-transfer was attenuated 4,5-fold (Sagulenko
et al., 2001). The C58 VirB11 protein used in the present work carries H instead of a Q in
position 135, and this may explain the complementation phenotype described here.
Moreover, results from the cited publication show that stronger expression of A348 virB11
WT resulted in decreased efficiency of IncQ transfer. It is therefore assumed that the strong,
trc promotor-driven expression of C58 virB11 carrying a substitution at the position
corresponding to Q135 is even less supportive for complementation of IncQ-transfer. Taken
together, the above findings give a clear indication as to why strain C58 VirB11 does not
substitute in the pLS1 transfer assay for its very similar ortholog from strain A348.
4.  Interaction of VirB11 and VirB5
Like all other proteins encoded by the A. tumefaciens virB operon, VirB11 is required
for T-DNA transfer and T-pilus elaboration (Lai et al., 2000). Many interactions of this protein
with other components of the T4SS have been proposed (Ward et al., 2002; Zhou and
Christie, 1997). The absence of pili in a virB11 deletion mutant was always regarded as a
consequence of the loss of T4SS assembly caused by the absence of the energy provided
by the ATPase. In the course of previous studies on VirB11, certain variants of the conserved
His box (258-270) were found to uncouple the contribution of VirB11 to pilus formation and
substrate translocation. Most significantly, the protein VirB11I265T mediated transfer of T-DNA
and IncQ-plasmids at wild type levels but T-pili were not detected (Sagulenko et al., 2001).
Western blot analysis demonstrated that quantity of the pilus-associated protein VirB7 (Krall
et al., 2002) in exocellular fractions of a VirB11I265T–producing virB11 mutant was
indistinguishable from the WT, whereas correct localization was impaired in a non-polar
virB11 mutant (Sagulenko et al., 2001). As the mutation has an effect exclusively on pilus
biogenesis, it was hypothesized that VirB11 may guide VirB2 folding and pilus assembly.
Overlay assays did not give evidence for direct interaction between VirB11 and VirB2, but in
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contrast, an interaction of the minor pilus component VirB5 and VirB11 was detected (Krall,
1999), which prompted further analysis of this question. The original result was confirmed in
this study, but only in case of the A. tumefaciens T4SS. Neither the orthologs from B. suis
nor IncN-plasmid pKM101 interacted in a comparable manner with their respective VirB11
orthologs. Since this method relies on re-naturation of membrane-bound VirB11 orthologs
and interaction with soluble VirB5 orthologs, there are many possible explanations for our
inability to observe interactions, such as not suited buffer conditions, refolding times or
temperatures. Other biochemical methods need to be applied in future to assess whether the
interaction between A. tumefaciens VirB5 and VirB11 reflects a biologically relevant
phenomenon.
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 Summary
The aim of this study was to unravel general properties of two VirB proteins that
participate in the biogenesis of T4SS in the human and animal pathogenic bacterium B. suis
and the plant pathogen A. tumefaciens. Using biochemical and functional studies and the
comparative analysis of orthologs from different T4SSs we gained novel insights into the
mechanism of these macromolecular translocation systems. The work focused on VirB1, a
lytic transglycosylase present in many but not all T4SS, and on VirB11, a hexameric ATPase
ubiquitously present in all type II and type IV secretion systems.
VirB1 orthologs share a conserved active site signature. A C-terminal domain,
classified as structurally unordered NORS-region, characterizes some members of this
family. In A. tumefaciens, this region is proteolytically cleaved, possibly by action of
periplasmatic proteases or of SPI, and it is then secreted. Functional studies showed that a
highly conserved active site E is crucial for its activity and that VirB1-like proteins are to
some extent interchangeable between different T4SSs. In A. tumefaciens, an active site
variant of VirB1 partially complemented the non-polar virB1 mutant. This may be explained
by the fact that the C-terminal VirB1* domain is involved in stabilizing interactions with other
T4SS components. Not surprisingly, variations of the C-terminal processing site reduced the
complementation of the virB1 deletion strain, showing that the processing event is
functionally important.
Different biochemical techniques were applied to characterize interactions of B. suis
VirB1 with other T4SS components. Genes from the B. suis virB operon were cloned into
expression vectors, and large amounts of affinity-tagged Brucella proteins were purified and
applied to various assays. VirB1 interacted with itself, possibly forming dimers, and the
binding of GroEL, likely to the VirB1 C-terminus, was observed. Subsequent experiments
demonstrated interactions of VirB1 with VirB9 and VirB11, whereas tests of the VirB8
interaction yielded contradictory results and VirB10 did not interact with VirB1. Mapping of
VirB1 peptides that interact with other VirB proteins underscored the importance of the C-
terminus, especially for the VirB1-VirB9 interaction. Heterologous expression of different B.
suis virB operon constructs in A. tumefaciens revealed functional assembly of the T4SS, but
also emphasized the importance of the contribution of VirB1. Taken together, the data
suggested a refined model of VirB1 action in T4SS biogenesis.
The VirB11 orthologs from two mammalian pathogens, a plant pathogen and two
broad-host-range plasmids were cloned into vectors suited for protein overproduction. The
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active hexameric ATPases were purified as N-terminal fusion proteins and their enzymatic
properties were characterized. The effect of MTFPT, a putative lead for novel anti-infective
drugs targeting the H. pylori ortholog of VirB11, was tested both in vitro and in vivo. Enzyme
assays demonstrated non-competitive inhibition of all tested ATPases and similar effects on
T4SS function were observed in vivo. The unsaturated fatty acids oleic- and linoleic acid also
inhibited some of the VirB11 orthologs in vitro, among them HP0525 from H. pylori, and this
finding may be relevant for anti-Helicobacter drug discovery programs.
The complexity of VirB11 functions was illustrated by the fact that an ortholog with
90% sequence identity failed to fully complement a non-polar virB11 mutant, thereby
uncoupling T-pilus formation and transfer of only one of the substrates (pLS1). Direct
interaction of the pilus component VirB5 with VirB11 was demonstrated in case of the A.
tumefaciens orthologs in an overlay assay. Using this assay it was not possible to
demonstrate similar interactions of the respective orthologs from the pKM101 tra region and
B. suis. Nevertheless, the interaction of VirB11 and VirB5 from B. suis was demonstrated in a
pulldown assay.
The results in this work did not confirm all the data from the first characterization of
MTFPT, which suggested a considerably lower IC50 in the nano-molar range. Nevertheless,
the results presented here are qualitatively consistent with previous reports. Since the effects
of this inhibitor extend to many VirB11 orthologs it appears to be very promising to further
pursue this line of research. Further development of this molecule may lead to the creation of
new drugs to fight bacterial infectious diseases, and the characterisation of VirB11 inhibitors
gained in this work may contribute to reach this goal in future.
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